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Burn injuries represent a significant medical burden and poor healing can lead to 
loss of function, substantial scarring and morbidity. Several studies suggest that 
mesenchymal stromal cell (MSC) therapy may be efficacious in accelerating 
wound healing. For the majority of these studies bone marrow-derived MSC (BM-
MSC) have been utilised. However, from a clinical perspective BM-MSC have 
several drawbacks. Adipose-derived MSC (AD-MSC) on the other hand, present 
an abundant, readily available source of MSC. Which source of MSC is 
therapeutically superior has not been well established, especially in large 
clinically relevant animal models. 
Therefore, we investigated the efficacy of BM-MSC and AD-MSC in the treatment 
of burn wounds in a large porcine model. Donor matched allogeneic AD-MSC and 
BM-MSC were applied onto partial thickness burns within a fibrin hydrogel. MSC 
therapy was similarly efficacious in both groups, increasing wound closure, 
angiogenesis and collagen content, associated with increased wound maturity at 
two weeks.  
To augment this therapeutic response, priming of MSC with inflammatory 
cytokines was explored. Pre-treatment of MSC with TNFα has been reported to 
be beneficial in several models but has not been previously established in a burn 
wound model. Administration of MSC primed with TNFα resulted in a significant 
acceleration of burn wound closure, re-epithelialisation and increased 
angiogenesis, AD-MSC and BM-MSC were therapeutically equivalent in their 
response to TNFα. 
x 
 
To understand the mechanism behind this observation, a mouse model of 
excisional wound healing was employed. MSC have immunomodulatory effects 
impacting macrophages, promoting polarisation towards a reparative 
phenotype. CCL-2 is a potent cytokine involved in the recruitment of 
macrophages. We hypothesised that MSC derived CCL-2 may be involved in the 
MSC therapeutic effect by facilitating macrophage repolarisation and may also 
play a role in TNFα pre-treatment as CCL-2 is greatly induced by TNFα. To further 
delineate this mechanism, MSC isolated from CCL-2 deficient mice (CCL-2 KO) 
were applied to excisional wounds in wild-type (WT) mice. Interestingly, CCL-2 
deficiency in MSC completely abrogated the therapeutic response compared to 
WT MSC.  CCL-2 KO MSC were unable to repolarise macrophages to the same 
extent as WT and this was accompanied by a reduced angiogenesis and re-
epithelialisation of the wounds at day 10.  
TNFα pre-treatment of WT MSC significantly increased therapeutic efficacy, 
resulting in complete re-epithelisation of all wounds by day 10. CCL-2 KO MSC 
responded somewhat, with increased CD206+ macrophages and reduced Ly6G+ 
neutrophils present within the wound, but this biology had no effect on re-
epithelialisation. 
In summary, this thesis provides new insights into the role of CCL-2 in MSC 
therapy. Additionally, it was established that AD-MSC are therapeutically 
equivalent to BM-MSC and are a more optimal source MSC for practical clinical 
use. Furthermore, TNFα pre-treatment of MSC is beneficial in both a porcine burn 
model and an excisional mouse model and may be an advantageous method to 




I would like to express my gratitude to Professor Noel Caplice for seeing the 
potential in me and for giving me the opportunity to undertake my PhD in the 
CRVB, for his constant enthusiasm and motivation and honest critiques. 
 
I would also like to thank my co-supervisor Dr. Jim Clover, for his support, guidance 
and constant encouragement. For always championing my cause, promoting my 
research and for giving me the opportunity to expand my professional network and 
collaborate with other research groups.  
 
To all the staff of the CRVB past and present, to Janet, Libby, Gopal for helping me 
with image analysis, to Ken for his help with the flow cytometer and for reviewing 
my thesis. I would especially like to thank Vincent for all his help. To Sharon for all 
her help and support, from organising my swipe access on my first day to organising 
my viva and everything else in between. 
 
A special thanks to my family, for all their support and kindness; in particular, my 
parents, who’ve always been very supportive throughout my many years of 
education and for the work ethic they have instilled in me. 
 
To Amy, I dedicate this thesis to you. For all of your love and support throughout the 
years.  When the PhD consumed me, you motivated me, took over all the household 
duties and always had a warm meal waiting for me. Without you, this would not have 
been possible.  
xii 
 
List of publications 
 
Fibrin as a delivery system in wound healing tissue engineering applications. 
Whelan D, Caplice NM, Clover AJ. 
J Control Release. 2014  
 
Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity 
and Cause Microvascular Obstruction Following Intracoronary Delivery: 
Amelioration by Antithrombin Therapy. 
Gleeson BM, Martin K, Ali MT, Kumar AH, Pillai MG, Kumar SP, O'Sullivan JF, Whelan D, 
Stocca A, Khider W, Barry FP, O'Brien T, Caplice NM. 
Stem Cells. 2015  
 
Synthetic chemically modified mRNA-based delivery of cytoprotective factor 
promotes early cardiomyocyte survival post-acute myocardial infarction. 
Huang CL, Leblond AL, Turner EC, Kumar AH, Martin K, Whelan D, O'Sullivan DM, 
Caplice NM. 
Mol Pharm. 2015 
 
Mesenchymal Stem Cells and Cutaneous Wound Healing: Current Evidence and 
Future Potential. 
Isakson M, de Blacam C, Whelan D, McArdle A, Clover AJ. 
Stem Cells Int. 2015 
 
Allogeneic mesenchymal stem cells, but not culture modified monocytes, improve 
burn wound healing. 
Clover AJ, Kumar AH, Isakson M, Whelan D, Stocca A, Gleeson BM, Caplice NM. 
Burns. 2015  
 
A Novel Selectable Islet 1 Positive Progenitor Cell Reprogrammed to Expandable 
and Functional Smooth Muscle Cells. 
Turner EC, Huang CL, Sawhney N, Govindarajan K, Clover AJ, Martin K, Browne TC, 
Whelan D, Kumar AH, Mackrill JJ, Wang S, Schmeckpeper J, Stocca A, Pierce WG, Leblond 
AL, Cai L, O'Sullivan DM, Buneker CK, Choi J, MacSharry J, Ikeda Y, Russell SJ, Caplice NM. 




Novel methods of local anesthetic delivery in the perioperative and postoperative 
setting-potential for fibrin hydrogel delivery. 
Kearney L, Whelan D, O'Donnell BD, Clover AJ. 
J Clin Anesth. 2016 
 
Allogeneic MSC persistence may not be necessary for a beneficial effect in burn 
wound healing. 
Whelan D, Caplice NM, Clover AJ. 
Burns. 2017. 
 
Selective M2 Macrophage Depletion Leads to Prolonged Inflammation in Surgical 
Wounds. 
Klinkert K, Whelan D, Clover AJ, Leblond AL, Kumar AH, Caplice NM. 
















 Comparison of allogeneic bone marrow derived mesenchymal stem cell 
and adipose tissue derived mesenchymal stem cell therapy in porcine 
burn wound healing. 
D. Whelan, G. Krishnan, V. Mehigan, NM. Caplice, AJP. Clover 
45th annual European Society for Dermatology Research (ESDR), 9-12th 
September 2015 
 
 Rapid re-epithelialisation for accelerated wound healing 
D. Whelan, L. Turner, NM. Caplice, AJP. Clover 
Irish Association of Plastic Surgeons (IAPS) summer meeting May12-13th 2016  
 
 Pre-treatment of mesenchymal stem cells with TNF alpha increases 
efficacy in promoting wound healing 
D. Whelan, G. Krishnan, V. Mehigan, NM. Caplice, AJP. Clover 











Abbreviation Meaning Abbreviation Meaning
ACKR Atypical Chemokine Receptor  GVHD Graft versus host disease
Allo Allogeneic h Hours
ANOVA Analysis of variance H&E Hematoxylin and eosin 
BCL-2 B-cell lymphoma 2 HC Hypoxic conditioning 
BM Bone marrow HGF Hepatocyte growth factor 
BMP Bone morphogenetic protein HIF-1 Hypoxia inducible factor 1 
BSA Bovine serum albumin HO Heme oxygenase 
CCL C-C motif chemokine ligand HPF High power field
CCR C-C chemokine receptor HPRA
Health product regulatory 
authority
CFU-F Fibroblast colony forming unit HSC Hematopoietic stem cell 
CM Conditioned media HUVEC
Human umbilical vein 
endothelial cell
COX Cyclooxygenase ICAM-1
Intracellular adhesion molecule 
1 
CXCL C-X-C motif chemokine ligand ID Intradermally
CXCR4





d Day IFN-γ Interferon-gamma 
DAPI 4',6-diamidino-2-phenylindole IGF Insulin like growth factor 
DC Dendritic cell IL Interleukin
DMEM
Dulbecco's Modified Eagle 
Medium 
IL-1β Interleukin 1 beta 
DSLR Digital single lens reflex IM Intra muscular
EDTA Ethylenediaminetetraacetic acid IP Intraperitoneal











FAK Focal adhesion kinase LPS Lipopolysaccharides
FBS Foetal bovine serum MCPIP
Monocyte chemotactic protein 
induced protein 
FGF Fibroblast growth factor MHC
Major histocompatibility 
complex
FoxP3 Forkhead box P3 MI Myocardial infarct 












Abbreviation Meaning Abbreviation Meaning
MNC Mononuclear cells rmANOVA
Repeated measures analysis of 
variance 
mRNA Messenger RNA ROS Reactive oxygen species 
MSC Mesenchymal stromal cell rRNA Ribosomal RNA
MSC-KO CCL-2 KO MSC rt Room temperature
NF-κB
Nuclear factor kappa-light-chain-
enhancer of activated B cells 
s Second
NK Natural killer cells SDF-1 Stromal derived factor-1 
NO Nitric oxide SEM Standard error mean 
NOS Nitric oxide synthase SMC Smooth muscle cell 
o/n Overnight Src Sarcoma
OCT
Optimal temperature cutting 
compound
STAT
Signal transducer and activator 
of transcription
p Passage SVF Stromal vascular fraction 
PB Peripheral blood TBSA Total body surface area
PBMC
Peripheral blood mononuclear 
cell 
TGF-β Transforming growth factor beta 
PBS Phosphate buffer saline Th1 Type 1 T helper cells 
PBST PBS + 0.1% Tween TLR Toll like receptor
PCR Polymerase chain reaction TNFα Tumour necrosis factor alpha 
PDGF Platelet-derived growth factor T-reg T- cell regulator 
PFA Paraformaldehyde TSG-6 TNF stimulated gene 6 
PGE2 Prostaglandin E 2 VCAM-1






Vascular Endothelial Growth 
Factor 
PKC Protein kinase C VSMC Vascular Smooth muscle cell





Dulbecco's Modified Eagle 
Medium alpha modification
qRT-PCR 




1. Introduction  
 
 
1.1. Etiology and pathophysiology of burn wounds 
 
Burn injuries are caused by excessive heat to the skin, which cannot be 
adequately dissipated, leading to tissue necrosis and disruption of the epidermal 
barrier, with the temperature and duration of contact of the thermal insult 
determining the scale of tissue damage. Burn injuries on a global scale affects 
more people than HIV and Tuberculosis combined, resulting in over 300,000 
deaths annually and is a major dilemma for both developed and developing 
nations [1]. In the United States, 486,000 burn injuries required medical 
attention with 40,000 requiring further hospitalisation, resulting in an overall 
mortality rate of 3.2%. Severe burning of over 60% of total body surface area 
(TBSA) results in systemic shock and significantly increases the mortality rate to 
45-85% [2] 
Burn injuries arise from a variety of sources and burns due to flame or fire 
account for the majority of cases (43%) while scald injuries account for 34% [2]. 
The vast majority of scald burns occur in 1-2 year olds, accounting for 68% of all 
burn injuries in this age group, the bulk of which occur at home [2]. 
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Burn injuries can result in systemic complications including; pneumonia, 
cellulitis, septicaemia, wound and urinary tract infections are all increasingly 
associated with age [2]. 
The skin consists of three main layers; the epidermis, composed of stratified skin 
cells called keratinocytes (as shown in Figure 1.1), the dermis and hypodermis. 
Superficial burns are minor and are restricted to the epidermis, typically being 
induced by UV radiation from exposure to the sun. The skin reddens and is 
usually painful. In cases of large areas of severely sunburnt skin, medical 
attention may be required but generally, no treatment is required other than 
moisturisation of the affected areas.  
Partial thickness burns involve the burn extending into the dermis; this layer 
contains fibroblasts cells and a matrix of collagen fibres that house various skin 
structures such as hair follicles and sensory nerves (see Figure 1.1). In 
superficial partial thickness burns, tissue damage extends to the hypodermis. 
These burns are characterised by the formation of a blister and are quite painful 
due to the proximity of the burn to sensory neurons in the skin.  The burnt skin 
will appear pink due to the intact vasculature and will blanche upon applied 
pressure. These wounds will heal through re-epithelisation from the surrounding 
undamaged skin and hair follicles, generally within 10-14 days (d) based on its 





Figure 1.1 The anatomical structure of skin 
Figure demonstrating the different layers and organelles contained in skin [4]. 
 
 Deep partial thickness burns involve the lower parts of the dermis, damaging 
superficial adnexal structures such as hair follicles, nerve endings and other skin 
appendages. The wound may appear pale or red due to the extravasation of blood 
cells from the damaged capillary beds leading to no, or greatly reduced, capillary 
refill (see Figure 1.2). Healing time can be in excess of 21 d and may result in 
scaring with or without adverse hypertrophic scarring. Surgery is often required 
to debride necrotic tissue and skin grafts applied to facilitate re-epithelisation 
and wound closure. Complications of such burns include wound infection, 
septicaemia and cellulitis. 
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In a full thickness burn, both the epidermis and dermis are destroyed, in some 
instances penetrating down into the underlying adipose tissue and bone. 
Sensation is lost due to the destruction of sensory neurons. Skin may be waxy or 
charred in appearance with no capillary refill. All skin structures such as hair 
follicles and sweat glands are destroyed and will not regenerate. The wound will 
result in scar formation, requiring surgery to excise the dead tissue, relieve 
contractures and will generally need grafting to restore the epithelial layer 
promptly. Such burns are very prone to infection and loss of barrier function also 
induces massive transdermal water loss.  
 
1.1.1. Biology of burns 
As postulated by Jackson et al, burns are made up of different zones of damage 
due to heat transfer through the tissue [5]. The zone of coagulation is a central 
zone of irreversible skin damage. Surrounding this is the zone of stasis; this is a 
transitionary zone, which has the potential to be saved or may succumb to 
inflammatory reaction if the burn is not adequately treated. Adjacent to this is 
the zone of hyperaemia; this is the zone of least damage and the site of early skin 
regeneration.  
The body usually reacts to gradual heat changes by vasodilation and increased 
perspiration, which dissipates heat from the dermis through latent heat of 
evaporation. However, if there is excess heat, for example due to fire or scald, the 
capacity of the skin to dissipate the heat can be insufficient to prevent tissue 
damage. If heat is prolonged the damage begins to travel through the deeper 
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structures. Tissue damage is proportional to the temperature and duration of the 
thermal insult. For instance, it takes 5-minute (min) exposure to water at 48°C to 
induce a partial thickness burn, however when the temperature of the water is 
increased to 70°C a similar degree of injury will result after just 1-2 seconds (s) 
of exposure [6, 7].  
 
Figure 1.2 Burn victims 
Images show patients with various partial thickness, deep partial thickness and full thickness 
burns. 
 
In response, a large inflammatory reaction (mediated by activation of the kinin 
system and release of histamine) is incited by widespread necrosis of thermally 
damaged cells leading to vasodilation of the wound area. Extensive degradation 
of hyaluronate and collagen fibres promotes extravascular osmotic activity and 
microvascular permeability  also rapidly increases during this time period, 
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leading to excessive fluid loss proportional to burn surface area [8]. In cases of 
burn areas involving > 30% TBSA, fluid loss involves all tissues through increased 
microvascular permeability [7]. 
Hypercoagulability ensues due to complement activation and inhibition of 
fibrinolysis [8, 9]. Complement activation induces major polymorphonuclear 
neutrophil leucocytes (PMNL) recruitment and wound infiltration with the 
release of multiple factors such as prostaglandins and thromboxanes. At 12-24 
hours (h) tissue perfusion deteriorates due to the no reflow phenomenon [10]. 
Local tissue ischemia sets in leading to further necrosis and cell death. 
Complement activation and ischemia elicit increased production of oxygen free 
radicals which further exacerbate the inflammatory response [10].  
A late wound healing phase develops as reperfusion increases, PMNL are 
gradually replaced by macrophages, which secrete an array of wound healing 
cytokines. Impairment of PMNL function may be a contributory factor to 
microorganism invasion. Burns not only destroy cells but also eradicate 
commensal bacteria present on the skin. However, burn wound microbial re-
colonization occurs within the first 48 h from gram positive bacteria deep in hair 
follicles which escaped the initial thermal insult [10]. These initial colonisers are 
gradually replaced by gram negative bacteria (such as E. coli) over the course of 




1.1.2. Systemic effects 
Once the burn surface area increases beyond 30%, systemic inflammatory effects 
become problematic [7]. Thermal injury and the systemic release of 
inflammatory mediators push the body into a state of shock where tissue 
perfusion is insufficient to meet the cellular demands. In patients with very high 
percentage TBSA burnt, large-scale fluid movement initiates hypovolemia, where 
blood plasma volume is markedly decreased potentially leading to reduced 
cardiac output. Sympathetic over correction and hypovolemia result in the 
release of many factors (such as angiotensin II, catecholamines) which cause a 
contraction of the smooth muscle cells (SMC) lining the arteries, giving rise to 
increased peripheral vascular resistance. Loss of contractility of myocardial cells 
has also been observed after thermal injury [6].  
Hypovolemia also leads to renal failure due to decreased kidney perfusion and 
increased free hemoglobin. The gastrointestinal tract is a highly vascularised 
region, which can also become ischemic after a large burn injury. Thus, increasing 
permeability and translocation of the endogenous bacteria across the 
gastrointestinal wall, which may also lead to sepsis and increased morbidity [6]. 
The end result is acute renal failure, immunosuppression leading to systemic 
infection, major cardiac dysfunction and eventual death. 
 
1.1.3. Clinical management of burn injuries 
Further skin damage can be halted by the application of appropriate first aid to 
all burns. For minor burns, running cool water over the burn for 15 min, even up 
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to 3 h after the incident, will reduce the injury [6]. Upon admission into hospital, 
the TBSA, depth, possible inhalation injury and the cause of the burns are 
assessed. Burns are then cleaned of debris before applying non-adherent anti-
bacterial dressings. Fluid resuscitation through intra venous (IV) administration 
may be required (in cases with TBSA > 15%) to prevent further burn shock. In 
burns causing large-scale fluid shifts, fluid resuscitation reduces depth of tissue 
damage due to hypovolemia and increases perfusion of damaged tissues [3]. In 
some instances, further pharmacological treatments are administered to 
suppress inflammatory response and subsequent burn shock, such as steroids 
and antihistamines [7]. Other drugs may also be administered to promote 
vasodilation and reperfusion of burn wounds [7]. 
Wound depth is assessed over several hours as it typically evolves and this will 
dictate management of the wound. For partial thickness burns, wounds are 
cleaned followed by application of topical antibiotics such as silver sulfadiazine 
[7]. A range of dressings may be used to provide hydration as well as absorption 
of wound exudates. Most partial thickness burns will heal through re-
epithelialisation from undamaged dermal appendages. If wounds do not show 
signs of healing after 1-2 weeks they may require intervention [3]   
For deeper partial thickness burns and full thickness burns excision of dead 
tissue, skin grafting or free flap surgery may be required (as shown in Figure 
1.3). 
Excision of the dead tissue is performed by microtome or Goulian Weck knife (see 
Figure 1.3). Tissue is removed until a healthy bleeding viable wound bed is 
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established [3]. Early removal of necrotic tissues attenuates systemic 
inflammatory response and leads to accelerated wound closure and survival [11]. 
Skin grafting is a process where skin is harvested from an undamaged donor site. 
This graft is used to restore epithelial layer to the wound. The harvest site will 
also repair through re-epithelialisation.  
In a split thickness graft both the epidermis and a small layer of dermis is 
harvested. The graft may be meshed to allow it to cover a greater area. 
Keratinocytes from the graft proliferate and migrate out from the mesh to re-
epithelialise the wound. However, mesh grafts are generally not used where a 
good cosmetic appearance is required such as on the face [3]. 
Full thickness grafts contain both the epidermal and dermal layers. The donor 
site may be sown together to close the deficit. However, grafting is problematic 
in that it only replaces lost dermis and does not provide dermal structures such 
as sweat glands, sensory nerve endings or hair follicles. For large-scale burns, 





Figure 1.3 Excisional grafting  of burn wounds 
Patient receiving tangential excision of the wound (left) Meshed graft is then applied to the excised 
burn (right) [12]. 
 
Although much progress has been made in reducing mortality in the case of 
severe burn wounds, primarily through reduction in sepsis and better 
management of systemic inflammatory responses, burn injuries remain 
problematic due to poor wound healing outcomes and extended hospital stays.  
The significance of skin grafting cannot be understated, providing an epidermal 
barrier at an early time point reduces water loss, bacterial infection and 
consequently, reduces mortality. While grafting solves that problem, it does not 
prevent scarring. Once the initial excision of the wound is complete, there may 
be several follow-up surgeries required for skin grafting. As the scars begin to 
form, the skin in that area will tighten due to myofibroblast contraction. This can 
lead to loss of function and reduced range of motion of limbs and joints etc. 
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(Figure 1.4). Further revision surgeries will be required along with prolonged 
physical therapies to manage this.  
 
Figure 1.4 The effects of untreated burns 
Images above shows result of burns that did not receive surgery to relieve contractures. Limb 
mobility and function is greatly reduced.  
 
The current treatment of skin grafting and mesh skin grafting provides a cheap 
readily available source of epidermis. However, these treatments fall far short in 
terms of regenerating skin structures (such as sweat glands and hair follicles), 
retaining cosmetic appearances and have serious shortcomings in large-scale 




What is required? An alternative therapy that will accelerate wound 
closure, reduce the fibrotic response and promote the regeneration of 
dermal structures. 
In this context, the development of cellular therapies may prove to be fruitful 
alternatives to current treatments. Research is ongoing in developing cellular 
therapies using a variety of stem cells and engineered skin substitutes. This can 
be broken into three primary categories; replacement tissue, temporary 
replacement tissue and augmentation of wound healing therapies. 
 
Replacement tissue  
Off the shelf fully functional replacement skin would be ideal; however, there are 
major technical challenges.  Skin is highly immunogenic, therefore, replacement 
tissue would be quickly rejected if allogeneic. Developing fully functional skin in 
the laboratory is currently beyond our reach technically due to the multi cellular 
complexity, but research is ongoing in this area [13, 14]. Finally, the microsurgery 
required to install the skin would be highly laborious requiring many hours of 
surgery, and the graft could possibly fail due to ischemia. 
 
Temporary replacement tissue 
Tissue engineered skin substitutes, such as Apligraf, consisting of allogeneic 
fibroblasts and keratinocytes have shown some promise in reducing scarring and 
promoting wound closure [15]. They provide temporary wound closure; the 
extra cellular matrix in these skin substitutes may provide directional cues to the 
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invading recipient cells, while the allogeneic fibroblasts may provide other 
trophic cues to promote wound healing [16]. Autologous cells would be ideal, 
however would require the culture of vast amounts of cells from small quantities, 
which can take time. Research is ongoing in this area to develop novel methods 
to accelerate epithelial cell culture [17, 18]. 
Augmentation of wound healing therapies 
This rapidly developing paradigm of wound therapy, which holds much potential, 
harnesses the body’s innate ability to heal and regenerate. The progression of 
wound healing can be controlled using a variety of stem cells, growth factors and 
biomaterials leading to accelerated and improved wound healing outcomes. 
Much of this research has been conducted using mesenchymal stromal/stem 
cells, which is outlined in the next section. 
 
1.2.  Mesenchymal stromal cell therapy for cutaneous wound 
healing  
Burns and traumatic injuries by their nature result in the destruction of large 
amounts of skin tissue and cellular therapies provide a potential way to repair 
and regenerate this lost tissue by providing the fundamental building blocks. 
Attempts date back to the 1970’s when Rheinwald and Green developed methods 
to serially culture sheets of keratinocytes which were then transplanted onto 
burn wounds [19]. Mesenchymal stem cells or stromal cells are a promising 
candidate as they have unique ability to modulate inflammatory responses and 
elicit innate healing responses [20]. To date these cells have been applied to 
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multiple pathologies in both human and animal disease models and are safe and 
broadly efficacious. 
Stem cells have the ability to self-renew and can differentiate into multiple cell 
types in order to replace and replenish cells lost from tissue damage and general 
attrition. Mesenchymal stem cells are a population of multi-potent cells with the 
ability to differentiate into cells of the mesoderm lineage (see Figure 1.5). Non 
hematopoietic cells were first identified in the bone marrow (BM) in 1867 by 
Conheim [21]. However, it was not until 1966 that a population of fibroblast like 
non-hematopoietic cells derived from the bone marrow that were plastic 
adherent and had tri-lineage (osteoblast, adipocyte and chondrocyte) 
differentiation potential were identified [22]. This cell population has been 
identified by several names including skeletal stem cells and mesenchymal 
stromal cells, In 1991 Coplain et al, described these BM derived cells as 
mesenchymal stem cells [23]. Today however, there is still no clear consensus on 
the nomenclature for this cell population. 
Mesenchymal stem cells were first identified in the BM using single cell colony 
expansion [24]. These cells could recapitulate a complete heterotrophic bone 
morrow organ (bone, pericytes, adipocytes and fibroblasts) in vivo. Since then, 
many similar cell populations have been found to reside in various niches around 
the body, such as in adipose tissue [25], dental pulp [26], skeletal muscle [27] and 
numerous other locations. In fact, these cells are believed to reside in the 
connective tissue surrounding most organs and have been generally termed 




Figure 1.5 Mesenchymal stem cell differentiation potential 
Mesenchymal stem cells can be isolated from the bone marrow and differentiated into various cells 
of the mesoderm lineage [29] 
  
1.2.1. Defining the mesenchymal stem cell population 
A widely cited position paper published by International Society for Cellular 
Therapy (ISCT) in 2006 tried to further define this population of cells by the 
expression of surface cell receptors, multi-lineage differentiation potential and 
plastic adherence [30]. 
Mesenchymal stem cells commonly express a number of cell surface receptors 
including: CD90, CD73, CD105, CD29, CD44, CD166 and Stro1 while they lack 
expression of CD45, CD34, CD11b and CD14 and CD19. Due to the general 
isolation and expansion methods commonly employed, mesenchymal stem cells 
are a heterogeneous cell population consisting of multi, uni and null potent cells 
and it is because of this heterogeneity that there is much debate on whether this 
population should indeed be called stem cells. The ISCT took the position that 
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this cell population should be referred to as mesenchymal stromal cells [30], 
while there has been some uptake of this, many researchers still refer to them as 
stem cells. Indeed, several controlled clonal studies of this cell population have 
demonstrated that they have self-renewal potential and multipotency. Although 
the majority of these studies were conducted on cells isolated from BM and there 
is lack of clonal studies of mesenchymal stem cells isolated from other tissue 
sources. Moreover, no single isolation strategy has been defined as standard in 
the field, and mesenchymal stem cells are grown under a variety of culture 
conditions further adding to the heterogeneity. Recognising this, and for the 
purposes of clarity, this cell population shall be referred to as mesenchymal 
stromal cells (MSC) throughout this thesis. 
1.2.2. MSC biology 
The purpose and anatomical locations of native MSC within the body is not well 
understood. Tracking these cells in vivo is difficult, due to the paucity of unique 
cell markers. However, there is good evidence to suggest that MSC reside in the 
BM sinusoids closely associated to endothelial cells and pericytes where they 
help to maintain the hematopoietic niche [31] and maintain homeostasis by 
generating multiple types of stromal cells [32]. Nestin+ MSC (about 4% of CD45- 
stroma) were located in close proximity with hematopoietic stem cell (HSC) and 
adrenergic nerve fibres and highly expressed HSC maintenance genes such as 
angiopoietin, C-X-C motif chemokine 12 (CXCL12) and c-kit [31]. Depletion of 
nestin+ cells reduced BM homing of hematopoietic stem cells. In vitro, this cell 
population was plastic adherent and quickly differentiated into the various 
mesenchymal lineages [31].  
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The classical CD105 marker identifies cells representing 2.5% of total BM 
fraction. These cells are able to form colony-forming units and can differentiate 
into the various mesenchymal lineages [33]. A population of BM cells, selected 
for using the markers D7- FIB+ CD45- and representing 0.01% of BM cells, was 
found to be CD34- CD90+ CD105+ CD271+ STRO-1+ and have tri-lineage 
potential [34] . Similarly, CD45- CD271+ lin- BM cells also give rise to standard 
MSC cultures that are also CD105 CD90 and CD73 positive [35].  
The functional significance of these various stromal populations within the BM 
and their interactions with other cells is still to be delineated, but these cells 
appear to have major roles in maintenance of the hematopoietic niche, 
orchestrating the innate immune response and tissue repair.  
During infection and wounding, MSC, pericytes and CXCL12 abundant reticular 
cells (CAR) within the BM detect low levels of circulating toll like receptors (TLR). 
In response to this, they release Chemokine Ligand 2 (CCL-2) which acts on 
Chemokine Receptor 2 (CCR-2) of inflammatory monocytes and induces their 
immobilisation into the circulation [36].   
BM resident MSC are involved in maintenance and repair of bone and cartilage. 
Human CD105+ cells isolated from BM differentiate into osteoblasts in vivo in 
response to bone morphogenetic protein 2 (BMP-2) [33] while other studies 
suggest endogenous BM MSC migrate to sites of injury and are incorporated into 
new bone and BM stroma during fracture repair [35, 37]. Several studies have 
evaluated the role of endogenous BM derived cells in cutaneous wound healing 
with differing results [38, 39]. This work has been hampered by the fact that MSC 
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appear to be resistant to irradiation and do not expand significantly in host BM 
[40]. BM transplantations using a transgenic mouse that have a promoter 
sequence of α2(I) collagen gene linked to enhanced green fluorescent protein 
(GFP) show that BM derived cells did not participate significantly in collagen 1 
production during excisional wound healing. However, about 6% of CD45+ 
transplanted BM derived cells were producing collagen within the wound 
following bleomycin injection to induce fibrosis [39]. Parabiosis studies, where 
two animals are surgically joined together, so that their circulatory systems mix, 
also indicate that BM derived cells do not differentiate into collagen expressing 
fibroblast cells during wound healing [41]. MSC like cells have also been detected 
in the peripheral blood and were mobilised from the BM after acute burn injury 
[42]. Other studies suggest that CD29+ stromal cells capable of multi-lineage 
differentiation were mobilised into circulation on induction of burn wounds [43]. 
This mobilisation was mediated through substance P, a highly conserved 11-
amino acid neuropeptide. Blockade of substance P inhibited mobilisation of 
CD29+ stromal cells and increased wound healing time [43].  
In summary, it appears that as in vitro, MSC in vivo are a heterogeneous 
population with varying and distinct functions, with certain populations having 
roles in maintaining homeostasis and others in responding to trauma. Research 
is ongoing in this area to establish unique biomarkers for MSC. This will allow for 





1.2.3. Clinical applications of MSC therapy 
To date, multiple clinical trials have been undertaken to assess the safety and 
efficacy of MSC in the treatment of a wide-range of pathologies. So far, 156 clinical 
trials have been completed, as registered on clincaltrials.gov [44], a fourfold 
increase since 2011 [45].  
The delivery of MSC to patients appears to be relatively safe and well tolerated in 
a wide variety of conditions. Primarily, this cell population excels in 3 specific 
areas, inflammatory driven conditions such as; diabetic wound healing, graft 
versus host disease (GVHD) [46],  in tissue repair;  wound healing [47] and non-
union bone fractures and bone defects [48] and also, to some degree, in 
myocardial repair [49]. 
In the regeneration and repair of cutaneous wounds, MSC therapy holds much 
promise and several clinical studies have been completed, demonstrating 
improved wound healing after application of MSC. In a seminal paper by Falanga 
et al, autologous MSC were topically delivered to acute (n=5) and chronic wounds 
(n=8) in a fibrin spray [50]. No adverse events were observed and the wounds 
healed well [50]. Large chronic wounds (<1year) in older patients were treated 
with topically applied MSC (n=3) and healed within 5 weeks after application 
[51].  
Other clinical investigations have used composite grafts consisting of autologous 
BM MSC cultured on collagen sponges. These grafts were then applied to patients 
suffering from non-healing wounds. Complete closure of wound was recorded in 
13 of the 18 patients [52].  
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Dash et al conducted the first published controlled and randomised clinical trial 
to assess the efficacy of MSC in the treatment of chronic wounds [47]. A total of 
24 patients with non-healing ulcers were enrolled in the study and were given 
either autologous BM MSC along with standard wound dressing or standard 
dressings alone. After 12 weeks the treated wounds had decreased significantly 
compared to untreated controls. No adverse effects were reported and biopsy of 
tissue showed development of dermal cells and infiltration of inflammatory cells 
associated with progression of wound healing [47]. 
MSC have also been used in several single case studies to treat burn wounds [53] 
and radiation induced wounds [54] with good healing outcomes and no adverse 
effects reported.  
 
1.2.4. Mechanism  
Initial pre-clinical studies in mice suggested that MSC engrafted into the wound, 
based on the ability of MSC to differentiate in vitro into cells of the mesoderm 
lineage and their wound healing properties, differentiating into various skin cell 
types and helping to rebuild the wound [55, 56]. 
Sasaki et al injected (IV) 1x106 GFP+ allogeneic MSC in mice that were subjected 
to 10mm full thickness punch wounds. MSC expressed keratinocyte, endothelial 
and pericyte markers within the wound. They also showed some evidence for 
MSC transdifferentiation in vitro [55]. 
In another study, allogeneic GFP+ MSC were intradermally (ID) injected into 
wounds of normal and diabetic mice [56]. Application of MSC significantly 
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accelerated wound healing in both compared to neonatal fibroblasts or vehicle 
alone. Increased angiogenesis was noted as well as co-expression of keratinocyte 
markers and GFP, indicating potential transdifferentiation of MSC into 
keratinocytes [56]. 
Others have reported that regeneration of tissue is not through 
transdifferentiation of MSC but through cell fusion [57]. In both cases however, 
the frequency of these events is so low as to have no significant contribution. 
Furthermore, studies using conditioned media (CM) from cultured MSC have 
reported similar accelerated wound healing suggesting a paracrine effect [58]. 
While IV injection of MSC usually become embedded in the lungs or other filter 
organs such as the liver (as cultured MSC are large cells about 15-19 μm in 
diameter) and therefore cannot contribute directly to rebuilding of the wound 
[59]. Therefore, it is unlikely that transdifferentiation or cell fusion explains the 
reparative effects of MSC. 
It is now widely accepted that MSC promote wound healing predominately 
through paracrine mechanisms. MSC secrete many different cytokines, 
chemokines and growth factors which have a multitude of effects on cell 
proliferation, angiogenesis, migration of keratinocytes and fibroblasts, 
recruitment of inflammatory cells and immunomodulation [60]. Much research 
has been conducted and is still ongoing; to comprehend which growth 




1.2.4.1. Engraftment and persistence of MSC in the wound 
The persistence of MSC in the wound is dependent on several factors, such as 
allogeneicity and administration route. A study by Chen et al demonstrated that 
similar amounts of topically applied allogeneic or syngeneic GFP+ MSC persisted 
in the wounds at d-7, d-14 and d-28, while there was a marked decrease in 
allogeneic fibroblasts [61]. Both allogeneic and syngeneic MSC persisted until 4 
weeks with 75% turnover after 1 week. Other studies have reported a difference 
in persistence between allogeneic and syngeneic MSC. Zangi et al delivered MSC 
by intraperitoneal (IP) injection and demonstrated that MSC persisted for 20 d in 
allogeneic recipients and 40 d in syngeneic recipients, while injected fibroblasts 
lasted only 10 d in allogeneic animals and 40 d in syngeneic animals [62]. 
Delivery of MSC by IV injection usually results in much lower persistence of MSC 
[63]. Whether this is because ID injection may infer some protection from 
initiating an immune a response, compared to IV injection or whether the tissue 
provides a source for cell attachment is not known. It may also be a result of MSC 
becoming entrapped in other organs such as the lungs [59]. 
 
1.2.4.2. MSC Angiogenic response 
One of the key therapeutic properties of MSC is their ability to induce 
angiogenesis, that is the sprouting of capillaries from existing blood vessels [64].  
MSC have been used to treat both coronary and peripheral vascular ischemia, 
increasing vascular density and perfusion downstream of the occlusion [65-67]. 
In one study, digital capillaries were increased in number and size, along with a 
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reduction in vascular resistance in the affected extremities following the 
administration of MSC [66].  
MSC have been commonly utilised in ischemic hind limb animal models, inducing 
revascularisation and limb salvation. Transplantation of human MSC 1 to 7 d after 
ligation of the proximal femoral artery significantly increased laser Doppler 
perfusion index in a mouse model [68]. Histological examination illustrated 
increased vessel density as compared to controls [68]. In another study, up to 
60% of hind limbs were salvaged with application of human MSC in nude mice 
[66]. 
Several other studies support the premise that MSC induce tissue repair and 
improve cardiac function in the setting of ischemia. After 5 hours of ligation of 
the coronary artery, 5x106 MSC were IV injected into Lewis rats. Capillary density 
was increased and cardiac infarct size was smaller with associated improved 
cardiac output [69]. In a model of cerebral artery occlusion, MSC treatment 
increased Angiopoietin (a factor involved in the production of blood vessels) and 
its receptor, Tie 2, in the ischemic border. Induced inhibition of either Vascular 
Endothelial Growth Factor (VEGF) receptor 2 or Tie 2 in mouse brain endothelial 
cells significantly reduced tube formation in an angiogenic assay with MSC CM 
[70]. 
MSC therapy may also have an angiogenic role in cutaneous wound healing. Mice 
with excisional wounds treated with a topical application of autologous MSC, had 
increased capillary density after 1 week, as assessed by CD31 immunofluorescent 
staining, with enhanced vascularity observed in whole section mounts of the 
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wound [56]. The transplanted MSC were situated in close proximity to blood 
vessels occupying perivascular locations. 
Subsequent studies have confirmed that treatment of wounds with MSC CM 
increased CD31+ vascular cells and accelerates wound closure [58] further 
demonstrating that angiogenic potency may also be derived through a paracrine 
factors. MSC CM contains a variety of growth factors associated with angiogenesis 
such as VEGF, endothelial growth factor (EGF), CCL-2,  Matrix metalloproteinase 
9 (MMP-9), angiopoietin 1, 2 and 3, Insulin like growth factor (IGF), CXCL10 and 
CXCL16 as well as a host of other factors [58, 71].  
The microenvironment in which the cell resides also affects cytokine production. 
Under hypoxic conditions or in reaction to tumour necrosis factor alpha (TNFα), 
MSC secrete nearly two fold more VEGF mediated through nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) activation [72]. In vitro, co-
culture and tube formation assays show that MSC interact with endothelial cells 
and release soluble factors that mediate endothelial cell proliferation, migration 
and protect these cells from hypoxia induced apoptosis [71, 73, 74]. In particular, 
Interleukins-6 (IL-6) and IL-8 secretion are increased during TNFα stimulation 
of MSC and depletion of these factors from MSC CM abrogated MSC induced limb 
reperfusion effect in a rat ischemic hind limb model [75]. The chemokines IL-6 
and IL-8 induced migration and homing of endothelial progenitor cells in vivo.  
It is clear that angiogenesis is driven by a variety of growth factors and several 
knockout (KO) studies have been performed to further delineate this mechanism. 
Knockout of α6β1 integrin adhesion receptor on MSC was found to reduce 
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angiogenic sprouting of endothelial cells [76]. Presumably, this integrin is 
required for interaction and support of developing tube network. In another 
study, knockdown of VEGF in MSC was found to abolish in vivo protective effects 
of MSC form hyperoxia induced lung injury [77]. Upstream VEGF is regulated to 
some extent by microRNA 377 (miR377), knockdown of miR377 increased VEGF 
while over-expression of mir377 subsequently reduced VEGF protein, which was 
associated with reduced in vitro tube formation, in vivo vessel density and 
cardiac function in a myocardial infarct (MI) model. Similar studies have been 
conducted in ischemic kidney rat models showing that VEGF knockdown in MSC 
reduces microvessel density [78]. 
 
1.2.4.3. MSC Immunomodulatory response 
 
 MSC possess a unique ability to modulate immune responses, through a variety 
of mechanism involving T-cell inhibition, expansion of regulatory T-cell 
populations, inhibition of natural killer cells (NK) and polarisation of 
macrophages towards a more reparative phenotype.  
The first step in this process involves the activation of MSC. MSC alter their 
response towards a pro-inflammatory pathogen clearance or an 
immunosuppressive phenotype based on the inflammatory environment and 
specific TLR stimulation. In particular pro inflammatory cytokines TNF-α, 
interferon-gamma (IFN-γ) and interleukin 1 beta (IL-1β) induce 
immunosuppressive properties [79]. Recent data also suggests that MSC 
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therapeutic efficacy can be enhanced by pre-stimulation with these factors [75, 
80] 
T-cell proliferation 
Most of the current knowledge about MSC immunosuppressive effects has been 
garnered from in vitro co-culture studies which show MSC are able to inhibit T-
cell proliferation [81]. T-cells are part of the adaptive immune system which is 
responsible for antigen specific response and development of immunological 
memory [82]. Several studies demonstrate inhibition of T-cell proliferation of 
both CD4+ and CD8+ through the release of soluble factors such as hepatocyte 
growth factor (HGF) heme oxygenase (HO), Indoleamine-pyrrole 2,3-
dioxygenase (IDO) Nitric oxide (NO), Prostaglandin E 2 (PGE2) and transforming 
growth factor beta (TGF-β) in a dose dependent manner [82, 83]. However, 
important differences exist between species, for instance in human cells IDO is 
required for inhibition of T-cell proliferation while in mice MSC utilise NO to 
suppress T-cell proliferation demonstrated by the addition of NO synthase (NOS) 
inhibitor NG-Monomethyl-L-arginine, monoacetate salt (L-NMMA) [84]. 
Upon stimulation MSC release chemoattractant cytokines such as CXCL9, CXCL10 
and CCL-2 which bring a variety of immune cells into contact with MSC, allowing 
for direct cell contact and modulation [85]. 
Another mechanism of T-cell modulation is through Fas induced apoptosis. 
Akiyama et al elegantly demonstrated that MSC induced apoptosis in T effector  
cells through Fas ligand-/Fas system which was dependent upon CCL-2 [86]. 
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CD4+ T-cells can either differentiate into Type 1 T helper cells (Th1) with a pro-
inflammatory cytokine expression, Th2 that have anti-inflammatory profile or 
Th17 that secrete IL-17 and are largely associated with autoimmune and allergic 
responses. A body of evidence now suggests that MSC are also able to shift this 
balance of helper T-cell subtypes from a Th1 or Th17 driven response to a 
reparative Th2 profile [85, 87]. Th1 cells secrete TNFα and IFNγ, promoting 
further inflammatory responses, MSC act like a damper, promoting a Th2 
phenotype and increasing the secretion of key anti-inflammatory mediators such 
as IL-4 and IL-10 [87]. Conversely, in Th2 driven pathologies, MSC can act to skew 
the balance towards a Th1 response, increasing Th1 associated cytokine release 
and decreasing Th2 related cytokines [85]. In response to TNFα and other pro-
inflammatory molecules, cell contact dependent expression of Cyclooxygenase-2 
(COX-2) in MSCs initiates PGE2 synthesis. PGE2 is then secreted and binds to EP4 
receptors inhibiting Th17 differentiation [88]. 
The T-cell population is made up of CD8+ effector cells and CD4+ T helper cells. 
Among the latter population, are T- cell regulator (T-reg) cells, which function as 
suppressor cells, damping down the T-cell effector response and regulating the 
immune response, preventing autoimmune diseases. This population is 
characterised by the expression of the forkhead box P3 (FoxP3) transcription 
factor. MSC can induce T-cells towards this regulatory phenotype, the expansion 
of which requires MSC secretion of PGE2 and TGF-β [85]. This ability to expand 
the T-reg population may in part explain MSC efficacy in preventing graft versus 




Inhibition of DC maturation 
MSC play a key role in modulating dendritic cells (DC). These cells are responsible 
for initiating the adaptive immune response. DC, upon engulfing a pathogen 
migrate to the lymph node where they present the antigen to activate naive T-
cells. MSC can interfere with several of these functions. Cultures of DC and MSC 
show down regulation of key DC maturation markers such as MCHII, CD80 and 
CD86 [89] which are involved in antigen presentation and co-activation of T-cells. 
MSC also inhibit the migration of DC to the lymph nodes through down regulation 
of chemokine receptor CCR-7 [89]. Similarly to macrophages, DC can be directed 
towards a pro or anti-inflammatory phenotype, the latter having increased 
secretion of IL-10, reduced levels of pro inflammatory IL-12 along with enhanced 
phagocytic activity and reduced ability to activate CD4+ T-cells [90]. 
Cell contact dependent mechanism  
MSC employ several cell contact dependent mechanisms to regulate immune 
responses. Expression of vascular cell adhesion molecule 1 (VCAM-1) and 
intracellular adhesion molecule 1 (ICAM-1) by MSC are required for interaction 
with T-cells, both of which are upregulated upon stimulation with inflammatory 
cytokine such as IFNγ and to some extent TNFα [91] 
Inhibition of NK activation 
MSC and NK cells interact in vitro and MSC strongly inhibit IL-2 induced cell 
proliferation through IDO and PGE2 pathways. Furthermore, MSC co-culture 
reduce NK activation, cytokine release and induce down regulation of NK key 




During acute phase of inflammation, Neutrophils infiltrate the wound using 
oxidative molecules to kill pathogens as well as having a phagocytic role. How 
MSC modulate neutrophil activation is complex, they can reduce the influx of 
neutrophils in an endotoxin induced lung injury model [93] and  can  also protect 
neutrophils from apoptosis through IL-6 - Signal transducer and activator of 
transcription 3 (STAT3) mechanism preventing the degranulation and 
subsequent oxidation burst [94]. MSC may also have secondary inhibitory effects 
based IL-10, increasing IL-10 from other immune cells, such as macrophages, to 
inhibit rolling, adhesion and trans-epithelial migration of neutrophils [95] and 
may prevent neutrophil re-entry into the wound cutting off the negative feedback 
loop in response to macrophage stimulation. 
Macrophage polarisation 
In wound healing the main myeloid effector cells are macrophages, an essential 
component of the immune system. Macrophages can be generally classified into 
two broad sub types, the classically activated M1 macrophages and the 
alternately activated M2 type. M1, macrophages are characterised as pro 
inflammatory, secreting large amount of TNFα, NO and reactive oxygen species 
(ROS). M2 macrophages are characterised as reparative, with greater phagocytic 
activity, reduced levels of TNFα and increased secretion of anti-inflammatory 
cytokines such as IL-10, TGF-β and Arginase 1. Several studies demonstrate that 
MSC can skew the macrophage phenotype towards a more reparative M2 
phenotype [20, 96, 97]. 
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In a seminal paper by Nemth et al (2008), application of MSC isolated from BM 
(BM-MSC) reduced mortality in a mouse model of sepsis [96]. TNFα was reduced 
and IL-10 was increased in MSC administered mice compared to control treated 
mice. Isolation of monocytes from septic lungs showed that MSC treated animals 
had more monocytes expressing IL-10. Through a series of blocking and knock 
out studies they determined that PGE2 secreted from MSC bound to EP2 and EP4 
receptors on macrophages and monocytes. This subsequently reprogrammed the 
macrophages, increasing IL-10 secretion. TNFα binds to TLR4 and TNFR1 on MSC 
resulting in the translocation of NF-κB into the nucleus in a NO dependent 
fashion. Subsequent binding initiated downstream COX-2 production, which is 
required for synthesis of PGE2 [96].  
Stimulation of MSC by inflammatory mediators such as IFNγ and TNFα, induce 
human MSC to express IDO. This catalyses the degradation of tryptophan (a key 
amino acid required for bacteria) into kynurenine. As previously discussed, the 
metabolites of tryptophan degradation inhibit T-cell proliferation, but also play 
a role in differentiation of monocytes towards an M2 (reparative) phenotype 
[98]. Inhibition of IDO enzymatic activity in MSC monocyte co-culture 
significantly reduced IL-10 compared to control co-cultures [98]. Depletion of 
monocytes from MSC/ peripheral blood mononuclear cell (PBMC) co-cultures 
significantly increased T-cell proliferation. Thus, it appears that the increased M2 
population also has bystander effects on other cells such as T-cells, amplifying 
the immunosuppressive effects of MSC [98, 99]. 
Crucially, in vitro experiments demonstrated that MSC/macrophage cell contact 
was required for increased IL-10 production [96]. Similar in vitro experiments 
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show greater polarisation towards M2 phenotype when cells are co-cultured as 
opposed to using MSC CM, resulting in greater cell surface receptor expression of 
CD206 and increased gene expression of TGF-β1 and Arginase 1 [97]. 
However, in some studies of human MSC, cell contact was not required for 
induction of CD206 in human macrophages [20]. Both co-culture and transwell 
culture of PBMC and gingiva derived MSC were able to increase CD206 
expression in ~30% of CD14+ cells compared to controls. This may well be a 
function of MSC cell source or inflammatory state as in a study by Hematii et al, 
where transwell co-culture was able to induce CD206 expression, nevertheless it 
was not as efficient as co-culture [100].  Induction of CD206 could be blocked by 
either IL-6 or Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
neutralising antibodies [20]. Interestingly and in support of MSC 
activation/licensing (Section 1.2.4.3), addition of MSC to monocytes only 
modestly increases IL-10, it is not until monocytes are stimulated with 
Lipopolysaccharides (LPS) that significant increase in IL-10 is induced by MSC 
[20]. TNF α is significantly reduced in monocyte/MSC co-culture stimulated with 
Phorbol 12-myristate 13-acetate (PMA). Other soluble factors increased during 
co-culture are CCL-2, CCL8, IL-6, CXCL1 and GM-CSF [20]. Functionally, 
phagocytic activity of these macrophages increased after co-culture with MSC 
[100]. 
Tumour necrosis stimulating factor 6  
In conjunction with the other soluble factors outlined, such as PGE2, IDO and NO, 
TNF stimulated gene 6 (TSG-6) is another potent Immunomodulatory factor that 
is secreted by MSC. TSG-6 is a 30kDa hyaluronan binding protein, secreted by 
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many cells, which has diverse roles in physiological and pathological processes 
such as inflammation. TSG-6 has a variety of biologic effects such as inhibition of 
neutrophil migration, modulation of protease network and binding of a variety 
proteins and glycosaminoglycan such as heparin, aggrecan and hyaluronan 
[101]. 
TSG-6 is involved in MSC accelerated cutaneous wound healing [102]. Analysis of 
wounds showed a significant decrease in macrophage derived TNFα in MSC 
treated wounds, which was not observed in MSC with TSG-6 knock down. 
Treatment with MSC reduced TGF-β1 and increased TGF-β3 concentration 
within the wound, an unbalancing that is thought to result in an anti-fibrogenic 
effect.  
 
Figure 1.6 The mechanism of MSC immunomodulation 
 Several mechanisms have been identified that contribute to macrophage repolarisation by MSC. 
TNFα stimulates MSC to produce TSG-6 and COX-2 which inhibit inflammatory macrophages and 





Other studies have demonstrated this effect in other models of inflammation 
such as cornea chemical injury [104]. Notably, TSG-6 was also a key marker of 
efficacy as opposed to MSC tri differentiation potential which bore no correlation 
to in vivo efficacy [104]. 
Mechanistically, TSG-6 binds to CD44 receptor on macrophages. Upon binding, 
TLR2 activation of NF-κB and subsequent release of pro inflammatory cytokines 
such as TNFα is blocked [105]. This inhibits the negative feedback loop by 
reducing the stimulation of surrounding cells of proinflammatory cytokines and 
subsequent further recruitment of neutrophils and macrophages.  
 
1.2.5. Source of MSC 
Currently, one of the major questions in the field of MSC therapy for tissue repair 
is the role of MSC source. For the majority of these wound healing studies BM 
MSC have been utilised. However, from a clinical prospective BM isolated MSC 
have several drawbacks. Isolation of BM is quite an invasive and painful 
procedure. Generally, a large 4 mm pin is inserted through the skin, which 
forcefully punctures the iliac crest. The inner mandrel is removed and the BM is 
aspirated. Using this method a total of 10 ml of BM aspirate can be obtained 
without diluting it with peripheral blood [106]. To obtain adequate amounts of 
cells multiple punctures and aspirates must be performed. In cases of severe 




MSC reside in multiple niches in the connective tissue and in a perivascular 
locations and adipose tissue is another potential source of MSC. With over 
400,000 liposuctions performed in the United States each year, adipose tissue 
presents a readily available source of  MSC [109]. The tissue is first digested using 
collagenases and then centrifuged at high speed to separate the cells from the fat. 
After centrifugation, the floating lipid rich tissue is removed and the pelleted 
stromal vascular fraction (SVF) can be observed. This can then be used directly 
as SVF or else is further cultured and characterised before application. From 1g 
of tissue, 40-80 x106 MSC can be isolated making it a much more efficient process 
than BM isolation.   
 
1.2.6. ASC vs MSC Comparative studies 
As adipose derived MSC (AD-MSC) are a much more clinically translatable source 
of MSC, much research is now being conducted using AD-MSC. Several studies 
have corroborated their efficacy in pre-clinical models of wound healing [110-
113]. However, there is still a paucity of equivalency studies that have examined 
the efficacy and mechanism of action. Recent studies suggest that AD-MSC are 
more immune suppressive than BM-MSC taken from aged matched donors [114]. 
In vitro studies showed no difference in differentiation capacity and expression 
of MSC markers barring CD34 (AD-MSC had a significantly higher expression). Co 
culture of MSC with PBMC demonstrated a greater ability of AD-MSC to inhibit 
PBMC proliferation, increasing IL-10 in stimulated PBMC MSC co-cultures. 
Differences were also observed in IL-12 and TGF-β1 in unstimulated MSC 
cytokine secretion [114]. 
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In a pig model of cutaneous wound healing of excised skin both AD-MSC and BM-
MSC enhanced wound repair, there was no statistical difference between the 
groups however, sample size was small n=2 per time point and the study was 
limited in terms of mechanistic insights [115]. Larger studies are required to 
determine the role of cell source in terms of efficacy using matched donors in 
clinically relevant models. 
 
 
1.3.  The role of CCL-2 in MSC mediated inflammation 
resolution within the wound  
 
Chemokines are small proteins used to signal extracellularly throughout the 
body, primarily for the purpose of cell recruitment. Chemokines are vital in 
orchestrating the wound healing process and are required for the biological 
processes of angiogenesis and tissue remodelling, but they also have detrimental 
roles such as in fibrosis. Monocyte chemoattractant protein 1 (CCL-2), renamed 
under the CC ligand (CCL) nomenclature, belongs to a family of chemokines called 
CC chemokines, due to similarities in structure based on the positioning of two 
highly conserved cysteine residues at the N terminus. All chemokines have a 
similar 3-dimensional structure, however their amino acid sequence may differ 
as much as 90% [116, 117]. CCL-2 consists of three distinct domains; a highly 
flexible N-terminal domain attached to two disulphide bonds, followed by a long 
loop leading into three anti-parallel β pleated sheets over which the C terminal α 
helix domain extends. 
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The chemokine CCL-2 first discovered in mouse fibroblasts stimulated with 
Platelet-derived growth factor (PDGF) [118] was later determined to be the same 
gene product as CCL-2 in humans.  Subsequently, several other members of CCL 
family have been identified including; CCL8 (or its old naming convention MCP-
2 ) CCL7 (MCP-3) CCL13 (MCP-4) CCL12 (MCP-5) [119]. CCL-2 is a 15 kDa 
heparin binding protein [120] thought to be involved in many pathologies and 
biological processes including Inflammation, bone re-modelling, angiogenesis, 
atherosclerosis and tumour development. Accordingly, a variety of cells produce 
and secrete CCL-2 such as MSC, monocytes, macrophages, endothelial cells, 
epithelial cells,  fibroblasts and some types of tumour cells [58, 118, 120-123].  
 
1.3.1. CCL-2 induced Monocyte, macrophage chemotaxis 
Induced chemotaxis CCL-2 is initiated upon CCR-2 binding and detection of CCL-
2 gradient. Polarisation of the cell in the direction of the stimuli allows for the 
formation of the leading edge pseudopod through activation of G-protein coupled 
receptor via Gi alpha sub unit protein whereas G12/13 activation is required for 
uropod formation at the rear. This binding of CCL-2 drives a cascade of signalling 
events, which alter cellular structures and drive cell migration. 
Upon protrusion of lamellipodia, integrin activation occurs further stabilising the 
protrusion. Integrin activation is mediated through Protein kinase C (PKC), Rap1 
and Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI-3K) signalling pathways 
leading to integrin clustering and recruitment of structural proteins to focal 
adhesion sites to drive motility [124]. In the rear of the cell, adhesion sites are 
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disassembled and retracted. Several signalling pathways mediate this process 
including myosin II, sarcoma (Src)/ Focal adhesion kinase (FAK)/extracellular 
signal–regulated kinases (ERK) and Rho [125]. 
 
1.3.2. CCL-2 in wound healing 
The chemokine CCL-2 has a pivotal function in the progression of normal wound 
healing. Mice deficient for CCL-2 had poor revascularisation in a skin flap injury 
model and at day (d) 10 had significantly reduced monocyte/macrophage 
recruitment as well as a reduced angiogenic response [126]. CCL-2 peaked in 
mouse excisional wounds at 24 h, significantly reducing by d-3 and disappearing 
after d-7 [127]. Treatment of wounds with anti CCL-2 reduced macrophage 
recruitment into the wounds by 46% on d-3. Topical application of recombinant 
CCL-2 (5ng) increased macrophage recruitment by nearly 24%. Re-
epithelialisation however, was only marginally improved with a slight increase 
in wound strength [127]. 
Recruitment of Ly6C hi monocyte/macrophages (M1) is CCL-2 dependent, when 
anti-CCL-2 was administered in spinal cord injury, M1 recruitment was 
diminished. However, this did not affect recruitment of Ly6C low CCR-2 negative 
monocytes from which, it is believed, the M2 population is derived [128]. 
Depletion of CCR-2+ monocytes also inhibited recovery from spinal cord injury 
indicating that the CCL-2/CCR-2 axis plays a fundamental role in orchestrating 
the recruitment of various cell populations, which are crucial for the orderly 
transition through the phases of wound healing [129].  
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1.3.3. The role of CCL-2 in MSC paracrine function 
One of the first (and widely cited) papers to describe paracrine function of MSC 
in wound healing [130] demonstrated that MSCs secrete a wide variety of 
cytokines including CCL-2. However, its role has never been defined or robustly 
investigated. MSC CM induces monocyte and keratinocyte migration in a dose 
dependent manner [58] and also induces endothelial cell migration and 
proliferation [58]. Blocking of VEGF and fibroblast growth factor (FGF) in CM 
with neutralising antibodies only partially reduced endothelial cell proliferation 
[130]. In vivo, MSC CM also accelerated wound closure in sutured punch wound 
mouse model [58]. Chen et al demonstrated increased presence of F4/80, CD68+ 
macrophages and CD31, c-kit+ endothelial cell infiltration into the treated 
wounds [58]. This makes biological sense, as classically, CCL-2 is known as a 
potent chemotactic factor for monocytes/macrophages. 
Under unstimulated conditions, MSC secrete significant quantities of CCL-2 
(about 0.2-2 ng/ml) [20, 131]. When stimulated with TNFα, MSC secrete up to 10 
fold more CCL-2 and were found to recruit Ly6C hi CD11b monocytes, F4/80 
macrophages and CD11b+Ly6G+ neutrophils in a CCR-2 dependent manner in 
vivo [132]. When cultured with macrophage CM, MSC displayed an altered gene 
expression with a fourfold increase in CCL-2 expression. MSC CM enhanced 
monocyte migration and this could be attenuated with magnetic bead CCL-2 
depletion of MSC CM [133]. 
MSC are efficacious in cutaneous wound healing and have an immune 
modulatory effect on both the innate and adaptive immune systems. MSC can 
induce an M2 like phenotype when co-cultured in vitro, giving rise to increased 
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CD206 expression, increased IL-10, IL-6 secretion, reduced TNFα and decreased 
ability to induce Th-17 cell expansion [20]. It is important to highlight that while 
CCL-2 is classically associated with the innate immune system, there is a 
significant lack of research investigating the role of CCL-2 in MSC modulation of 
the innate immune system. However, its modulation of the adaptive immune 
system has been well described in the literature. 
 
1.3.4. Complexity and redundancy in CCL-2 signal transduction 
Despite a wealth of literature demonstrating CCL-2 as a potent inducer of the 
recruitment of monocytes/macrophages, its role in MSC modulation of wound 
healing is still not clear due in part to the complexity and redundancy of 
downstream signalling cascades, posttranslational modifications and decoy 
receptors involved in CC signalling [134-136]. Its role remains an important 
question to be answered for further development of this therapy. 
 
1.4. Thesis outline 
 
 
The role of cell source in clinically relevant animal model of burn wound 
healing 
As outlined in section 1.2.3 there is a substantial amount of pre-clinical and 
clinical studies that have demonstrated BM-MSC accelerate wound healing. 
However, as a clinical source of cells, BM is not ideal. AD-MSC are isolated from 
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adipose tissue and this represents a very large and easily obtainable source of 
these cells [109]. There is growing evidence that AD-MSC also have a therapeutic 
effect in both cutaneous wound healing and other applications [109, 111, 113, 
137]. However, there is a little research exploring the role of cell source in a 
clinically relevant model of cutaneous wound healing or burn wound healing. In 
this study, we compare the efficaciousness of allogeneic AD-MSC and BM-MSC 
derived from donor matched animals in a clinically relevant large animal model 
of burn wound healing. 
 
Improving efficacy of MSC through pre-stimulation with inflammatory 
cytokine TNFα 
MSC both promote and reduce inflammatory responses under certain 
circumstances (section 1.2.4). In certain models, MSC activation with pro-
inflammatory cytokines was necessary to induce its immune modulatory 
properties. MSC pre-treated with either or both TNF and IFNγ have 
demonstrated enhanced reduction in TNFα and increased M2 polarisation. While 
this method of MSC pre-stimulation has shown promise, it has not been 
attempted in a cutaneous injury model. We performed pre-stimulation of MSC 
with TNFα to determine if this pre-treatment would enhance the efficacy of these 
cells in a clinically relevant large animal model of burn wound healing and also 





The role of CCL-2 CCR-2 axis in MSC mediated cutaneous wound healing 
In cutaneous wound healing, monocyte/macrophages are the dominant 
leukocyte effector cell secreting greater quantities of both pro and anti-
inflammatory cytokines compared to other leukocyte subsets [138] and while 
CCL-2/CCR-2 axis is classically associated with the innate immune system, to 
date the role of MSC secreted CCL-2 in cutaneous wound healing has not been 
addressed. Furthermore, TNFα pre-treatment has shown promise in enhancing 
 
 
Figure 1.7 Thesis outline 
In this work, efficacy studies of MSC therapy in a clinically relevant porcine model of burn wound 
healing were performed. To explore the mechanism in detail, in particular the role of CCL-2, a murine 




the immune-modulatory properties of MSC and is (as outlined in section 1.3.3) 
a significant inducer of CCL-2 secretion in MSC. The apparent redundancy of 
chemokine signalling poses some challenging and complex questions as to the 
nature and roles of those individual chemokines. If we wish to further refine our 
understanding of its mechanism and enhance its efficacy, it is necessary to 
unravel the complexities of chemokine promiscuity and apparent redundancy. 
To this end, we used CCL-2 deficient MSC to determine the role of CCL-2 
signalling in MSC treated wounds with and without TNFα pre-treatment.  
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2. General materials and methods 
 
 
In this chapter general methods and materials are described that are common to 
several chapters. Specific methods used in each study are detailed in each 
corresponding chapter. 
 
2.1. Cell culture 
 
All the cell lines were cultured in a class II biohazard safety cabinet at 37°C under 
5% CO2 atmosphere. Cells unless otherwise stated were maintained in Dulbecco's 
Modified Eagle Medium alpha modification (α-MEM) media (Sigma Aldrich, 
Ireland) supplemented with 10% foetal bovine serum (FBS, Life technologies) 
and antibiotic antimycotic solution (Sigma Aldrich, Ireland) containing penicillin 
(100 units/ml) streptomycin (0.1 mg/ml) and amphotericin B (0.25 μg/ml). For 
passaging (p), cells were washed once with phosphate buffer saline (PBS, Sigma 
Aldrich, Ireland) and detached from the tissue culture flask by incubating at 37°C 
in 0.25% trypsin/ Ethylenediaminetetraacetic acid (EDTA) solution (Life 
technologies) until cells had detached. Trypsinisation was followed by, 
neutralisation of trypsin with equal volume of serum supplemented media. Cells 
were then recovered by centrifugation at 500 g for 5 min, followed by re-
suspension in appropriate volume of cell growth specific medium. 
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2.1.1. Macrophage cell culture 
Murine macrophages were obtained from American type culture collection 
(ATCC). RAW 264.7 macrophage cell line was established from a tumour induced 
by Abelson murine leukemia virus on Balb/c mice.  RAW cells are cultured in 
Dulbecco's Modified Eagle Medium (DMEM, Sigma Aldrich, Ireland) 
supplemented with 10% FBS and 1x antibiotic antimycotic. 
 
2.2. Flow cytometry analysis of cell surface antigens 
Flow cytometry was used to analyse the level of MSC associated surface markers 
present to characterise isolated MSC populations. Expression of associated MSC 
markers was evaluated to ensure pure population of stromal cells. Cultured cells 
at P2-3 were washed once with PBS and detached from the tissue culture flask 
by incubating at 37°C in 0.25% trypsin/EDTA solution until cells had detached. 
Trypsinisation was followed by, neutralisation of trypsin with equal volume of 
serum supplemented medium (10% FBS). Cells were then recovered by 
centrifugation at 500 g for 5 min, followed by re-suspension in PBS and aliquoted 
out into several tubes containing 1x105 cells for primary antibody staining. Cells 
were centrifuged and re-suspended in 100 μl of diluted antibody in Fluorescence-
activated cell sorting (FACS) buffer (PBS containing 1% FBS and 0.1% EDTA) and 
incubated for 1h at 4°C cells were then washed in PBS centrifuged and re-
suspended in 100 μl of secondary antibody solution for 30 min in the dark at 
room temperature (rt). Cells were then re-suspended in 100 μl FACS buffer and 
analysed on flow cytometer (BD FACSARIA II running BD FACSDIVA flow 
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cytometry software v6.1). Cell populations were gated to remove debris and dead 
cells from analysis and control isotypes were used to determine positive cell 
populations. 
 
2.3. Animal experimental models 
All animal experiments performed were approved by University College Cork 
Animal Experimentation Ethics Committee (AEEC) and project authorisation was 
granted by the Health Product Regulatory Authority (HPRA), the governmental 
regulatory body for experimental animal studies in Ireland. Animal experiments 
are detailed in chapter specific methodology (porcine burn induction, section 
4.2.1 and murine excisional wounding, section 6.2.8) 
 
2.4. CCL-2 deficient mice 
Three breeding pairs of CCL-2 knockout mice (CCL-2tm1Rol) were obtained from 
JAX laboratories (Unites States). CCL2 -/-  mice were created by introduction of a 
small deletion and an in frame stop codon created in exon 1 [139]. A PGK-
neomycin resistance cassette was also inserted into exon 2 and the construct was 
electroporated into 129S4/SvJae derived J1 embryonic stem cells [139]. 
Correctly targeted embryonic stem cells were injected into C57BL/6 blastocysts. 
The resulting chimeric animals were crossed to C57BL/6 mice, and then 
backcrossed to C57BL/6 for ten generations. Mice that are homozygous for the 
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targeted mutation are viable, fertile, normal in size and do not display any gross 
physical or behavioural abnormalities [139]. 
2.5. Wound healing image analysis 
 
Wounds were imaged with a graduated ruler, using a Canon DSLR camera, at 
various time points. Images were imported into ImageJ image analysis software 
(National institute of health, USA) (v1.48g) where wound area was calculated and 
expressed as a percentage of original wound area at d-0. Using the following 
formula: [(total section length – unepithelialised length)/total section 
length]x100 [140]. 
 
2.6. Immunostaining of wound tissue sections 
Tissue samples were rinsed with chilled PBS, followed by immediate fixing with 
4% paraformaldehyde (PFA, Sigma Aldrich, Ireland) for 1 h (or overnight (o/n) 
for thicker porcine tissues) at 4°C. Tissue samples were then rinsed in PBS and 
stored o/n at 4°C in 15% sucrose followed by 30% sucrose o/n to dehydrate 
tissues and reduce ice crystal artefacts.  Samples were then embedded into the 
optimal temperature cutting compound (OCT, Cellpath, UK), and frozen 
immediately at -80°C. Embedded tissue samples were cut at 10 μm slices onto 
Superfrost plus glass slides (Thermo Fisher Scientific, UK). Slides were stored at 
-80°C until ready to be stained.  
Slides were removed from the freezer and allowed to come to room temperature 
for 30 min. Sections were then rehydrated in PBS for 10 min followed by blocking 
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for 1 h in 10% normal goat serum and PBS + 0.1% Tween 20 (Thermo Fisher 
Scientific, UK) (PBST). Primary antibodies were diluted at various concentrations 
(see chapter specific methods) in 1% bovine serum albumin (BSA, Sigma Aldrich, 
Ireland) in PBST and 100 μl of antibody solution was applied to each section. 
Slides were incubated o/n at 4°C in a humidified chamber. Slides were then 
washed 3x in PBST 0.1% for 5 min followed by application of secondary antibody. 
Secondary antibodies were diluted in 1% BSA in PBST and 100 μl was applied to 
each tissue section. Slides were incubated at rt for 1 h in the dark humidified 
chamber. Slides were washed 3x in PBST for 5 min and stained with 4',6-
diamidino-2-phenylindole (DAPI, Sigma Aldrich, Ireland) at final concentration 
of 1ug/ml for 10 min. Slides were again washed 3x in PBS for 5 min and mounted 
with coverslip using immunomount (Thermo Fisher Scientific, UK). 
 
2.7. Histology 
Harvested tissue samples were fixed overnight in 4% PFA at 4°C. Next day, 
samples were then processed in automatic benchtop tissue processor 
(Histokinette, Leica, Germany) overnight and embedded in paraffin blocks. 
Sections 10 μm in thickness were cut from the paraffin blocks and plated on 
charged glass slides. These slides were then heated overnight at 60°C to remove 
excess paraffin and then deparaffinised by 2x washes in xylene for 3 min, 
followed by 3 min in 1:1 xylene/ethanol solution. Slides were cleared in series of 
graded alcohol changes. Slides were washed 2x for 3 min in 100% ethanol, 1x 3 
min in 95% ethanol and 1x 3 min in 75% ethanol followed by a 3 min in 50% 
ethanol. Slides were then placed under running tap water for 10 min prior to 
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further staining using Hematoxylin & Eosin (Sigma Aldrich, Ireland)or Tri-
chrome staining (Abcam, UK). 
 
2.7.1. Hematoxylin and Eosin staining 
Deparaffinised slides stained with Mayer’s Hematoxylin (Sigma Aldrich, Ireland) 
stain for 15 min followed by 15 min rinsing in cold tap water. Slides were then 
immersed in eosin (Sigma Aldrich, Ireland) for 30 s, dehydrated through series 
of alcohol changes, then cleared in xylene prior to mounting with distyrene, 
plasticiser, and xylene (DPX, Thermo Fisher Scientific, UK) and cover slipped.   
2.7.2. Trichrome staining 
Slides were first deparaffinised and Trichrome staining was performed using a 
kit purchased from Abcam (UK). The slides were heated in Bouin’s solution for 
15 min at 56 °C. Slides were then rinsed and nuclei stained with Hematoxylin for 
5 min. Cytoplasmic and muscle tissues were then stained with scarlet acid 
Fucshin followed by counter staining of collagens with Aniline Blue before 
rinsing with acetic acid, dehydrating in ethanol, clearing in xylene and mounting 
with DPX and coverslip. 
 
2.8. Quantitative Reverse-Transcription PCR 
RNA was isolated from wound samples using rotar stator (IKA, Germany) in a 
solution of phenol, guanidine isothiocyanate (Qiazol, Qiagen, UK) for 1 min. RNA 
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purification was then performed using RNAeasy universal kit (Qiagen, UK) as per 
manufactures instructions.  
Purity (A260/A280) and concentration of isolated RNA was measured using 
Nanodrop spectrophotometer (Thermo Fisher Scientific, UK). Integrity of RNA 
was assessed using denaturing agarose gel electrophoresis and ethidium 
bromide staining. Only high purity (A260/A280 >1.8) RNA samples that had sharp 
bands of 28s and 18s ribosomal RNA (rRNA) and apparent 2:1 ratio were used.  
RNA (1 μg) was reverse transcribed into cDNA using Qiagen RT2 First Strand Kit 
(UK). This was then used for each qRT-PCR (Real-Time Quantitative Reverse 
Transcription PCR) reaction with RT2 SYBR Green Mastermix containing Hotstart 
DNA Taq polymerase (Qiagen, UK). This was added to RT2 profiler array (Qiagen, 
UK) Data was analysed using the ΔΔ CT method, quantification was calculated in 
relation to 18s expression in each sample calculated before 35 cycles. Both 
positive, negative and genomic DNA contamination controls were included in the 
assays. The minimum information for publication of quantitative real-time PCR 
experiments (MIQE) guidelines were followed as described by Bustin et al [141].  
 
2.9. Statistical analysis 
All data are represented as mean ± standard error mean (SEM). Difference 
between groups was analysed by unpaired Student t-test or when more than two 
groups by analysis of variance (ANOVA) followed either Mann-Whitney or 
Tukey’s post-hoc testing. All statistics were carried out using Graphpad Prism 
v7.03 (Graphpad software, USA)  
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3. Isolation and characterisation of porcine adipose and 





Pre-clinical research allows us to translate basic science into clinical practice. 
Using clinically relevant animal models, we can further optimise and develop a 
greater understanding of how these new therapies may work.   
Rodents have been used to model various diseases and are an invaluable tool for 
mechanistic studies and for preliminary evaluation of therapies. However, in 
some cases their findings do not translate well into clinical studies [142, 143]. 
Often large animal models provide more realistic scenarios and have more 
clinically relevant and scalable findings [144, 145]. 
While much research has been conducted into MSC therapy for burn wound 
healing in rodents, they are not ideal as they have loose skin structure and a well-
developed panniculus carnosus, which allows them to heal primarily through 
wound contraction whereas humans have a fixed skin structure which adheres 
tightly to sub dermal structures and heals primarily through re- epithelialisation. 
For pre-clinical evaluation of efficacy, the porcine burn model is quite 
advantageous. Histologically porcine skin is quite analogous to human skin, 
containing similar epithelial and dermal layers and similar sub dermal fat 
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deposits [146] (rodents have a sub dermal layer, which is not present in either 
human or porcine skin) and contains a similar number and distribution of 
sebaceous glands and hair follicles [146]. Pigs are relatively hairless compared to 
rodents, and as re-epithelialisation of partial thickness wounds is driven to a 
large extent by the epithelial cells lining hair follicles, the density and pattern of 
hair growth of the surrounding hair can influence wound healing dynamics. As 
porcine skin is also rigidly attached to the underlying facia, it heals primarily 
through re-epithelialisation. Anatomically, pigs are also quite similar, their large 
size allows for topical application of treatment (without systemic effects) and 
importantly, they have immune systems comparable to humans [146, 147]. 
As well as establishing the efficacy of MSC therapy in a large animal model of burn 
wound healing, the role of cell source will also be addressed. MSC can be isolated 
from many locations in the body and not just the bone marrow. In the field of 
plastic surgery, adipose tissue provides an easy and abundant source from which 
to harvest MSC. However, it is not well established if adipose derived MSC have 
equivalent efficacy to that of bone marrow MSC. 
 
3.1.1. Chapter aims 
This chapter lays the groundwork for subsequent in vivo chapters, which 
evaluate the efficacy, the ideal cell source and explore potential ways to increase 
the efficacy of this therapy.  
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 In order to evaluate these therapies, a reproducible porcine MSC  cell 
culture must first be established for both AD-MSC and BM-MSC and to 
demonstrate that these cells can be repeatedly isolated, expanded and 
meet the minimum criteria for defining MSC as set out by the ISCT [30].  
 To validate that MSC can be delivered viably to the wound and survive for 
a sufficient period 
 
 
3.2. Materials and methods 
 
3.2.1. Isolation of porcine BM-MSC 
Aspirates of BM were taken from approx. 3-month-old female landrace pigs 
during terminal procedures. Pigs were anesthetised by intramuscular (IM) 
injection of ketamine (10 mg/kg) (Vetoquinol, UK) and xylazine (2 mg/kg) 
(Vetoquinol, UK). While anesthetised, an area above the iliac crest was 
disinfected with povidone-iodine. The aspiration needle (11 gauge 6”) was 
advanced through the skin until it contacted bone. To penetrate into the bone 
cavity, the needle was rotated while applying steady pressure. Once the needle 
was in the marrow, the stylet of the aspiration needle was removed and a 
heparinised luer-lock syringe was attached. 15-30 ml of bone marrow aspirate 
was removed and transferred into 9 ml vacuum tubes (Greiner-bio-one, Austria) 
containers. Under a sterile laminar flow hood, cells were washed by diluting 
(1:10) in in PBS and then centrifuging for 10 min at 900 g. To quantify cell 
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number a diluted BM suspension (1:5) was added to 4% (v/v) acetic acid (Sigma 
Aldrich, Ireland) solution (1:2) and allowed to sit for approximately 1 min to 
allow for sufficient lysing of erythrocytes. Cell numbers were then counted using 
a hemocytometer. The cells were re-suspended in αMEM supplemented with 
10% FBS and 1x antibiotic antimycotic solution and plated at a density of 2.2x105 
cells/cm2 in a T-175 flask (Sarstedt, Germany). On d-3, 15 ml additional fresh 
media was added to each flask. Cells were then washed in PBS and non-adherent 
cells were removed on d-5. Fresh complete media was also added. After 1 wk, the 
formation of discrete colonies was observed. Colonies were grown until quite 
confluent and then were passaged and further expanded prior to 
characterisation.  
 
3.2.2. Isolation of porcine AD-MSC  
Adipose tissue was isolated from matched BM donor pigs. During anaesthesia, an 
area on the gluteal region was sterilised by application of povidone-iodine. An 
incision was then made and the cutaneous layer was peeled back to reveal 
subcutaneous white adipose deposits. These were then removed by scalpel, 
taking care not to include muscle tissue. Approx. 10-20 g of adipose tissue was 
isolated from each donor pig and put into a tube containing αMEM and 2x 
penicillin, streptomycin and amphotericin. Working under a laminar flow hood 
in sterile conditions the tissue was then finely minced using a sharp sterile 
scissors. The minced tissue was incubated in a shaker for 2 h in αMEM containing 
2 mg/ml collagenase II (Sigma Aldrich, Ireland) at 36°C to breakdown the tissue 
and release the cells. To isolate the SVF, the digested tissue was centrifuged at 
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1200 g for 10 min. The supernatant and floating lipid deposits was removed 
while the pelleted cells were then re-suspended and filtered prior to counting. 
Cells were then plated at a density of 1x105/cm2 in a T-175 flask. After 24 h non 
adherent cells were removed and fresh media was added. Cells were grown to 
confluency prior to passaging for characterisation and further expansion. 
 
3.2.3. Flow cytometry analysis of cell surface antigens 
Flow cytometry was used to analyse the level of MSC associated surface markers 
present to characterise isolated BM and AD cell populations. Expression of 
associated MSC markers CD29, CD90 and CD105 along with absence of CD45 
(common leukocyte antigen) was evaluated to ensure pure population of stromal 
cells. Cultured cells at P2-3 were washed once with PBS and detached from the 
tissue culture flask by incubating at 37°C in 0.25% trypsin/EDTA solution until 
cells had detached. Trypsin was neutralised with equal volume of serum 
supplemented medium. Cells were then recovered by centrifugation at 500 g for 
5 min, followed by re-suspension in PBS and aliquoted out into several tubes 
contain 1x105 cells for primary antibody staining. Cells were centrifuged and re-
suspended in 100 μl of diluted antibody (see table below) in FACS buffer (PBS 
containing 1% FBS and 0.1% EDTA) and incubated for 1 h at 4°C cells were then 
washed in PBS centrifuged and re-suspended in 100 μl of secondary antibody 
solution for 30 min in the dark at rt. Cells were then re-suspended in 100 μl FACS 
buffer and analysed on flow cytometer. Control isotypes were used to determine 
positive cell populations. 
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Table 3-1 Antibodies used in flow cytometry characterisation of porcine MSC 
Primary 
antibody 





BD Pharmingen  1 μg/ml Mouse IgG1 
CD45 N-19 Santa Cruz 2 μg/ml Goat polyclonal  
IgG 
CD90  5E10 BD Pharmingen 5 μg/ml Mouse IgG1  
CD105 MEM-229 Acris 1 μg/ml Mouse IgG2a 
Isotype control 
Mouse IgG1  
MOPC-
31C 













Clonality Manufacturer Concentration Host 
488 αMouse IgG 
H+L  
polyclonal Abcam, UK 2 μg/ml Goat 
 
 
3.2.4. Lineage differentiation assays 
MSC phenotype was validated by subjecting BM-MSC and AD-MSC to in vitro 
differentiation assays to confirm their potential to differentiate into adipocytes, 
chondrocytes and osteocytes. Tri-differentiation potential was verified using 
well established previously published protocols [25, 148]. 
Briefly, for adipogenic differentiation, cells in culture were subjected to 3 cycles 
of adipogenic induction media for 3 d followed by adipogenic maintenance media 
for 1 d. Adipogenic induction media consisted of DMEM with dexamethasone 
1 mM, insulin 1 mg/ml (Sigma Aldrich, Ireland), indomethacin 100 mM (Sigma 
Aldrich, Ireland) and 500 mM MIX (Sigma Aldrich, Ireland), the adipogenic 
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maintenance media contained insulin 1 mg/ml in DMEM. Adipogenic 
differentiation was confirmed with Oil red O (Sigma Aldrich, Ireland) staining.  
The cells were fixed in 10% formalin (Sigma Aldrich, Ireland) for 10 min. Oil Red 
O stock solution contains 0.3 mg Oil Red O in 100 ml of isopropanol (99%) (Sigma 
Aldrich, Ireland). To make Oil Red O working solution, 6 parts of stock Oil Red O 
was mixed with 4 parts of distilled water and allowed to stand for 10 minutes. 
The solution was filtered using Whatman no. 1 filter paper. Cells were stained 
with oil red o working solution for 5 min, rinsed with tap water and 
counterstained with H&E. Oil red o stains lipid vacuoles present within the cells 
red. 
For osteogenic differentiation, cells were cultured in osteogenic differentiation 
media, DMEM containing β glycerol phosphate (Sigma Aldrich, Ireland) 1 M and 
ascorbic acid (Sigma Aldrich, Ireland) 2-P 10 mM for 21 d. Osteogenic 
differentiation was confirmed by Alizarin Red staining. Cells were washed in PBS 
and then fixed in 10% formalin for 10 min at room temperature. Cells were 
washed and 1 ml of Alizarin Red solution was added to the fixed cells and allowed 
to stain for 20min. Excess stain was removed and the cells were washed with 
dH2O. Finally, 1ml of dH2O was added to each well and cells were examined 
under the microscope for red deposits indicating the presence of calcium 
deposits associated with osteocyte differentiation. 
For chondrogenic differentiation, pelleted cells were cultured for 21 d in 
chondrogenic differentiation media, DMEM containing 10 ng/ml TGF-β3 (Sigma 
Aldrich, Ireland). After 21 d, pellets were incubated in 4% PFA overnight (o/n). 
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Pellets were then removed from PFA and carefully placed on wattman paper, 
folded over and placed in paraffin embedding cassettes. Pellets were embedded 
in paraffin and 10 μm thin sections were cut and adhered to glass slides. Slides 
were then deparaffinised (as described in section 4.2.3) and chondrogenic 
differentiation was confirmed by positive staining with toluidine blue (Sigma 
Aldrich, Ireland). 
 
3.2.5. Formulation of fibrin gel 
To make fibrin gels 100 μl fibrinogen and 100 μl thrombin were quickly mixed.  
A range of concentrations were evaluated to assess gel capacity to support cell 
viability.  Fibrinogen was reconstituted in PBS to stock concentration of 100 







3.3.1. Isolation and expansion of porcine AD-MSC and BM-MSC 
To determine if either cell source was more efficacious, AD-MSC and BM-MSC 
were isolated from matched female landrace pigs of 3-4 months of age. Isolation 
of adipose tissue and BM was performed on eight pigs. Adipose tissue was 
isolated from the gluteal region (as shown in Figure 3.1) The adipose tissue was 
washed in PBS and then digested in collagenases before centrifugation to isolate 
the SVF (as detailed in section 3.2.2) On average about 10-15 g of tissue was 
excised and from this, about 20x106 cells were isolated. The cells quickly adhered 
to plastic and formed large colonies of rapidly growing cells. These cells were 
then expanded for 2-3 wk prior to characterisation. To isolate BM-MSC, 10-15 ml 
bone marrow was extracted from iliac crest using puncture technique (Figure 
3.1). From this, approximately 5-10 x106 cells were retrieved. After 1 wk, plastic 
adherent cells began to form colonies, which subsequently became confluent. 
These cells were expanded through several population doublings until 
approximately 50 x106 cells were obtained, enough to provide sufficient cells for 
in vivo study and characterisation. 
3.3.2. Porcine MSC characterisation 
Culture expanded MSC were then further characterised using flow cytometry to 
assess cell surface receptor expression (representative plots shown in Figure 
3.2, n=6). As no single unique marker exists for MSC, a profile of expression 
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associated with MSC was used to characterise this cell population. Flow 
cytometry indicated both populations were positive for CD29, CD90 and CD105 
and negative for the leukocyte common antigen CD45 [30]. After flow cytometry, 
multipotency of the cells was determined (representative images shown in 
Figure 3.3 n=6). Samples from both cell populations were cultured in various 
differentiating conditions using well established protocols (as previously 
described [149, 150]). Adipogenic differentiation was confirmed in both cell 
types by the presence of lipid vacuoles stained with oil red O (Figure 3.3 A). 
Strong Alizarin red staining indicated the presence of calcium deposits associated 
with osteoblast formation (Figure 3.3 B). Chondrogenic differentiation was 
confirmed using toluidine blue staining of pellet cultures. Both BM-MSC and AD-
MSC pellets had deep purple staining indicative of the presence of sulfated 
glycosaminoglycans  (Figure 3.3 C) 
3.3.3. Fibrin gel optimisation 
Cells were to be delivered topically to the wounds in a fibrin gel. Fibrin is 
composed of fibrinogen that is polymerised with thrombin. To validate that 
sufficient viable cells could be delivered topically various concentrations were 
tested to determine optimal formulation. Figure 3.4 A shows cell viability assay 
using a cell permeable peptide substrate (fluorescein diacetatecetate) which 
when cleaved by enzymatic processes within live cells will fluoresce green under 
a blue light. Three concentrations of fibrinogen were formulated (3 mg/ml, 6.25 
mg/ml and 12.5 mg/ml) based on previous studies [50, 151] and polymerised 
using thrombin at a final enzymatic activity of 12.5 U. After 24 h there was a small 
reduction in viable cells in the two higher concentration fibrin groups (3 mg/ml 
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group; 98.4% ± 0.34, vs 6.25 mg/ml group; 80.24% ± 0.05, vs 12.5 mg/ml group 
72.0% ± 0.01,   Control vs. 3mg/ml p=0.931,   Control vs. 6.25mg/ml, p<0.001,   
Control vs. 12.5mg/ml, p<0.001, ANOVA, n=3 ), however, cell viability  
normalised between groups to some degree after 48 h (3 mg/ml group; 90.02% 
± 0.02, vs 6.25 mg/ml group; 83.09% ± 0.002, vs 12.5 mg/ml group 83.15% ±0.02, 
Control vs. 3mg/ml p<0.001,  Control vs. 6.25mg/ml, p<0.001,   Control vs. 
12.5mg/ml, p<0.001, ANOVA n=3) (Figure 3.4 A). 
In terms of usability, the lowest concentration fibrin gel was very slow to 
polymerise and unpolymerised liquid remained.  This was not suitable for 
application onto wounds, as unpolymerised liquid containing cells was likely to 
run off the wound. The 6.25 mg/ml concentration was found to be optimal, 
polymerising quickly but not resulting in an overly rigid gel. This gel formulation 
was easily degraded by the cells with approximately 50% reduction in gel size 
observed after 7 d in culture (Figure 3.4 B). This formulation was selected based 
on its usability and propensity for maintaining cell viability. 
Following on from this, long-term viability was assessed in–vitro using 
propidium iodide staining (Figure 3.4 B). After 1 wk in culture, the gel was 
digested using trypsin and non-viable cells were assessed by flow cytometry 
using propidium iodide. No significant difference was observed (Control; 8.93% 
± 0.72, Fibrin; 11.03% ± 0.24, p= 0.057, Mann-Whitney test, n=3) suggesting 




3.3.4. Porcine burn model 
The pig burn model is a previously established model in the Centre for Research 
in Vascular Biology lab. A deep partial thickness burn is induced in anaesthetised 
pigs using a solid metal bar preheated in water bath to 80°C (specific 
methodology is detailed n section 4.2.1). Pressure is applied using the weight of 
the metal bar for 20 s, this produces consistent, deep partial thickness burns 
(Figure 3.5 A). Images taken two hours after the induction of partial thickness 
burn show the formation of a leathery white eschar and surrounding erythema 
(Figure 3.5 A). Mass cell death and denaturation of tissue proteins initiate large 
inflammatory response that increases local vascular permeability [152]. 
Histological sections, taken at 2 h post burning and stained with Hematoxylin and 
eosin (H&E) show loss of epidermal layer, coagulation and tissue necrosis 





Figure 3.1 Isolation of adipose tissue and bone marrow aspirates from the pig 
A) AD-MSC were isolated from subcutaneous adipose tissue that was harvested from the gluteal 
region. Adipose tissue was stored in PBS until digestion and isolation of SVF. B) BM-MSC were 
isolated from bone marrow aspirates obtained from the iliac crest. The bone marrow was stored in 
heparinised tubes prior to further processing. Adipose tissue and bone marrow aspirates were 





Figure 3.2 MSC cell surface receptor profiling by flow cytometry 
Isolated BM-MSC and AD-MSC were characterised for expression of cell surface markers. A) 
Representative plots, both cell types were positive for mesenchymal markers CD29, CD90 and CD105 
whilst negative for common leukocyte antigen CD45 (shown in orange histograms, control IgG are 
shown in grey histograms). B) In culture both AD-MSC and BM-MSC show large fibroblast spindle 





Figure 3.3 Tri-lineage differentiation of isolated MSC 
AD-MSC and BM-MSC were exposed to various differentiating media and subsequently differentiated 
into A) adipocytes (verified with Oil red o) B) osteocytes (alizarin red stain) and C) chondrocytes 
(toluidine blue stain). Both cell populations were readily able to differentiate into these lineages, 








Figure 3.4 MSC viability in fibrin gels of various composition 
A) Cell viability was assessed at 24h and 48h using cell permeable cell substrate in fibrin gels of 
various compositions. A reduction in viability was observed at 24 h in high fibrinogen concentration 
gels however, this recovered somewhat after 48 h (n=3 *** P<0.001). B) Upper panel, 6.25 mg/ml 
concentration of fibrinogen was selected based on usability and long-term cell viability was assessed 
by propidium iodide (PI) uptake as determined by flow cytometry, Increased fluorescence, as 
represented by red histogram, compared to unlabelled control indicates PI uptake and cell 
apoptosis. B) Lower panel left, graphical representation of cell viability quantification. B) Lower 
panel right, fibrin gel containing MSC at d-7 show significant size reduction as approximated by 




Figure 3.5 Induction of burns in porcine pig model 
A) Experimental setup demonstrating induction of deep partial thickness burns to dorsum of pig 
using a preheated solid brass rod. Photographic images taken 2 h post wounding show erythema 
and leathery white appearance of skin, consistent with partial thickness burns [149]. B) Left, 
Histological sections of burns stained with H&E show detachment and loss of epidermal layer 
(indicated with black arrows), tissue coagulation and necrosis. B) Right normal skin shows intact 






In this chapter, robust and reproducible protocols were established to isolate 
both AD-MSC and BM-MSC from pigs. These cells were then characterised and 
identified as MSC as set out by ISCT criteria [30]. Namely, it was confirmed that 
MSC expressed cell surface markers associated with MSC (CD29+, CD90+ CD105+ 
and were negative for Leukocyte markers such as CD45) and have multipotent 
differentiation potential. Here it was demonstrated that both of these cell 
populations could differentiate towards adipo- chondro- and osteo- lineages. 
 
3.4.1. Identification of MSC 
As no MSC specific marker exists, a minimum criterion was previously defined by 
the ISCT, which involves several conditions a cell population must meet [30]. This 
requires positive and negative expression of a broad range of surface antigens 
which define the population as mesenchymal and not of leukocyte origin. These 
cells are also required to be plastic adherent and capable of multipotency, which 
usually involves the ability to differentiate towards adipo, chondro and osteo 
linages. Unfortunately, this still leaves a broad and heterogeneous population of 
cells that can increase experimental variability and lead to conflicting results as 
illustrated by prolonged debate in the literature [28]. The term bestowed on this 
cell population has also added further confusion, with some researchers 
referring to them as stromal cells while others using the term stem cells. 
Variations in isolation and non-standardisation of culture conditions also add to 
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the complexity of interpreting the data across studies. Clearly, the field could 
benefit from a unique marker however to date none have been discovered. While 
a unique marker may be helpful, industry and some research groups are 
attempting to further characterise these cells based on the expression of multiple 
receptors to build a unique fingerprint of MSC. The field has readily adopted the 
basic ISCT criteria and could benefit from an updated and expanded criteria to 
better define these cells for experimental studies. 
 
3.4.2. ASC as a source for MSC 
BM-MSC have shown much promise in cell therapy [50, 153], however invasive 
and painful isolation procedures limit its future widespread use [154] leading to 
evaluation of alternative tissue sources of MSC for therapeutic use. MSC can be 
isolated from multiple tissues within the body such as synovial membrane [155], 
skin [156], skeletal muscle [157], umbilical cord [158] and adipose tissue [159].  
Over 400,000 liposuction procedures are performed in the United States 
annually yielding between 0.1-3 L of aspirate, the majority of which is discarded 
[109]. Adipose tissue is derived from the mesodermal layer during embryonic 
development [109]. It is a highly complex tissue composed mainly of lobules of 
adipocytes. Within this is the stromal vascular fraction which contains; pericytes, 
pre-adipocytes, fibroblasts, vascular SMCs, endothelial cells and AD-MSC [109]. 
 Adipose tissue can be broken down in two types, white adipose tissue (energy 
storage) and brown adipose tissue (heat generation). Anatomically, adipose 
tissue can be found in sub cutaneous depots, as visceral fat around organs,  in the 
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bone marrow,  in muscle and in the mammary gland, each with distinct functions 
[109]. AD-MSC are frequently isolated from white subcutaneous fat deposits 
which offer the greatest yields, plasticity and ease of access [160], but AD-MSC 
can also be isolated from brown adipose tissue [161]. 
The primary benefit of AD-MSC is that adipose tissue is the largest reservoir of 
stem cells in the body. AD-MSC are routinely isolated at concentrations of 
approximately 30x106 per 100 ml lipo-aspirate [162] which equates to 5,000 
fibroblast colony forming units (CFU-F) per gram of adipose tissue, significantly 
higher than the estimates of 100-1000 CFU-F per ml of bone marrow [163]. Bone 
marrow isolation can result in donor site morbidity and this significantly limits 
amount of bone marrow that can be aspirated, this then extends the amount of 
culture time to generate a therapeutic dose. From this perspective AD-MSC may 
be superior to BM-MSC in terms of expansion potential and density but, it 
remains to be determined which one is therapeutically superior, this will be 
addressed in greater detail in chapter 4.   
 
3.4.3. Fibrin as a delivery vehicle  
The choice of delivery vehicle for cells onto the wounds is an important 
consideration. Fibrin is an ideal substrate for delivery of cells for wound healing. 
Its biological effects have been well characterised [164-166] and it has been 
utilised as a delivery system in many tissue-engineering applications [50, 167, 
168]. Fibrin hydrogels have a very high water content mimicking that of soft 
tissues and also provide efficient cell seeding, ensuring even distribution and 
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immobilisation. Fibrin has been used extensively for delivery of many cell types 
such as keratinocytes [168], fibroblasts [169] and MSC [50]. A variety of cell types 
are able to proliferate, remodel and migrate out of fibrin gels [151, 170]. Fibrin 
is formed from the cross linking of fibrinogen fibres by thrombin. This 
polymerisation can be controlled by the concentration of each factor. A range of 
concentrations were evaluated to achieve a gel that would quickly polymerise but 
not too rapidly so as the cells can be dispersed in the gel and be uniformly 
delivered onto the wound. Both thrombin and fibrinogen concentrations will 
alter polymerisation kinetics; therefore, thrombin was kept constant at 12.5 
U/ml (higher thrombin concentrations in fibrin gels can induce apoptosis in 
some cell types [171]). Increased concentrations of fibrinogen provided more 
substrate for cross linking, resulting in a more rigid gel which increased time 
taken for embedded cells to migrate out of the gel [151, 172].  Fibrin gels with 
concentration 6.25 mg/ml were found to have the most suitable polymerisation 
time, taking about 1-2 min to set, which allowed time for even distribution of cells 
and application to the wound. This reduced reaction time and allows time for 
greater self-organisation and gel homogeneity. 
 Initial cell viability was assessed and while some reduction was observed at 24 
h by 48 h this had mostly recovered. This may be due to an initial culture shock, 
loss of cell-cell contact or reduction in nutrient supply. MSC secrete various 
fibrinolytic enzymes that break down the fibrin fibres allowing the re-
establishment of cell-cell contact with other cells and formation of characteristic 
fibroblast morphology [151].  Subsequent analysis demonstrated that gels at this 
concentration were able to support MSC viability for at least 7 d and the gel was 
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easily degraded by the cells, allowing for migration into the wound. This is in 
agreement with several other studies which have assessed viability of human 
BM-MSC in fibrin gels of similar concentrations [151, 173].  
Generally, cell proliferation is greatest in low fibrinogen concentrations and 
medium to low thrombin concentrations [174, 175]. However, where 
proliferation was slow initially, it increases rapidly after several days [174]. 
Increasing fibrinogen concentrations can decrease MSC proliferation and alter 
cell morphology [175]. Human MSC in low concentration fibrinogen gels, at 5 
mg/ml, are elongated and stretched while at higher concentrations MSC appear 
rounded [175]. Lower fibrinogen concentrations yield fibrin clots with a more 
open pore ultra-structure and greater structural homogeneity, this observed 
level of structural homogeneity is due to a reduced reaction time because of the 
low thrombin concentration [175]. Increased pore quantity and distribution 
throughout the gel is important because it allows the cells to form a network 
throughout these pores. 
In this study, the optimal concentration of fibrinogen and thrombin in terms of 
usability and acceptable cell viability was found to be 6.25 mg/ml fibrinogen and 
12.5 U/ml thrombin, other studies have also reported using similar 
concentrations [50, 176, 177].  In a seminal paper by Falanga et al, they use MSC 
to treat cutaneous wounds on humans and mice which were topically applied in 
a fibrin spray at a concentration of 5 mg/ml fibrinogen and 25 U/ml thrombin.  
Fibrin has also been used to deliver keratinocytes in a porcine wound healing 
model [178]. Autologous fibrinogen was extracted from plasma and used to 
deliver autologous keratinocytes at a final concentration of approx. 10 mg/ml 
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fibrinogen, endogenous prothrombin on surface of wound initiates coagulation 
cascade [178]. Several formulations of fibrinogen and thrombin were examined 
in a rabbit model of wound healing, and the investigators found increased 
granulation in gels with a reduced fibrinogen concentration (17 mg/ml 
fibrinogen vs 50 mg/ml) when delivered with fibroblasts [176]. No difference 
was observed when fibrin was used without cells, suggesting that fibrinogen 
concentration alters outward migration of encapsulated cells [176]. 
In summary, AD-MSC have the potential to be a very useful source of MSC in the 
context of plastic surgery and wound healing. Both AD-MSC and BM-MSC can be 
isolated and fulfil the minimum criteria as set out for MSC by the ISCT. Fibrin gel 
can be used to deliver these cells topically to the wound and can support their 
viability for at least 7 d. In the next chapter, the efficacy of these cells in a porcine 





4. AD-MSC and BM-MSC are therapeutically equivalent 





Burn injuries are the fourth most common trauma worldwide. While significant 
advances have been made in reduction in mortality, through better management 
of sepsis and fluid loss, scarring and wound closure remain problematic [6]. It 
has been well established that MSC therapy can improve wound healing and this 
has been validated in several animal models including; radiation [179], excisional 
[50] and burn wounds [180].  As detailed in section 1.2.4, central to this process 
are the secretion of paracrine factors that influence immune response and 
promote angiogenesis and granulation tissue formation [29]. 
 Currently, there are only a handful of human clinical studies on the efficacy of 
MSC, mostly in chronic wound healing (summarised in Table 4-1). A major 
clinical trial investigating the efficacy of MSC in burn wounds is on-going [181] 
and another trial has been completed, but no results have been reported (NCT 
02394873).  In general, MSC therapy is efficacious in treating both chronic and 
acute wounds  [51, 182]. 
Many phase I and phase II clinical trials have been conducted to assess safety and 
efficacy of MSC in other pathologies such as; GVHD and non-union bone fractures 
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[183-185].To the best of the author’s knowledge, these clinical trials have 
demonstrated little if any adverse events associated with the safety of MSC 
therapy. However, due in part to heterogeneity present in the human population 
(compared to laboratory animals), the rigorous design of clinical trials and inter 
species variation, the effectiveness of MSC therapy has declined somewhat 
compared to pre-clinical studies [186]. More robust pre-clinical studies are 
required to determine optimal parameters of MSC therapy before entering into 
further clinical trials. This will allow for the better design and optimisation of 
clinical trials to evaluate these potential therapies. 
 
Table 4-1 Clinical studies of MSC therapy used in cutaneous wounds 
Wound 
type 












3 [51] Non healing wounds (1yr +) 












[50] Reduction in wound size 
Chronic 
wounds 




[47] Reduced wound size increased 













[187] Accelerated healing rate 
compared to BM-MNC. 













Cell source of MSC is one parameter that has not been well established, MSC from 
a variety of sources have been utilised in pre-clinical studies including BM-MSC, 
AD-MSC, umbilical cord and Wharton’s jelly [188-191]. However, few 
equivalency studies have examined the efficacy of these cells, and it remains to 
be determined which cell source is therapeutically superior. 
 AD-MSC as a potential source  
As discussed in section 3.4.2, adipose tissue is an advantageous candidate 
source as it is a readily available tissue for plastic surgeons, easily harvested 
under routinely performed procedures, has less donor site morbidity compared 
to BM isolation and provides a much greater yield of stromal cells [192]. AD-MSC 
have superior growth characteristics and a significantly lower population 
doubling time when in logarithmic growth phase [193, 194]. Although BM-MSC 
are a more widely studied cell type, BM isolation is a more invasive and painful 
procedure and may be more beneficial if reserved for hematopoietic stem cell 
transplantations [192]. 
AD-MSC are thought to be biologically equivalent to BM-MSC, express similar 
immuno-phenotypic profiles and have comparable multipotency [159]. 
However, some notable differences have been reported, that suggest that these 
different cell types may not be therapeutically similar [195]. For example, a 
certain population of AD-MSC express CD34 when freshly isolated, which BM-
MSC lack, expression then begins to decline and is subsequently lost during cell 
culture [195, 196]. Several other immuno-phenotypic differences have been 
reported with some estimates of up to 10% difference in expression profile [159]. 
However, as such profiles are largely influenced by culture and isolation 
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conditions, not to mention differential binding of various antibody clones, there 
is much disparity in these studies [195]. Other global proteomic studies suggest 
that 23% of proteins are  specifically expressed in one cell type and not the other 
and differential expression of over 30 other proteins was noted (such as VEGF, 
VCAM-1 and angiopoietin, all increased in AD-MSC), further suggesting innate 
difference in these cell types [196]. 
Furthermore, AD-MSC and BM-MSC employ distinct molecular mechanisms by 
which they induce angiogenesis, a key component of MSC therapy.  The formation 
of new blood vessels involves the recruitment of endothelial cells, degradation of 
the basement membrane in surrounding vessels, endothelial cell proliferation, 
vessel maturation and subsequent pruning of vessels [197]. Proteases are crucial 
mediators of this process and are required for the remodelling of fibrin matrices 
in the wound clot, either through plasmin dependent serine proteases or plasmin 
independent MMPs [197]. AD-MSC mediated vessel morphogenesis primarily 
occurs through plasmin family of proteases (and to a lesser degree MMPs) which 
are required for endothelial cell invasion and elongation similar to fibroblasts 
whereas BM-MSC rely solely on MMPs [197]. Analysis of secreted soluble factors 
that promote angiogenic response suggest AD-MSC secrete larger quantities of 
VEGF-D; however, no differences were observed in secretion of VEGF-A and FGF-
2 [198]. Conversely, in another study, analysis of messenger RNA (mRNA) 
expression suggests an increased expression in BM-MSC [193]. Similarly, other 
studies have observed differential secretion of angiogenic factors FGF-2, stromal 
derived factor-1 (SDF-1) and HGF (increased in BM-MSC) under normal culture 
conditions [194]. Co-culture of MSC with HUVECs resulted in significant 
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induction in HGF in AD-MSC but not BM-MSC co-cultures [197]. The expression 
of various soluble factors alters in response to time in culture and growth 
conditions, and may account for some of the observed discrepancies [193]. 
One of the other primary mechanisms of MSC therapy is through their immune-
regulatory function, and again key difference have been observed between these 
cell types suggesting they may have different therapeutic responses in vivo [199]. 
Both BM-MSC and AD-MSC can reduce NK cell proliferation to a similar extent 
[199] and in co-culture with activated T-cells both cell types are able to inhibit T-
cell proliferation associated with reduced TNFα and increased secretion of IL-10 
[199, 200]. However, in vitro co-culture experiments suggest human AD-MSC are 
more potent in suppressing peripheral blood mononuclear cell (PBMNC) 
proliferation [114]. Similarly, AD-MSC are more potent inhibitors of DC 
differentiation [114, 201]. Taken together these data suggests AD-MSC may be 
more efficacious in resolving inflammatory responses and accelerating wound 
healing.  
 
Comparative Wound healing studies 
At the outset of this PhD study, there were no comparative analysis studies of AD-
MSC and BM-MSC in cutaneous wound healing described in the literature, and to 
the best of the author’s knowledge, only three such studies have since been 
published (summarised in Table 4-2), none of which involve burn wounds.  
The fact that three separate studies have been published since the beginning of 
this PhD, validates that this is a pertinent and relevant research question to be 
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addressed. However, distinct differences exist between excisional wounds and 
burn wounds which add further complexity in interpreting results and therefore 
require separate studies to validate therapeutic efficacy in pre-clinical burn 
wound models. 
In a recently published study, of a porcine model of excisional wound healing 
treated with either donor matched AD-MSC or BM-MSC, MSC therapy reduced 
scar index as assessed using the Vancouver scale, no difference was observed 
between cell groups [115]. Epidermal thickness measured at d-7, 10, 14 and 21, 
and was significantly increased in both MSC therapy groups compared to saline 
on d-21 only, again, no difference was observed between cell groups [115].  It 
should be noted that this study is not ideal, as the sample number is small (n=2 
per time point) and characterisation of wound healing is limited, as no 
assessment of re-epithelialisation was conducted. In addition, the Vancouver scar 
scale which assesses scar qualities like pliability, height and pigmentation is a 
subjective measurement designed for clinical evaluation of burn scars [202] and 
is not appropriate measurement in an animal model of excisional wounding after 
21 days. 
In a rabbit model of excisional wound healing using rabbit allogenic MSC, AD-
MSC were superior, promoting granulation tissue formation compared to BM-






Table 4-2 Comparative pre-clinical studies in cutaneous wound healing 
Wound 
type 









ID injection  
with autograft 
Pig [115] Accelerated re-
epithelialisation no 
significant difference 







ID injection Mouse [204] AD-MSC was 
significantly accelerated 
wound closure  
compared to BM-MSC, in 







vs BM-MSC vs 
dermal 
fibroblast 
Topical 7 μl 
PBS  
Rabbit [203] increased granulation 
tissue in AD-MSC treated 




Similarly, in a xenogeneic mouse model of wound healing treated with human 
MSC, AD-MSC significantly accelerated wound closure compared to BM-MSC at 
all time points. In vitro analysis demonstrated increased VEGF, TGF-β, FGF-2 and 
FGF-7 (factors associated with increased angiogenesis and wound healing) 
secretion from AD-MSC compared to BM-MSC and also greater dermal fibroblast 
recruitment [204]. 
It is apparent from the literature that there are some conflicting results and it has 
not been well established which cell type is therapeutically superior. 
Furthermore, while several studies have been conducted using BM-MSC in burn 
wound healing (summarised in Appendix I), only four studies could be identified 
that investigated the efficacy of cultured AD-MSC in burn wound healing 
(Appendix II). To the best of the author’s knowledge, no equivalency studies have 
been performed to determine optimal cell source in the context of burn wound 
healing.  Previous studies suggest that AD-MSC may be therapeutically superior, 
or at least a more abundant and scalable source of cells. The knowledge gained 
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from this study will allow us to determine if indeed adipose tissue is the optimal 
source and if so large scale dosage escalation studies can be conducted to further 
optimise this therapy. Thus, to address this knowledge deficiency, the role of cell 
source in MSC efficacy in a large animal model of burn wound healing was 
investigated. 
 
4.1.1. Chapter aims 
 Measure efficacy of MSC cell therapy in porcine burn wound model 
 Determine if either cell type is therapeutically superior 
 
 
4.2. Materials and methods 
 
In this study the therapeutic efficacy of allogenic MSC derived from either BM or 
adipose tissue was investigated. The study consisted of two experimental 
treatments; AD-MSC, BM-MSC and a control treatment of fibrin only. Each animal 
received all three treatments thus providing intra animal controls. Allogenic AD-
MSC and BM-MSC isolated from the same donor pig were characterised, as 
described in section 3.3.2, prior to use in following burn experiments.  
Cells were harvested prior to the procedure by trypsinisation, viable cells 
counted and aliquoted into separate tubes for each wound (4.5x106 cells). The 
81 
 
tubes were centrifuged and then re-suspended in fibrinogen at a concentration 
of 12.5 mg/ml and stored on ice until application onto burn wounds. 
 
4.2.1. Burn Induction 
Eight female landrace pigs (25-30 kg) were used in this study. Animals were 
housed in the animal facility for one week prior to experiments to acclimatise. 
Pigs were anaesthetised with IM injection of xylazine (2.0 mg/kg), ketamine 
(15 mg/kg) and glycopyrollate (0.01 mg/kg). An IV cannula was placed into the 
ear veins for administration of IV fluids and drugs. Propofol (3 mg/kg i.v.) was 
administered and the pig was then intubated and maintained on 2% Isofluorane 
administered by inhalation. The animal was placed on its side and the area to be 
burned was shaved with an electric clippers. The area was then treated with a 
povidone-iodine solution. A template was then used to mark the area to induce 
burns so that all burns were over the ribcage and spaced 5 cm apart. 
Burn wounds were induced as described by Brans et al [152]. A solid brass rod 
with a surface area of 4.5 cm2 was preheated in a water bath at 80°C for 30 min 
prior use, (three sections of brass pipe were used to facilitate timely induction of 
multiple burns) and then blotted dry before direct application onto the animal’s 
skin. The rod was balanced on the animal’s skin and the rods own weight (570 g) 
used to apply pressure. The brass rod was applied for 20 s, inducing a deep 
partial thickness burn. 12 burns, 6 on each side (4 wounds for each experimental 
and control group) were induced in each pig, approximately 5% total body 
surface area. The burn wounds were then debrided of the burn eschar to reveal 
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a wound bed with fresh punctate bleeding. Prior to treatment, the wounds were 
randomised, to proximal, medial and distal dorsal regions.  
 
 
Figure 4.1 Application of Fibrin gel containing MSC 
Fibrinogen was mixed with thrombin and allowed to polymerise forming a gel which was then 
covered using Tegaderm occlusive dressings. 
 
The cells, either AD-MSC or BM-MSC were (4.5x106) suspended in 500 μl 
fibrinogen were mixed with 500 μl thrombin (25 U/ml) to give a fibrin gel of final 
concentration 6.25 mg/ml fibrinogen 12.5 U/ml thrombin. This polymerised 
within 1-2 min and was applied to the wound as it polymerised and contained to 
the wound using a mould (as shown in Figure 4.1 top left) As a control, fibrin 
without any cells was applied to the wounds.  
 
The wounds were then dressed with an occlusive adhesive dressing (Tegaderm™, 
3M Healthcare, Belgium), followed by a layered non slip dressing composed of 
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gauze and melonin (Smith and Nephew, UK) secured with an adhesive tape and 
then covered with a double tubigrip and secured with further taping.  Dressings 
were changed on d-4, d-7, and d-10 at which time wounds assessed for healing 
and imaged using DLSR camera (Canon, Japan).  
 
4.2.2. Wound image analysis 
Wound area was calculated using ImageJ software (NIH.gov). Area was measured 
at d-0 and again at d-14. To measure percentage wound closure the following 
formula was used: [(area of wound d-0 – area of wound d-14) /area of wound d-
0] x 100 as previously described [205]. Wound closure image analysis was 
conducted by a blinded observer.  
 
4.2.3. Histology 
After the animal was euthanised (IV injection Pentababitone, 50mg/kg) a 4 cm2 
sample of both wound and wound margin was excised. Tissue samples were fixed 
overnight in 4% PFA at 4°C. The next day, samples were processed in histokinette 
overnight and embedded in paraffin blocks. 10 μm sections were cut from the 
paraffin blocks and plated on charged glass slides. Sections were then heated 
overnight at 60°C to remove excess paraffin and then deparaffinised by several 






To determine re-epithelialisation, wound sections were stained with H&E (as 
detailed in section 2.7.1). Several over lapping images were taken of the entire 
wound section at 4x magnification. These images were then spliced together and 
the percentage of section epithelialised was calculated by blinded observers 
using following equation [(total section length – unepithelialised length)/total 
section length]x 100 [140]. 
Collagen formation 
Early formation of granulation tissue of wounds is predicative good wound 
healing out comes [206]. To evaluate this response, histological sections were 
stained with Masson’s tri-chrome as detailed in section 2.7.2, which stains all 
collagen fibres blue and cell cytoplasm red. Nuclei were counter stained with 
Hematoxylin. Percentage area of blue staining present on each wound section is 
an indicator of collagen and thus, granulation tissue. Quantitative analysis by 
blinded observer was performed at five randomly sampled points across the 
wound section and percentage blue staining of each section was quantified using 
NIS elements software (Nikon). 
 
4.2.4. Immunofluorescent staining 
Wound samples were stored in 4% PFA overnight at 4°C, dehydrated in graded 
sucrose solution and then embed in OCT (as detailed in section 2.6). Sections 
were cut at 10 μm thickness in cryostat and stored at -80°C until required. Prior 
to staining, slides were removed and left to defrost for 30 min at rt.  
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Slides were rehydrated in PBS (10 min) and then blocked for 1 h in 10% normal 
goat serum in PBS-Tween (0.5%) solution. Sections were then incubated o/n at 
4°C with primary antibody diluted in antibody buffer (1% BSA PBST). The next 
day, sections were washed x3 in PBST and slides were incubated with secondary 
antibody solution in antibody buffer for 2 h at rt, followed by 3x washes in PBST. 
Nuclei were stained with DAPI (1 μg/ml) for 10 min followed by 3x washes in 
PBS prior to mounting in immunomount and cover slipped.  
 
Table 4-3 Immunohistochemistry antibodies used in porcine wound sections 
Primary 
antibody 
Clone Manufacture Final 
Concentration 
Isotype 
CD163 2A10/11 BioRad (USA) 10 μg/ml Mouse IgG1 
αSMA 1A4 Dako (Agilent 
USA) 
10 μg/ml Mouse IgG2a 
Isotype control 


















Clonality Manufacturer Concentration Host 
488 αMouse IgG 
(H+L) 
polyclonal Abcam, UK 2 μg/ml Goat 
 
4.2.4.1. CD163 quantification 
To determine the inflammatory response M2 macrophage (CD163+) populations 
within the wound were quantified. CD163 is a member of the scavenger receptor 
cysteine rich family and is expressed specifically on cells of the myeloid lineage, 
on macrophages it is expressed primarily on M2 type macrophages [207, 208]. It 
is strongly upregulated on monocytes differentiated with M-CSF and also in 
response to IL-10, whereas it is greatly suppressed by TNFα and LPS [207]. 
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Sections were imaged at five random points within the wound bed and CD163+ 
cells were quantified by blinded observer; three sections were analysed per 
animal.  
4.2.4.2. Smooth muscle actin alpha quantification 
To assess angiogenic response, wound sections from d-14 were probed with 
alpha smooth muscle actin (αSMA). This protein is expressed in vascular SMCs 
and pericytes that line arterioles and capillaries [209]. Sections were imaged at 
five random points within the wound bed and vessel density was calculated (by 
blinded observer) based on αSMA+ vessels; three sections were analysed per 
animal. 
 
4.2.5. RNA extraction and qRT-PCR 
A 4 cm2 template was used to excise wounds which contained both healed wound 
margin and wound. This was bisected and 1 quarter was snap frozen in liquid 
nitrogen. Samples were kept at -80°C until required. To extract RNA, samples 
were crushed using pestle and mortar in liquid nitrogen. Samples were then 
homogenised using rotar stator in a solution of phenol, guanidine isothiocyanate 
for 1 min. RNA purification was then performed using RNAeasy universal kit as 
per manufactures instructions.  
Purity (A260/A280) and concentration of isolated RNA was measured using 
Nanodrop spectrophotometer. Integrity of RNA was assessed using denaturing 
agarose gel electrophoresis and ethidium bromide staining. Only high purity 
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(A260/A280 >1.8) RNA samples that had sharp bands of 28s and 18s rRNA and 
apparent 2:1 ratio were used.  
Two wound samples from each treatment group per pig were used for RT2 
profiler array (n=6). RNA (1 μg) was reverse transcribed into cDNA using RT2 
First Strand Kit. This was then used for each qRT-PCR reaction with RT2 SYBR 
Green Mastermix containing Hotstart DNA Taq polymerase. This was added to 
RT2 profiler array containing 10 pre coated validated primer assays for TNFα, IL-
10, IL-6, IL-8, VEGF, MMP-2, Col1, Col3, CD206 and TGF-β. Data was analysed 
using the ΔΔ CT method, quantification was calculated in relation to 18s 
expression in each sample calculated before 35 cycles. Both positive, negative 
and genomic DNA contamination controls were included in the assays. 
 
4.2.6. Statistical analysis 
The sample size for each animal experiment calculated based on power analysis 
to detect a minimum of 10% difference between means in experimental and 
control groups with standard deviation less than 8 based on our own previous 
studies and results reported in the literature. The power of the test was set at 
0.80. The Type I error probability associated with the test was set at 0.05.  
Each animal received all treatments including control which reduces the effects 
of inter animal variability and allows the use of paired wound measurements.  
Difference between groups was analysed by repeated measures analysis of 
variance (rmANOVA) followed by Tukey’s post-hoc testing. Results are reported 





4.3.1. MSC treatment of burn wounds increased rate of wound 
closure 
The wounds were first debrided and imaged (Figure 4.2 A). Wounds with a 
combined mean area of  5.3 cm2  ± 0.1 were consistently produced and no 
significant differences were observed between the groups (Figure 4.2 B). Wound 
closure at d-14 was quantified as shown in Figure 4.2 B. Application of either 
BM-MSC or AD-MSC induced a modest, but significant enhancement in wound 
closure (Fibrin; 18.39% ± 1.9 vs AD-MSC; 13.95% ± 1.7 vs BM-MSC; 14.48% ± 2.1, 
Fibrin v AD-MSC p=0.26, Fibrin v BM-MSC p=0.3 n=7), no significant difference 
was observed between AD-MSC and BM-MSC (p=0.8). Eight animals were used 
for these experiments, however, one animal was excluded from wound image 
analysis as significant eschar was still present at d-14. In this case, the calculated 
percentage wound open was significantly deviated from the mean and was not 
suitable for inclusion in wound image analysis. These outliers are shown in 
Appendix III. 
 
4.3.2. Neither AD-MSC or BM-MSC significantly accelerated re-
epithelisation 
Re-epithelialisation of wounds is a primary determinant of wound healing. By d-
14, all wounds had re-epithelialised to some degree, with all wounds at least 
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over 50% re-epithelialised (Fibrin; 69.77% ± 3.6, AD-MSC; 80.32 ± 4.3, 
BM-MSC; 77.7% ± 4.1, Fibrin v AD-MSC p=0.27, Fibrin v BM-MSC p=0.34, n=8). 
There was improved re-epithelialisation in both AD-MSC and BM-MSC treated 
wounds however this was not significant when compared to control group 
(Figure 4.3 B). 
 
4.3.3. MSC therapy was associated with increased wound 
maturity 
As the wound matures more collagen is deposited giving the tissue greater 
strength. Initially collagen type III is deposited which is later replaced with 
stronger collagen type I. The quantification of collagen within the wound is an 
indicator of wound maturity. To evaluate this response, histological sections 
were stained with Masson’s tri-chrome (as described in section 4.2.3), which 
stains all collagen fibres blue and cell cytoplasm red (Figure 4.4 A). Nuclei were 
counter stained with Hematoxylin. Percentage of blue staining present on each 
wound section is a semi-quantitative indicator of collagen content and thus, 
wound maturity. Quantitative analysis of staining (randomly sampled at five 
points across the wound section) suggests significantly increased collagen 
content in both cell treated groups (Fibrin; 40.9% ± 2.1, v AD-MSC; 65.1% ± 3.1, 
v BM-MSC; 60.6% ± 3.3, Fibrin vs AD-MSC p<0.001, Fibrin vs BM-MSC p=0.002, 
AD-MSC vs BM-MSC p=0.13, n=8). Additionally, fibrin only treated wounds had 
markedly more cellular infiltrates within the wound bed, associated with ongoing 
inflammatory response.  
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The maturation of granulation tissue is driven by collagen formation but also by 
MMPs, which remodel and breakdown denatured proteins from the burn, and the 
TGF family of growth factors, which control fibrotic responses but also drive re-
epithelialisation [210]. Analysis of mRNA expression indicated neither collagen  
type I (COL1) (Fibrin; 1.05 ± 0.09 vs AD-MSC; 0.88 ± 0.06 vs BM-MSC; 1.08 ± 0.14) 
collagen type III (COL3) (Fibrin; 1.07 ± 0.11 vs AD-MSC; 0.88 ± 0.09 vs BM-MSC; 
1.12 ± 0.14) MMP2 (Fibrin;1.05 ± 0.09 vs AD-MSC; 0.88 ± 0.08 vs BM-MSC; 1.08 
± 0.10) or TGF-β ( Fibrin;1.04 ± 0.09  vs AD-MSC; 0.87 ±  0.09 vs BM-MSC; 1.16 ± 
0.15, n=8)  were significantly different in either MSC versus control group 
(Figure 4.4 B). For mRNA extraction, samples contained both healed wound 
margin and wound itself, which may have resulted in skewed qRT-PCR readouts.  
 
4.3.4. BM-MSC increased M2 macrophage population within 
wound 
To characterise the ability of MSC therapy to modulate inflammatory 
environment the M2 population within the wound bed was quantified using the 
M2 marker CD163. An increased number of CD163+ cells per high power field 
(HPF) was detected in BM-MSC treated wounds compared to fibrin treated 
wounds (Fibrin; 12.1 ± 4 v BM-MSC; 20.74 ± 6, AD-MSC; 20.49 ± 7.8, Fibrin vs BM-
MSC p=0.02, Fibrin vs AD-MSC p=0.16, AD-MSC vs BM-MSC p=0.99, n=8). Thus 
while AD-MSC treated wounds had a similar mean of CD163+ cells it was not 
statistically different as it had a greater variability. 
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The expression of several inflammatory cytokines at d-14 was analysed by qRT-
PCR, however, in all cases no significant differences were observed (Figure 4.5 
B). Cytokines assayed were IL-10 (Fibrin; 1.05 ± 0.23 vs AD-MSC; 0.91 ± 0.11 vs 
BM-MSC; 1.31 ± 0.44), TNFα (Fibrin; 1.20 ± 0.28 vs AD-MSC; 1.66 ± 0.63 vs BM-
MSC; 0.98 ± 0.2), IL-6 (Fibrin; 2.01 ± 0.82 vs AD-MSC; 1.30 ± 0.42 vs BM-MSC; 
4.34 ± 1.88) and IL-8 (Fibrin; 2.38 ± 0.86 vs AD-MSC; 2.33 ± 0.77 vs BM-MSC; 1.73 
± 0.66, n=8). 
 
4.3.5. Both AD-MSC and BM-MSC increased vessel density 
within the wound 
Immuno-histological staining demonstrated a modest but significant increase in 
vessel density per HPF in MSC treated wounds  as determined by quantification 
of αSMA+ vessels (Fibrin; 4.1 ± 0.8, v AD-MSC; 6.2 ± 0.9, v BM-MSC; 7.2 ± 1.3, 
Fibrin vs AD-MSC p=0.006, Fibrin vs BM-MSC p=0.04, AD-MSC vs BM-MSC 
p=0.29, n=8) (Figure 4.6 A). Increased αSMA vessel density is indicative of 
increased angiogenesis formation of stable vasculature and wound progression.  
Analysis of RNA expression of VEGF across wound and wound margin at d-14 
show no significant difference between groups (Fibrin 1.07 ± 0.12 vs BM-MSC; 




Figure 4.2 Application of MSC in porcine burn wounds increases wound closure at d-14 
A) Burn wounds were induced on dorsum of pigs and imaged on d-0 after debridement, prior to 
application of cells. Lower panel A) wounds were imaged on d-14 post wounding, blue drape in-
situ. B) Left - Quantification of wound area at d-0, no significant difference was observed. B) Right - 
Percentage wound open was calculated by dividing wound area at d-14 by original wound area. 
Treatment of wounds with either AD-MSC or BM-MSC improved wound closure, no significant 




Figure 4.3 MSC therapy did not increase re-epithelisation of burn wounds at d-14 
A) Histological samples of wounds taken at d-14 were stained with H&E to assess re-
epithelialisation. Several overlapping Images were taken at 4x and composite image formed of the 
entire section. Green arrows indicate epithelial front. Scale bar 500 μm. B) Percentage re-
epithelialisation was determined as epithelial gap divided by section length as measured using 




Figure 4.4 Application of MSC increased collagen deposition in porcine burn wound 
A) Histological samples of d-14 were stained with Masson’s tri-chrome as a semi quantitative 
measurement of collagen within the wound bed, scale bar = 100 μm. Percentage blue staining 
(indicative of collagen fibres) was quantified using NIS elements software. Increased collagen is 
associated with increased wound maturity (n=8, **p<0.05, *** p<0.001); presence of red staining 
(indicated with black arrows) suggests persistent inflammatory cellular infiltrate. B) qRT-PCR was 
performed on d-14 wound samples to evaluate the expression of collagen type 1(Col1), collagen type 





Figure 4.5 BM-MSC increased M2 macrophage population within the wound at d-14 
A) Wound sections from d-14 were probed with CD163 antibody (green) and nuclei stained with 
DAPI (blue) indicating increased M2 population in MSC treated wounds. However, only BM-MSC 
treated wounds had a statistically increase in CD163+ cells (n=8, ns, not significant, * p<0.05). B) 
Analysis of mRNA expression of several inflammatory cytokines across the wound and healed wound 
margin by qRT-PCR. No statistically significant differences were observed between any of the groups 




Figure 4.6 MSC therapy induced angiogenic response within the wound 
A) wound sections at d-14 were probed with SMA antibody (green) and nuclei stained with DAPI 
(blue). SMA+ vessels were quantified (intact vessel lumen highlighted with white arrows) within the 
wound bed. Both AD-MSC and BM-MSC treated wounds had increased vessel density per HPF (n=8, 
ns, not significant * p<0.05, ** p<0.01). B) Analysis of VEGF expression by qRT-PCR across the wound 
and wound margin showed no statistically significant difference between groups (n=8, ns, not 
significant)   
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4.4.  Discussion 
 
The aim of this chapter was to determine the optimal cell source of MSC used for 
treating burn wounds. AD-MSC has many benefits in terms of availability, ease of 
isolation and expansion potential. In vitro analysis of immune regulatory and 
angiogenic responses suggest that AD-MSC may also be more beneficial [114, 
201]. However, preclinical animal studies of AD-MSC in burn wound healing are 
lacking and to the best of the author’s knowledge, there are no published 
equivalency studies of AD-MSC and BM-MSC in burn wound healing. Pre-clinical 
studies in large animal models are required to validate and optimise potential 
therapies prior to clinical trials. The porcine burn model is beneficial as porcine 
skin is quite histologically similar to humans and is a good predictor of human 
response [211]. Pigs, like humans have a fixed skin, heal primarily through re-
epithelisation and do not have a panniculus carnosus, a subdermal muscle layer, 
which is present in rodents [211].   
 
4.4.1. Equivalency studies of AD-MSC and BM-MSC in wound 
healing models 
Donor matched MSC isolated from both adipose tissue and BM were used to treat 
deep partial thickness burns. The primary endpoints for the assessment of the 
rate of wound healing were wound size, as measured by image analysis; and re-
epithelisation, as measured by histology. Treatment of burns with either cell type 
significantly improved wound closure. Whilst this is the first equivalency study, 
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other studies have reported similar findings independently for each cell type. 
Previously, this lab has established a porcine burn model and published a pilot 
study (n=3) comparing efficacy of allogenic BM-MSC  in fibrin vs cultured 
autologous PBMNC in fibrin vs fibrin only vs dressings only [149]. In that study 
allogeneic MSC were the most efficacious treatment, increasing wound closure 
and granulation tissue [149].  There was no significant difference between fibrin 
only and dressing only groups [149]. Only three other studies using a pig burn 
model could be identified in a review of the literature (Appendix I). In one study 
by Mansilla et al (2010), a large 300 cm2 full thickness burn was induced on the 
pig [212]. The burnt tissue was immediately excised and a combination of two 
treatments of BM-MSC (2x106/cm2) delivered in fibrin and one treatment of a 
dermal matrix coated with CD44 antibodies was applied [212]. Mansilla et al 
report outstanding regeneration of both bone, muscle and dermal structures 
along with minimal scarring and regrowth of hair follicles [212].  However, this 
study is very limited as it does not have a control group and these findings are 
only from one pig. Despite such a positive outcome it is disappointing that no 
larger follow up studies have ever been performed.  
In a more comparable study, Liu et al induced deep partial thickness burns (19.6 
cm2, 100°C for 20 s) on the dorsum of anesthetised pigs and applied collagen 
scaffolds seeded with allogenic BM-MSC (1x105/cm2) to the wounds [180]. 
Similar to the findings reported here, MSC increased wound healing, reduced 
wound contraction at 4 weeks and improved histological appearance compared 
to control and scaffold only treated wounds [180]. However, Liu et al did not 
investigate any immune or angiogenic responses to the treatment. 
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Another study performed in pigs used autologous BM-MSC (ID injection of 
0.8x106/cm2) to treat deep partial thickness burns (100°C, 15 s under defined 
pressure of 0.5 kg/ cm2, wound area 2.5 cm2) [188]. Histological examination of 
wounds indicated a trend towards increased granulation tissue on d-14 and d-
21, increased capillary sprouting was observed in BM-MSC group but was not 
significantly different to control. No significant difference was observed in re-
epithelisation but, as seen in the current study, a trend towards increased re-
epithelialisation was noted [188].  
As stated above, there is a lack of studies investigating MSC in porcine burn 
models; however, AD-MSC and BM-MSC have been studied in a porcine excisional 
wound healing model [115]. Excisional wounds (4 cm2) were induced and treated 
with an ID injection of either AD-MSC or BM-MSC (1x106) [115]. Cosmetic 
appearance was improved with MSC treatment as assessed by Vancouver scar 
scale and importantly, no significant difference was observed between AD-MSC 
and BM-MSC groups [115]. In agreement to results presented here, no significant 
increase in re-epithelisation was observed between treated and non-treated 
groups [115]. However, an increase in epidermal thickness was noted at d-21 in 
MSC treated wounds compared to saline controls. Taken together our current 
results suggest that application of either cell type induces a biological response 
associated with improved wound healing and that neither cell type is more 
efficacious.  
Similar to Lui et al, the study by Hanson et al was limited in scope by assessing 
only histological features. The limited availability of antibodies and assays 
available made mechanistic insights of these therapies in porcine models 
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difficult, but valuable. In this study a modest increase in wound closure (and a 
trend towards increased re-epithelialisation) was observed in wounds treated 
with either BM-MSC or AD-MSC. This was associated with increased angiogenic 
and immune response. Several studies of burn wound healing in rat models 
support this finding as detailed in Appendix I and Appendix II [213-215]. 
In this study wound closure was calculated from images taken of the wound at d-
0 and d-14 and areas calculated from image analysis software. Wound closure is 
composed of both wound contraction and re-epithelisation components [216]. In 
full thickness excisional models wound contraction is the dominant component, 
as underlying dermis is removed, stimulating myofibroblast proliferation and 
subsequent activation of contractile proteins leading to wound contraction [211, 
217]. In this model the wound was not excised and underlying dermis was not 
disrupted which prevents major contraction. While image analysis of wounds is 
a good macro indicator of wound progression it is not ideal for assessing the 
contribution of contraction to wound closure. To better determine its 
contribution permeant marking of original wound outline using tattooing could 
be utilised.   As wound contraction was not expected to be a major component in 
this model, we used histological analysis of re-epithelialisation as a primary 
endpoint of wound healing, which gives much greater resolution to detect 




4.4.2. Mechanism of MSC accelerated wound healing  
Previously, it has been established that MSC can repolarise macrophage 
population towards a reparative M2 phenotype to elicit improved wound healing 
[20]. To characterise this response, sections were interrogated with a CD163 (M2 
marker) antibody. A greater amount of CD163+ cells were detected in wound 
beds of MSC treated wounds but this was only significant in BM-MSC treated 
wounds shown in Figure 4.5 A, AD-MSC displayed a trend toward increased 
CD163+ infiltration but increased variation between animals in this treatment 
group limited statistical significance. No significant difference between groups 
could be detected in the expression of several inflammatory cytokines by qRT-
PCR analysis (Figure 4.5 B). However, wound samples used for qRT-PCR analysis 
consisted of the whole wound plus outer healed wound margin which may have 
normalised the results. Although d-14 is not an ideal time point to capture some 
of the dynamics in expression of these cytokines, the fact that no significant 
difference was observed in any of the several cytokines and growth factors 
assayed is unexpected. The RNA used was validated as high purity and was not 
degraded, in addition the custom assay obtained from Qiagen contained both 
positive, negative and genomic DNA contamination controls, all of which were 
satisfactory. This possible sampling bias is apparent in all of the qRT-PCR 
results (no significant differences were detected in any of the assays). 
Immunofluorescent imaging was performed in the wound bed and may be more 
representative of the wound microenvironment. The immuno-staining results 
obtained here are in better agreement with previous findings in the literature. 
Similar findings of increased M2 population in MSC treated wounds have been 
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shown in MSC treated burn wounds of rats, mice and also in excisional wound 
healing [20, 191, 213]. 
Treatment of wounds with either cell type resulted in increased vessel density 
(Figure 4.6 A). Normally CD31 would be used as a marker for endothelial cells 
and vascular density, however two different CD31 antibodies were tested 
unsuccessfully on these porcine wound sections. An antibody for αSMA was 
successful however in detecting antigens in these wound sections and this was 
used to quantify vessel density. αSMA is a contractile protein expressed in 
pericytes that line capillaries and other larger vessels. During early phase of 
wound healing, VEGF stimulates the sprouting of endothelial tubes; after several 
days the new vasculature is stabilised by pericytes and VEGF is no longer 
required to maintain endothelial sprouts [209]. This may also account for The 
lack of difference in VEGF expression between experimental groups as detected 
by qRT-PCR on day 14. Many studies corroborate the finding of increased 
vascular density in response to MSC treatment in burn wounds [214, 215, 218, 
219]. While several in vitro studies suggest that AD-MSC may be more angiogenic 
[197, 198], no significant difference was observed in vessel density in the wound 
sections between BM-MSC or AD-MSC treated wounds in this study. A good blood 
supply is crucial for the formation of granulation tissue (and subsequent re-
epithelialisation) and for survival of cells, and this appears to be one of the 




In conclusion, the findings of this study suggest that both AD-MSC and BM-MSC 
have a biological response associated with improved wound healing. However, 
application of either cell type did not improve re-epithelisation, one of the 
primary endpoints. While a positive biological response was observed, it was 
quite modest.  In an effort to improve the efficacy of this therapy and to determine 
if either cell type has a differential response, cells were pre-stimulated with the 










5. TNF alpha pre-treatment of MSC enhances efficacy in 






MSC treatment in humans has been demonstrated to be safe; however, results 
from clinical trials indicate mixed and somewhat disappointing therapeutic 
results across a range of pathologies. Based on the modest therapeutic effect 
observed in chapter 4, a means of enhancing MSC efficacy was investigated. 
Recent studies emanating from our current mechanistic understanding of MSC 
therapy have attempted to promote or over-drive certain aspects of it, in order 
to increase the therapeutic effect. For instance, MSC are known to elicit a potent 
angiogenic response and are beneficial in ischemic limb studies [220].  One of the 
primary mechanisms of this is through VEGF. MSC engineered to over express 
VEGF, using a lenti-viral vector, had a fourfold increase in VEGF secretion [220]. 
Injection (IM) of MSC/VEGF significantly increased blood flow (at 6-11 weeks) as 
assessed by Doppler in a mouse model of hind-limb ischemia [220]. One of the 
primary deficiencies of MSC is their low engraftment and survival after 
transplantation, and thus several studies have investigated strategies 
overexpressing pro-survival factors including B-cell lymphoma 2 (BCL-2) [221] 
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or AKT [222] which enhanced their persistence within the tissue following 
transplantation.   
Lentiviral overexpression of SDF-1 in MSC enhanced cardiomyocyte survival in a 
mouse model of MI; through C-X-C motif chemokine receptor 4 (CXCR4) 
activation in cardiomyocytes within the border zone [223]. This approach was 
beneficial in terms of MSC retention and homing to sites of injury and was 
combined with over-expression of VEGF to further enhance efficacy [224].  
Other non-viral strategies to improve MSC functionality included 
preconditioning MSC in various culture conditions, such as under hypoxia; the 
rationale being that in vivo MSC usually exist in hypoxic conditions and culturing 
under such, may enhance their regenerative potential. Hypoxic conditioning (HC) 
increased MSC motility and responsiveness to HGF [225]. Significantly, HC-MSC 
induced revascularisation of mouse model in a hind limb ischemia at earlier time 
points than MSC cultured under normoxic conditions [225]. 
Recent studies have elucidated idiosyncrasies in MSC immunomodulation [226]. 
Unstimulated MSC injected prior to induction of dextran sulphate sodium 
induced  colitis had no therapeutic effect [226]. This observation led to the 
concept of MSC licensing or activation, which is a multi-step process defined as 
the functional maturation of MSC in response to inflammatory micro 
environmental cues [227]. Under resting conditions MSC can take on either anti-
inflammatory or antigen presenting and pro-inflammatory functions [227]. 
Activation or licensing of MSC in response to inflammatory cytokines such as 
TNFα, IL-β and IFNγ stimulate MSC to alter their secretome and to release 
106 
 
increased amounts of immunomodulatory factors such as TSG-6 PGE2, IDO and 
IL-4 [227].  
Previous studies indicate that pre-treatment of MSC with inflammatory cytokines 
may improve their therapeutic potential [79]. Pre-treatment of MSC with IFNγ 
prior to application to a model of colitis improved therapeutic efficacy through 
increased immunosuppressive capacity of transplanted MSC [228].  In a rat 
model of MI, TNFα activated (10 ng/ml 24 h) MSC increased expression of several 
factors including IL-6, BMP-2 and CCL-2 [229]. Pre-treated MSC were superior to 
untreated MSC in reduction of myocardial fibrosis and significantly improved 
recovery of ejection fraction post MI [229]. Similarly, TNFα activated MSC 
increased localisation of MSC in ischemic limbs, mediated in part through 
increased expression of ICAM-1 [230]. Other studies using MSC CM have shown 
beneficial results when pre-treated with TNFα [80]. Activation of MSC with a 
combination of TNFα, IL-1β and NO was beneficial improving radiation induced 
intestinal injury in rats [231]. In a mouse model of ischemic limb TNFα stimulated 
MSC CM significantly attenuated limb loss compared to non-stimulated MSC CM 
[75]. In cutaneous wound healing studies in mice, TNFα pre-treated MSC CM 
accelerated wound healing compared to saline control [80]. Normal MSC CM did 
not significantly increase wound closure. In TNFα MSC CM treated group, wound 
closure was significantly increased on d-6 and d-9, while epithelialisation was 
also improved [80]. Histological analysis demonstrated increased angiogenesis 
and significant recruitment of CD68+ macrophages on d-3 and d-6, in a IL-6 and 
IL-8 dependent manner [80].  
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Pre-treatment of MSC with TNFα is a potentially advantageous way to improve 
efficacy as it is a simple addition to culture medium and potentially improves 
several key aspects of MSC therapy, through increased angiogenesis [75], 
immunomodulatory capacity [79] and engraftment or persistence [229], all of 
which are particularly relevant to burn wounds.  
However, to the best of the author’s knowledge no studies have investigated the 
effect of TNFα in a burn wound model, nor in a porcine animal model. Moreover, 
several studies report MSC isolated from different tissues exhibit differential 
responses to inflammatory cytokines [83, 232, 233]. 
To test the hypothesis that TNFα pre-treatment of MSC would increase 
therapeutic response and to determine if either cell type responded more 
favourably, both AD-MSC and BM-MSC were pre-treated with TNFα prior to 
wound application and wound healing was evaluated.  
 
5.1.1. Chapter aims 
 To determine if TNFα pre-treatment of MSC will enhance therapeutic 
efficacy in porcine burn wound model 
 To establish if there is a differential response of MSC isolated from either 





5.2. Materials and methods  
 
5.2.1. TNFα pre-treatment of porcine MSC 
In this study, the therapeutic efficacy of allogenic MSC derived from either BM or 
adipose tissue pre-treated with recombinant porcine TNFα was investigated. The 
study consisted of two experimental treatments; TNFα pre-treated AD-MSC, 
TNFα pre-treated BM-MSC and a control treatment of fibrin only. A total of six 
animals were used in this study and each animal received all three treatments 
(12 wounds in total, 4 wounds per group) providing intra animal controls. 
Allogenic AD-MSC and BM-MSC isolated from the same donor pig were 
characterised, as described in section 3.2, prior to use in the following burn 
experiments. Cells isolated from six different donor pigs were used in the 
following experiments.  
Both AD-MSC and BM-MSC were pre-treated with 10 ng/ml of recombinant 
porcine TNFα (R&D systems) in complete culture media for 24 h prior to 
harvesting and administration in burn wound. 





5.3.1. MSC treatment of burn wounds increase rate of wound 
closure 
After induction of wounds and debridement, wounds were imaged (Figure 5.1 A 
upper panel), wound area was similar for all groups, combined mean was  4.8 
cm2 ± 0.08. After 14 d, wounds were imaged (lower panel Figure 5.1 A) and 
wound closure calculated as shown in Figure 5.1 B. Treatment of wounds with 
either cell type significantly increased wound closure on d-14 (Fibrin; 15.54% ± 
2.0 vs AD-MSC; 8.5% ± 1.9 vs BM-MSC; 7.7% ± 2.1, Fibrin v AD-MSC p=0.003, 
Fibrin v BM-MSC p<0.001, AD-MSC vs BM-MSC p=0.72, n=6). No significant 
difference was observed between AD-MSC and BM-MSC. Wound closure was 
superior in TNFα pre-treated MSC to untreated MSC (Figure 4.2 B) 
 
5.3.2. TNFα pre-treated MSC significantly increase re-
epithelisation 
One of the primary evaluations of wound healing is re-epithelialisation. This was 
determined from histological sections of the wound taken from d-14 and stained 
with H&E (Figure 5.2). At d-14 re-epithelialisation was significantly improved in 
both AD-MSC and BM-MSC groups (Fibrin 62.9% ± 5.9, vs AD-MSC 88.8% ± 3.6, 
vs BM-MSC 96.7% ± 2.0, Fibrin v AD-MSC p=0.003, Fibrin v BM-MSC p=0.014, AD-
MSC vs BM-MSC p=0.264, n=5). This is significantly greater re-epithelialisation 
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than observed in MSC without TNFα pre-treatment (Figure 4.3 B). Importantly, 
no significant difference was observed between AD-MSC and BM-MSC. Due to a 
paraffin embedding tissue processing error, samples from one animal could not 
be used for histological analysis (hence n=5) but samples from this animal were 
suitable for immunostaining and RNA extraction.  
 
5.3.3. MSC therapy is associated with increased wound 
maturity 
Collagen deposition was assessed using Masson’s trichrome staining. Histological 
sections from the wound were imaged at five random sections within the wound 
bed (data shown in Figure 5.3 A). Increased percentage of blue staining (semi 
quantitative indictor of collagen content) was observed in both MSC treated 
wounds in comparison to Fibrin alone (Fibrin, 34.9% ± 3.9, vs AD-MSC 75.32% ± 
4.3, vs BM-MSC, 74.2% ± 3.8, Fibrin v AD-MSC p<0.001, Fibrin v BM-MSC p<0.001, 
AD-MSC vs BM-MSC p=0.982, n=5), suggestive of more collagen content, a marker 
for wound maturity. Fibrin only treated wounds displayed more red staining, 
(cytoplasm stains red) indicative of cellular infiltrate still present within the 
wound, which was not observed in MSC treated groups. TNFα pre-treated MSC 
had greater percentage blue staining compared to untreated MSC (Figure 4.4 A) 
Analysis of mRNA expression at d-14 did not reveal any difference in expression 
of either COL1 (Fibrin; 1.32 ±  0.17 AD-MSC; 1.33 ± 0.14 BM-MSC; 1.15 ± 0.13) 
COL3 (Fibrin; 1.33 ±  0.16 AD-MSC; 1.28 ± 0.08 BM-MSC; 1.25 ± 0.1), TGF-β3 
(Fibrin; 1.25 ±  0.1 AD-MSC; 1.2 ± 0.07 BM-MSC; 1.06 ± 0.08) or MMP-2 (Fibrin; 
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1.01 ±  0.12,vs AD-MSC; 0.94.33 ± 0.09, vs BM-MSC; 0.81 ± 0.08) in samples 
containing both wound and healed wound margins (data shown in Figure 5.3 B). 
 
5.3.4. Pre-treated MSC significantly induce M2 population 
within the wound 
In the previous chapter (Figure 4.5 A), quantification of immunostaining 
indicated that application of BM-MSC induced a modest but statistically 
significant increase in M2 macrophages within the wound as demonstrated by 
increased CD163+ cells. Treatment of burn wounds with TNFα pre-treated MSC 
markedly increased CD163+ cells within the wound bed in contrast to findings 
from chapter 4 (section 4.3.4) and this was significant for both AD-MSC and BM-
MSC (Fibrin; 17.5 ± 2.7 vs AD-MSC; 35.2 ± 2.0, vs BM-MSC; 40.4 ± 3.0, Fibrin v AD-
MSC p=0.006, Fibrin v BM-MSC p=0.001, AD-MSC vs BM-MSC p=0.182, n=6) as 
shown in Figure 5.4 A., suggestive of an increased inflammatory resolution 
response and wound progression. Notably, no significant difference was 
observed between AD-MSC and BM-MSC groups.  
Analysis of RNA expression (Figure 5.4 B) at d-14 of several inflammatory 
cytokines across the wound and the wound margin by qRT-PCR did not 
demonstrate any significant differences between control and treatment groups 
for TNFα (Fibrin; 1.27 ±  0.15, vs AD-MSC; 1.74 ± 0.24, vs BM-MSC; 1.79 ± 0.26, 
Fibrin vs AD-MSC p=0.347, Fibrin vs BM-MSC p=0.375  AD-MSC vs BM-MSC 
p=0.988, n=6), IL-6 (Fibrin; 2.32 ±  1.49 AD-MSC; 0.69 ± 0.21 BM-MSC; 0.65 ± 0.25 
Fibrin vs AD-MSC p=0.55, Fibrin vs BM-MSC p=0.541 AD-MSC vs BM-MSC 
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p=0.942,) IL-8 (Fibrin; 1.75 ±  0.77 AD-MSC; 0.47 ± 0.14 BM-MSC; 0.64 ± 0.21, 
Fibrin vs AD-MSC p=0.902, Fibrin vs BM-MSC p=0.388  AD-MSC vs BM-MSC 
p=0.374, n=6) or IL-10 (Fibrin; 0.67 ±  0.07 vs AD-MSC; 0.65 ± 0.1 vs BM-MSC; 
0.62 ± 0.1, Fibrin vs AD-MSC p=0.981, Fibrin vs BM-MSC p=0.906  AD-MSC vs BM-
MSC p=0.968, n=6). 
 
5.3.5. TNFα pre-treated MSC significantly increase vessel 
density within the wound 
On d-14, both AD-MSC and BM-MSC treated wounds had significantly increased 
vessel density per HPF (Fibrin; 4.4 ± 0.4, vs AD-MSC; 12.2 ± 2.0, vs BM-MSC; 10.2 
± 0.5, Fibrin v AD-MSC p=0.031, Fibrin v BM-MSC p=0.001, AD-MSC vs BM-MSC 
p=0.569, n=6) as shown in Figure 5.5 A. Analysis of VEGF expression (in Figure 
5.5 B) by qRT-PCR across the wound and wound margin showed no significant 
difference between groups (Fibrin; 0.94 ±  0.09 AD-MSC; 0.86 ± 0.08 BM-MSC; 
0.87 ± 0.04, Fibrin v AD-MSC p=0.655, Fibrin v BM-MSC p=0.831, AD-MSC vs BM-









Figure 5.1 TNFα pre-treatment of MSC increased wound closure at day 14 
A) Burn wounds were induced on dorsum of pigs and imaged on d-0 after debridement, prior to 
application of cells. A) Lower panel - Wounds were imaged on d-14 post wounding. B) Left - 
Quantification of wound area at d-0. No significant difference was observed between wound areas 
at d-0. B) Right - Treatment of wounds with MSC significantly increased wound closure on d-14 




Figure 5.2 TNFα pre-treatment of MSC increased re-epithelialisation of burn wounds at d-14 
A) Histological samples of wounds taken at d-14 were stained with H&E to assess re-
epithelialisation. Several overlapping Images were taken at 4x and composite image formed of the 
entire section. Black arrows indicate epithelial front, inset shows magnified image of migrating 
front. Scale bar 500 μm. B) Percentage re-epithelialisation was measured using ImageJ software. 
MSC therapy primed with TNFα significantly increased re-epithelisation of wounds (n=5 ns, not 





Figure 5.3 TNFα pre-treated MSC increased wound maturity  
A) Histological samples of d-14 were stained with Masson’s tri-chrome. Scale bar 100 μm. 
Percentage blue staining (indicative of collagen fibres) was quantified using NIS elements software 
(n=5 *** p<0.001). B) qRT-PCR was performed on d-14 wound samples containing both the wound 
and wound margins to evaluate the expression of collagen type 1(Col1), collagen type 3 (Col3), MMP-





Figure 5.4 TNFα pre-treated MSC increased  CD163+ population within the wound 
A) Wound sections from d-14 probed with CD163 antibody (green), nuclei stained with DAPI (blue), 
indicate significantly increased M2 macrophage population within the wound bed of both AD-MSC 
and BM-MSC treated wounds (n=6, ns, not significant ** p<0.01) No significant difference was 
observed between AD-MSC and BM-MSC groups. B) Analysis of RNA expression of several 
inflammatory cytokines across the wound and the wound margin by qRT-PCR. No significant 




Figure 5.5 TNFα pre-treated BM-MSC induced angiogenic response within the wound 
A) wound sections d-14 were probed with SMA antibody(green), nuclei stained with DAPI (blue). 
SMA+ vessels were quantified within the wound bed; white arrows highlight intact vessel lumens. 
Both AD-MSC and BM-MSC treated wounds had increased vessel density per HPF (n=6, ns, not 
significant * p<0.05, ** p<0.01). B) Analysis of VEGF expression by qRT-PCR across the wound and 







In chapter 4, MSC were used to treat deep partial thickness burns in a pig model. 
Application of either AD-MSC or BM-MSC improved wound closure, however the 
effect was modest and no significant increase in re-epithelialisation, a primary 
determinate of wound healing, was observed in either group. Pre-stimulating 
MSC with inflammatory cytokines has been established to be beneficial in 
improving immunomodulatory and angiogenic functions of MSC therapy [75, 80]. 
However, this has not been explored in a burn wound model. In this study, the 
effectiveness of TNFα pre-treatment of MSC was investigated in a porcine burn 
wound model.  
Porcine MSC were incubated for 24 h in culture media containing 10ng/ml 
recombinant porcine TNFα. The cells were harvested and the porcine burn model 
was performed as described in section 4.2.1. Measurement of wound closure 
demonstrated an accelerated rate of wound healing. Crucially, TNFα pre-treated 
MSC significantly increased re-epithelisation, a primary determinant of wound 
healing. TNFα pre-treatment of MSC was superior to untreated MSC as neither 
AD-MSC or BM-MSC significantly increased re-epithelisation in as shown in 
Figure 4.3, chapter 4 (despite a trend towards increase). These results  are in 
agreement with  a previous study  by Heo et al, who used MSC CM  to treat rat 
excisional wounds [80]. Application of TNF MSC CM significantly enhanced 
wound closure and re-epithelialisation [80]. This latter finding would support a 
paracrine effect. Depletion of CM with IL-6 or IL-10 reduced re-epithelisation and 
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wound closure [80]. In an in vitro wound healing study using bronchial epithelial 
cells, treatment with TNFα and IL-1β pre-treated MSC CM resulted in enhanced 
wound closure compared normal MSC CM mediated through EGF receptor 
activation and downstream ERK signalling [234]. Stimulation of MSC with TNFα 
revealed increased expression of several factors including IL-6, EGF, FGF-2, VEGF 
[234]. TNFα also increased PGE2, HGF and TGF-β1 [79] along with TSG-6 [235] 
BMP-2, CCL-2 and VEGF [229]. 
In this study, quantification of αSMA positive vessels indicated an increased 
stable vascular density in burn wounds treated with TNF pre-treated MSC, 
suggestive of increased wound healing progression.  In line with results for re-
epithelialisation and wound closure, no significant difference was observed 
between AD-MSC and BM-MSC treated wounds. Increased vessel density was also 
noted compared to untreated MSC (Figure 4.6). Application of MSC therapy in 
burn wounds has been previously shown to induce an angiogenic response in 
mice [214],  rats [191] and in pigs [180].  TNFα pre-treated MSC provide a potent 
angiogenic stimulus driven through secretion of a factors such as  CCL-2, VEGF 
and HGF [72, 236]. In conjunction, increased VCAM-1 expression in MSC in 
response to TNFα may also augment endothelial cell interaction [237]. In this 
study, qRT-PCR analysis of treated wounds did not show any increased 
expression of VEGF. This discrepancy may be accounted for the timing of VEGF 
measurement. VEGF released from MSC may occur at an earlier time point and 
by d-14 MSC expressing VEGF are likely absent from the wound. The quantified 
αSMA+ vessel density accounts for stable non leaky vasculature that have 
pericyte covering and therefore do not require VEGF to sustain. TNFα stimulated 
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MSC CM increased αSMA+ vessel density and limb salvage in a mouse model of 
hind limb ischemia, partially mediated through IL-6 and IL-8 [75]. Increased 
endothelial cell migration was observed in response to TNFα MSC CM compared 
to control CM and this could be attenuated by IL-6 and IL-8 blocking antibodies 
[75].  
In addition to increased vessel density,  a significant increase in CD163+ cells was 
observed.  CD163 is a marker for M2 macrophages and this increase in M2 
population within the wound suggests a shift from inflammatory to reparative 
phenotype of the wound environment in line with other studies [191, 208, 216]. 
The induction of M2 macrophages was far superior in TNFα pre-treated MSC 
compared to untreated MSC Figure 4.5 A). qRT-PCR analysis of several pro/anti-
inflammatory cytokines did not detect a difference in expression between treated 
and untreated wounds. As discussed in section 4.4.2 the sample used contained 
both healed wound margin and unhealed wound and therefore may have skewed 
the result. It should also be noted that this study was not designed to capture 
these shifts in inflammatory phenotype of the wound. The primary endpoint of 
this study was to detect a difference in wound healing outcomes specifically, 
wound closure and re-epithelialisation. Analysis of d-3 or d-5 may be a more 
appropriate time point to capture these inflammatory cell dynamics within the 
wound.   
Macrophage repolarisation, a key feature of MSC therapy, has been reported in 
several other studies [20, 102, 191] and is associated with fibroblast proliferation 
and angiogenesis. This is in agreement with findings presented here, which show 
increased vessel density and increased collagen content within the wound (as 
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assessed by Masson’s trichrome staining). Taken together these studies support 
the concept that a reduced inflammatory response coupled with increased 
granulation tissue which in-turn is supported by increased vascularisation may 
be promoting accelerated re-epithelialisation and wound closure as observed in 
this study.  
Low or transient engraftment of MSC in many interventions and trials remains 
an issue that is seen to limit the therapeutic capacity of MSC [238]. TNFα 
stimulation of MSC can induce expression of ICAM-1 and VCAM-1, adhesion 
molecules involved in cell interactions and may also play a role in increased 
engraftment of MSC. In a rat model of MI, MSC were pre-treated with (10ng/ml) 
TNFα and stained with DAPI prior to IV injection [229]. Two weeks later heart 
tissue was collected and increased amounts of DAPI labelled TNFα pre-treated 
MSC were located in infarct boarder zone compared to untreated MSC. 
Functionally, TNFα pre-treated MSC were therapeutically superior, enhancing 
ejection fraction and reducing fibrosis of the left ventricle [229]. Previous studies 
in our lab have established that few MSC persist in wounds after two weeks [149] 
and it would be interesting to see if TNFα pre-treatment increased engraftment 
of MSC within the burn wounds and if this was indeed mediated through VCAM-
1 or ICAM-1 expression and if this was correlated with increased efficacy. Further 





5.4.1. TNFα induced immunomodulation in MSC 
Compared to the findings from chapter 4 an increased M2 population is observed 
within the wound at d-14. This increased presence of M2 macrophages is 
suggestive of increased immune regulatory capacity of MSC driven by TNFα pre-
treatment and several studies support this finding [79, 80, 105, 132]. In vitro 
stimulation of MSC with TNFα increases secretion of key immunomodulatory 
factors such as TSG-6 [105], CCL-2 [132] and COX-2 [79] which is metabolised to 
give PGE2 [79]. To further characterise total macrophage numbers within the 
wound, frozen sections were stained with several porcine specific antibodies 
(including SWC8-BioRad, CD68-BioRad, CD45-Abcam, UK) however these 
commercial antibodies were unable to successfully detect frozen tissue antigens, 
this is an acknowledged disadvantage of the porcine model in that limited tissue 
specific antibodies are available. It would be useful to determine if increased 
macrophage recruitment was occurring or if increased repolarisation was 
driving this process. It is plausible that both of these processes are contributing 
to increased M2 population in a synergistic way. A study by Ren et al elegantly 
demonstrated CCR-2 dependent recruitment of macrophages by tumour 
associated MSC is driven by the chemokine CCL-2 [132]. CCL-2 is a potent 
chemotactic factor for inflammatory macrophages. Polarisation of macrophages 
towards a M2 type was driven by tumour associated MSC and assisted tumour 
growth [132]. Analysis of tumour associated MSC showed that they secrete 
increased amount of CCL-2, and inhibition of CCL-2 prevented tumour growth 
[132]. Stimulation of normal MSC with TNFα increased CCL-2 and enhanced 
tumour growth, mimicking tumour associated MSC. Ren et al showed that MSC 
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are stimulated by the tumour through TNFα, this induces them to secrete 
increased amounts of CCL-2. This in turn recruits CCR-2+ macrophages to the 
tumour site [132]. They proposed that this interaction with macrophages and 
MSC drove inflammatory macrophages towards an M2 type (via PGE2 and other 
mechanisms) and facilitated growth of the tumour [132]. One could speculate 
that a similar mechanism is at play in the burn wounds treated with TNFα 
stimulated MSC. This may account for increased CD163+ cells and improved 
wound healing. Similarly, this same mechanism could also account for increased 
angiogenesis observed in the wounds which has been shown to be driven by a 
small population of CCR-2+ macrophages [239]. 
The results herein suggest that TNFα may promote increased wound healing 
through CCL-2 mediated interaction with macrophages. This is an interesting 
hypothesis that requires further investigation. However, while the pig is excellent 
for pre-clinical efficacy studies, it is not well suited for such mechanistic studies. 
To explore the role of CCL-2 would require knockdown or inhibition of CCL-2 in 
MSC. This would be challenging in a larger model as genetically modified pigs are 
not available and the production of a therapeutic numbers of CCL-2 deficient 
porcine MSC (via lentivirus or SiRNA knockdown) would be impractical (based 
on the amount of reagents required). In this context the mouse is more suitable, 
inducing a partial thickness burn in mice is technically challenging and highly 
variable due to its thin skin (50 μm thick) and small size [217]. A simpler, more 
practical and reproducible model is the mouse excisional wound healing model. 
While important differences exist between excisional wounds and burn wounds 
(such as increased necrosis, eschar and vascular permeability), this model allow 
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us to explore the role of MSC derived CCL-2 and gives us a basis for interrogation 
of the mechanism behind TNFα mediated increased efficacy demonstrated in this 
section. Therefore, in the next chapter the role of CCL-2 is investigated in a mouse 
model of excisional wound healing. 
 
In conclusion, pre-treatment of either AD-MSC or BM-MSC significantly 
accelerated wound closure and wound re-epithelialisation. This was associated 
with increased M2 population within the wounds at d-14 and increased 
angiogenesis. TNFα pre-treatment is an easy and less problematic method (then 
genetic modification) to increase the efficacy of MSC therapy for cutaneous 
wound healing. Co-stimulation with other inflammatory cytokines such as IFNγ 
may further increase efficacy.  Neither AD-MSC or BM-MSC were therapeutically 
superior. Therefore, based on findings from this study, AD-MSC would be the 
optimal cell source as it is therapeutically equivalent to BM-MSC but has more 
scalable potential and ease of isolation.    
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6.  MSC secreted CCL-2 has a non redundant role in 





Macrophages are pivotal in controlling the progression of wound repair phases 
[138, 240, 241] In cutaneous wound healing, macrophages are the principal 
producer of cytokines and chemokines involved in stimulating angiogenesis, 
collagen formation and re-epithelialisation [138]. Conceptually, macrophages 
can be broadly divided into two phenotypically distinct groups, M1 
(inflammatory) and M2 (reparative); however, in reality they exist in a 
continuum and alter their phenotype in response to cues from the local micro 
environment. In the early stages of wound healing M1 macrophages predominate 
and are associated with increased TNFα and NO. As the wound progresses, M2 
macrophages become more abundant and begin to dominate cytokine 
production, TNFα declines and IL-10 significantly increases.  Experimental 
depletion of either cell type can significantly hinder wound healing and several 
studies have demonstrated that dysregulation of this M1-M2 progression can 
lead to chronic non-healing wounds [205, 240-243]. 
Several studies have corroborated findings that MSC therapy accelerates wound 
healing, which is mediated through soluble factors and cell contact mechanisms 
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leading to increased angiogenesis, granulation tissue formation and re-
epithelialisation [20, 50, 58]. Previous studies have also established that MSC 
have immuno-modulatory properties and can skew M1 macrophages towards 
and an M2 phenotype, thereby accelerating wound healing progression [20]. This 
mechanism is cell contact dependent and involves PGE2, among others [96, 244].   
 The chemokine CCL-2 has many biological functions (as outlined in section 
1.3.3), in both the normal recruitment of monocytes and macrophages to 
inflamed tissues [122, 127], as a driver of angiogenesis [126] and in bone 
reabsorption [245]. CCL-2 is required for normal progression of wound healing 
phases, in a mouse model of excisional wound healing CCL-2 KO mice had 
reduced re-epithelialisation and reduced angiogenic activity and collagen 
deposition associated with reduced macrophage infiltration of wounds [127, 
246]. The concentration of CCL-2 within wounds peaks at d-1 and is associated 
with neutrophil driven monocyte recruitment to the wound [127].  
Several cell types including MSC, secrete CCL-2 and MSC derived CCL-2 has been 
suggested to be involved in recruitment of M1 macrophages in cutaneous wound 
healing [58], thereby allowing for polarisation towards an M2 phenotype. 
However, this has not been experimentally demonstrated. 
While there is much evidence for a role of CCL-2 in recruiting macrophages, the 
role of CCL-2 in MSC modulation of wound healing is not clear, due to the 
complexity and redundancy of downstream signalling cascades and post-
translational modifications in CC signalling, some of which are outlined below. 
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CCL-2 predominantly binds to a G coupled protein receptor named CCR-2. Once 
bound, CCL-2 initiates a cascade of signalling pathways. Chemokine receptors are 
categorised according to which chemokine family they belong to and annotated 
with R. For chemokines CCL1-10 the receptor is termed CCR1-10 and so on for 
the other respective sub families [247]. Chemokine receptors are notoriously 
promiscuous, binding several different chemokine ligands such as CCR-1 which 
reportedly binds CCL-2, CCL-3, CCL-4, CCL-5, CCL-13, CCL-14 as well as CCL-23 
[247]. CCL-2 can bind its primary ligand CCR-2 and will also bind scavenging 
receptors Atypical Chemokine Receptor 1 (ACKR-1) and ACKR-2 (previously 
referred to as D6) [248]. ACKR-1 also binds CCL-5, CCL-3and CCL-4. However, 
each receptor has varying degrees of affinity for each chemokine and will act with 
different extents of agonism. To complicate matters further, interspecies 
variations also exist, such as CCL8, which is also a ligand of CCR-2 in humans. In 
mice however, it only specifically binds CCR8 [249]. Similarly, CCL-1 is the 
primary ligand of CCR-8 while CCL-8 is also an agonist of CCR-8.  
CCL-2 stimulation of CCR-2 induces swift phosphorylation of ERK associated with 
integrin activation and chemotaxis [250-252]. The biological response of this 
signalling is associated with chemotaxis and superoxidase release [253]. 
Importantly, these signal transduction cascades are quite similar for a variety of 
CC chemokines and other G protein-couple receptors (GPCR) that seem to 
converge on common pathways suggesting functional redundancy.  
While GPCR signalling of CC chemokines seem to converge on common pathways, 
they can also have varying biological effects. How these subtle differences can 
have differing systemic effects yet maintain a level of redundancy remains to be 
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elucidated and begs the question whether one single CC cytokine like CCL-2 may 
have non-redundant roles?  
To determine if CCL-2 plays a non-redundant role in MSC accelerated wound 
healing, CCL-2 deficient MSC were isolated from CCL-2 KO mice and used in 
splinted excisional wound healing experiments on wild type (WT) mice and 
compared to WT MSC for efficacy.  
 
6.1.1. Chapter aims 
 Isolate BM-MSC from CCL-2 KO mice and demonstrate they can be 
identified as MSC 
 Determine ability of CCL-2 KO MSC to recruit macrophages in vitro 
 Determine if CCL-2 is required for accelerated wound healing in a mouse 






6.2. Materials and methods 
 
6.2.1. Isolation of murine MSC 
Primary MSC were isolated from C57 mice (8 wk old) as per protocol published 
by Soleimani et al [254]. Mice were first euthanised by cervical dislocation. The 
body was then disinfected by dipping twice in 70% ethanol. An incision was made 
on the limb and the skin was peeled back to expose underlying muscle. The hind 
limbs were then removed from the body. Working under sterile conditions, the 
hind limbs were further trimmed and outer skin removed. The muscle 
surrounding the femur and tibia was then removed and the ends of the bones 
were cut. The bone marrow was then flushed out of the femur and tibia and 
collected in a 15 ml centrifuge tube. 
The cell suspension was then filtered and plated at a density of 25x106 cells/ml 
in α-MEM media, supplemented with 10% FBS and 1x antibiotic/antimycotic. 
After two weeks, colonies formed and became confluent. Cells were then 
passaged and further expanded up to P5 prior to characterisation and 
subsequent experimental use. 
 
6.2.2. Isolation of murine CCL-2 KO MSC 
Using the same protocol as outlined in section 6.2.1, BM-MSC were isolated from 
8wk old CCL-2 deficient mice (referred to as MSC-KO). CCL-2 deficiency was 
validated by enzyme-linked immunosorbent assay (ELISA) as detailed in section 
6.2.7.   
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6.2.3. Flow cytometry analysis of cell surface antigens 
Expression of associated MSC markers CD44, CD90 and Sca-1 along with CD45 
were evaluated to ensure pure population of MSC. Cultured cells at P5 were 
washed once with PBS and detached from the tissue culture flask by 
trypsinisation followed by neutralisation with equal volume of serum 
supplemented medium. Cells were then recovered by centrifugation at 500g for 
5 minutes, followed by re-suspension in PBS aliquoted out into several tubes 
contain 1x105 cells for primary antibody staining. Cells were centrifuged and re-
suspended in 100 μl of diluted antibody (see Table 6-1) in FACS buffer 
(described in section 2.2) and incubated for 1 h at 4°C. Cells were then washed 
in PBS centrifuged and re-suspended in 100 μl of secondary antibody solution for 
30mins in the dark at room temperature (rt). Cells were then re-suspended in 
100 μl FACS buffer and analysed on flow cytometer. Control isotypes were used 
to determine positive cell populations. 
 
Table 6-1 Antibodies used in flow cytometry characterisation of murine MSC 
Conjugated antibody Clone Manufacturer Final 
Concentration 
CD90-APC-Cy7 53-2.1 BD Pharmingen 2 μg/ml 
CD44-PE IM7 eBioscience 2 μg/ml 
SCA-1-PE-Cy7 D7 BD Pharmingen 2 μg/ml 
CD45-PerCP-Cy5.5 104 BD Pharmingen 2 μg/ml 
Isotype Control- APC-
Cy7 
R35-95 BD Pharmingen Matched to 
primary ab 













6.2.4. Lineage Differentiation assays 
MSC phenotype was validated by subjecting BM-MSC isolated from both WT and 
CCL-2 KO mice to in vitro differentiation assays to confirm their potential to 
differentiate into adipocytes, chondrocytes and osteocytes. Tri-differentiation 
potential was verified using well established previously published protocols [25, 
148]. 
Briefly, for adipogenic differentiation, cells in culture were subjected to 3 cycles 
of adipogenic induction media for 3 d followed by adipogenic maintenance media 
for 1 d. Adipogenic induction media contained dexamethasone 1 mM, insulin 
1 mg/ml (Sigma Aldrich, Ireland), indomethacin 100 mM (Sigma Aldrich, 
Ireland) and 500 mM MIX (Sigma Aldrich, Ireland), the adipogenic maintenance 
media contained insulin 1 mg/ml. Adipogenic differentiation was confirmed with 
oil red O (Sigma Aldrich, Ireland) staining.  
For osteogenic differentiation, cells were cultured in osteogenic differentiation 
media containing β glycerol phosphate (Sigma Aldrich, Ireland) 1 M and ascorbic 
acid (Sigma Aldrich, Ireland) 2-P 10 mM for 21 d. Osteogenic differentiation was 
confirmed by Alizarin Red staining.  
For chondrogenic differentiation, pelleted cells were cultured for 21 d in 
chondrogenic differentiation media containing 10 ng/ml TGF-β3 (Sigma Aldrich, 
Ireland). Chondrogenic differentiation was confirmed by mounting the pellets in 





6.2.5. Transwell migration assay 
To determine the migratory response of macrophages towards WT and MSC-KO, 
with and without TNFα, MSC were plated in bottom chamber at a density of 
2.5x104 and grown overnight. RAW 264.7 macrophage cell-line were then plated 
in the top chamber of 8 μm transwell insert (Corning). Growth media was 
replaced with serum free media and incubated for 12 h. Transwell inserts were 
then removed and rinsed in PBS. A cotton bud was used to remove un-migrated 
cells from upper side of membrane. Membranes were further rinsed, then stained 
with Hoechst (Thermo Fisher Scientific, UK) live cell nuclear stain for 15 min and 
then imaged using a microscope (Nikon eclipse TE2000-E, Japan)  at five random 
locations and the amount of migrated cells quantified (Nis Elements v3.0, Nikon, 
Japan). All experiments were performed in triplicate and repeated three times. 
 
6.2.6. Macrophage MSC co-culture 
To determine the immunomodulatory capacity of WT MSC vs MSC-KO to polarise 
stimulated macrophages towards M2 phenotype. Macrophages were co-cultured 
in direct contact with MSC and culture supernatants were assayed for 
concentrations of TNFα and IL-10 (as previously described [255]). MSC (P5) 
were plated in 24 well plate at a concentration of 1x105. On the next day, 1x105 
macrophages (RAW 264.7) were plated with MSC. After 24 h culture, 
macrophages were stimulated with LPS (30 ng/ml). Culture supernatants were 
collected after 48 h. and centrifuged at 2000g to remove any cell debris before 
storing at -20°C prior to use in ELISAs. Experiments were performed in triplicate 
and repeated three times. 
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6.2.7. ELISAs  
To determine concentrations of IL-10, TNFα and CCL-2, ELISAs were performed 
on culture supernatants using kits provided by R&D systems (USA). Following 
manufacturer protocols 96 well clear plastic plates were coated overnight at 
room temperature with capture antibody (0.2 μg/ml) (R&D systems). 100 μl of 
diluted culture supernatants was added to the plate for 2 h at room temperature. 
The plate was washed and detection antibody (50 ng/ml) (R&D systems) applied 
for 2 h. After washes, streptavidin conjugated horseradish peroxidase (R&D 
systems) was incubated for 20 min on the plate followed by substrate colour 
solution (hydrogen peroxide and tetramethylbenzidine) (R&D systems). The 
reaction was then stopped after 20 min by addition of 100 μl of 2N sulphuric acid 
(Sigma Aldrich, Ireland). The optical density was measured using microplate 
reader (Molecular Devices, Spectra Max, UK) and sample concentration was 
calculated from a generated standard curve (Soft Max pro v5.4.3, UK). Each 
standards and sample was measured in duplicate and experiments had multiple 
replicates. 
 
6.2.8. Excisional sutured wound induction 
This protocol was adapted from a published protocol by Wang et al [256]. The 
day before surgery following anaesthesia by an IP injection of Ketamine (90 
mg/kg) and Xylazine (10 mg/kg), the dorsum of the mouse was shaved using 
clippers and hair depilated using hair cream remover.  
On the day of wounding, mice were anaesthetised and skin was sterilised with 
70% (vol/vol) ethanol swab. To induce the punch wounds, the loose dorsal skin 
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was gently pulled away from the back, and placed on a hard flat surface. Once the 
skin was extended far enough, the punch biopsy was firmly pushed down 
through the skin creating two 5 mm punch wounds. Images of the wounds were 
taken using canon DLSR camera. 
Wounds were injected at four points in the dermis at the edge of the wound with 
a total of 1x106 MSC in 100 μl PBS. A silicone splint was used to prevent 
contraction of the wound, allowing it to heal in a similar fashion to human 
wounds. The silicone ring was attached with an adhesive and then sutured into 
place. The wounds were covered with a non-occlusive dressing (Tegadem) and 
then covered with a self-adhering elastic bandage (Optitape) and care was taken 
not to impede movement or breathing of mice with the bandage. 
Dressings were changed and wounds imaged on d-3, d-5, d-7, and d-10. On d-10, 
the mice were euthanised by CO2 administration and wounds were harvested for 
further analysis.  
Several animals had to be excluded from all groups as the sutured ring came off 
at an early time point. In the control group two animals were excluded (n=9), in 
WT MSC group three animals was excluded (n=9), while in CCL-2 KO group one 
animal were excluded (n=8). 
 
6.2.8.1. Re-epithelialisation 
Wounds were excised, and trimmed to 1 cm2. This was bisected and one half was 
stored in 4% PFA o/n. To determine re-epithelialisation, wound sections were 
stained with H&E (as detailed in section 2.7.1). The wound section was imaged 
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at 4x magnification. Unepithelialised length (or wound gap) was measured using 
ImageJ software by blinded observers  
 
6.2.8.2. Granulation tissue area 
The area of granulation tissue was assessed from previously stained H&E 
sections (as described in section 2.7.1. Area was quantified form 4x images using 
ImageJ software, by a blinded observer. 
 
6.2.9. Immunofluorescent staining 
Wounds were excised, and trimmed to 1 cm2 containing both wound and healed 
wound margins. This was bisected and one half  was stored in 4% PFA for 1 h at 
4°C, then dehydrated in graded sucrose solution and then embed in OCT (as 
detailed in section 2.6). Frozen sections were cut at 10 μm thickness in cryostat 
and stored at -80°C until required. Prior to staining, slides were removed and left 
to defrost for 30 min at rt.  
 
Slides were rehydrated in PBS (10 min) and then blocked for 1 h in 10% normal 
goat serum in PBS-Tween (0.5%) solution. Sections were then incubated o/n at 
4°C with primary antibody diluted in antibody buffer (1% BSA PBST). The next 
day, sections were washed x3 in PBST and slides were incubated with secondary 
antibody solution in antibody buffer for 2 h at rt, followed by 3x washes in PBST. 
Nuclei were stained with DAPI (1 μg/ml) for 10 min followed by 3x washes in 
PBS prior to mounting in immunomount and cover slipping.  
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Table 6-2 Immunohistochemistry antibodies used in murine wound sections 
Primary 
antibody 
Clone Manufacture Final 
Concentration 
Isotype 
Ly6G RB6-8C5 Abcam, UK 5 μg/ml Rat IgG2b 
CD3 SP7 Abcam, UK 1:100 Rabbit IgG 
CD31 NA Abcam, UK 1:100 Rabbit IgG 
CD206 NA Abcam, UK 10 μg/ml Rabbit IgG 


















Clonality Manufacturer Concentration Host 
488 αRabbit IgG 
(H+L) 
polyclonal Thermo Fisher 
Scientific 
2 μg/ml Goat 
546 αRat IgG 
(H+L) 
polyclonal Thermo Fisher 
Scientific 
2 μg/ml Goat 
 
6.2.9.1. Neutrophil infiltration quantification  
Neutrophils are the most abundant cell type of the innate immune system and 
are the first immune cell to infiltrate the wound, beginning to accumulate within 
minutes after injury [257]. Neutrophils are relatively short lived and usually 
begin to decline in the wound after 48-72 h post injury [258]. The neutrophil 
marker Ly6G is a 25 kDa glycosylphosphatidylinositol linked differentiation 
antigen that is predominantly expressed by neutrophils and transiently 
expressed on some monocytes in the bone marrow. It is a well-established 
marker of neutrophils [259]. Neutrophils were quantified as follows; wound 
sections were imaged at five random points within the wound bed and Ly6G+ 




6.2.9.2. T-lymphocyte quantification  
MSC induced response of T-lymphocyte wound infiltration was quantified by 
probing tissue sections with the pan T-cell marker CD3 as previously established 
[61, 260] . Sections were imaged at five random points within the wound bed and 
CD3+ cells were quantified by blinded observer; three sections were analysed 
per animal.   
6.2.9.3. M2 macrophage response 
Overall determination of macrophage population was assessed by staining with 
pan macrophage marker F4/80 [242, 261]. To determine the polarisation of 
macrophages to reparative M2 phenotype, co-staining of F4/80 and the M2 
marker CD206 was performed. The mannose receptor (CD206) is highly 
associated with macrophage M2 phenotype; it is significantly upregulated on IL-
4 treated macrophages and is widely used to quantify M2 macrophages [20, 257, 
262]. Sections were imaged at five random points within the wound bed and 
CD206+ cells were quantified by blinded observer; three sections were analysed 
per animal.   
6.2.9.4. Angiogenic response 
To assess angiogenic response, wound sections from d-10 were probed with 
endothelial cell marker CD31. Platelet endothelial cell adhesion molecule-1 or 
CD31 is an adhesion molecule expressed on endothelial cells that line capillaries 
and other blood vessels and is widely used to quantify angiogenesis [263]. 
Sections were imaged at five random points within the wound bed and vessel 
density was calculated (by blinded observer) based on CD31+ vessels (as 
determined by intact open lumen); three sections were analysed per animal. 
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6.2.10. RNA extraction and qRT-PCR 
Wounds were excised, and trimmed to 1 cm2 containing both wound and healed 
wound margins. This was bisected and 1 half was snap frozen in liquid nitrogen. 
Samples were kept at -80°C until required. To extract RNA, samples were crushed 
in using pestle and mortar in liquid nitrogen. Samples were then homogenised 
using rotor stator homogeniser in a solution of phenol, guanidine isothiocyanate 
(Qiazol) for 1 min. RNA purification was then performed using RNAeasy 
universal kit (Qiagen, UK) as per manufactures instructions.  
Purity (A260/A280) and concentration of isolated RNA was measured using 
Nanodrop spectrophotometer. Integrity of RNA was assessed using denaturing 
agarose gel electrophoresis and ethidium bromide staining. Only high purity 
(A260/A280 >1.8) RNA samples that had sharp bands of 28s and 18s rRNA and 
apparent 2:1 ratio were used. Degraded RNA was apparent in several samples, in 
addition some samples we not of sufficient purity and were excluded, this left n=5 
in all groups.  
Five samples were used from each treatment group for RT2 profiler array. RNA 
(1 μg) was reverse transcribed into cDNA using Qiagen RT2 First Strand Kit. This 
was then used for each qRT-PCR reaction with RT2 SYBR Green Mastermix 
containing Hotstart DNA Taq polymerase (Qiagen, UK). This was added to RT2 
profiler array (Qiagen, UK) containing 10 pre coated validated primer assays for 
IL-10, IL-6, CCL-2, VEGFa, and CD31. Data was analysed using the ΔΔ CT method, 
quantification was calculated in relation to 18s expression in each sample 
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calculated before 35 cycles. Both positive, negative and genomic DNA 
contamination controls were included in the assays. 
 
6.2.11. Statistical analysis 
Difference between multiple groups was analysed by analysis of variance 
(ANOVA) followed by Tukey’s post-hoc testing. Results are expressed as mean ± 






6.3.1. Isolation and characterisation of MSC from WT and CCL-2 
deficient mice 
MSC were expanded to p5 and samples were taken for flow cytometry and for tri-
lineage differentiation assays (as described in section 6.2.4). Samples from both 
cell populations were cultured in various differentiating conditions using well 
established protocols (as previously described [149, 150]). Adipogenic 
differentiation was confirmed in both cell types by the presence of lipid vacuoles 
stained with oil red O (Figure 6.1 A). Positive Alizarin red staining indicated the 
presence of calcium deposits associated with osteoblast formation (Figure 6.1 
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B). Chondrogenic differentiation was confirmed using toluidine blue staining of 
pellet cultures (Figure 6.1 C). 
Cell surface antigen expression was determined using flow cytometry. Both 
MSC-WT and MSC-KO were positive for CD44, CD90 and SCA-1, while also 
negative for CD45  
6.3.2. WT MSC express CCL-2 and stimulate macrophage 
migration in vitro 
 Unstimulated MSC-WT secreted 0.3ng/ml ± 0.04 CCL-2 (n=3) Figure 6.3 A. No 
signal was detected from MSC-KO. Transwell experiments were used to 
determine migratory response of macrophages towards MSC in response to CCL-
2 (Figure 6.3 B). MSC-WT group had significantly more migrated macrophages 
(MSC; 42 ± 5.9 vs Control; 9 ± 1.65 vs CCL-2 KO; 20 ± 4.94) compared to control 
and to MSC-KO group (Control vs MSC-WT, p<0.001, Control vs MSC-KO p=0.112, 
MSC-WT vs MSC-KO, p=0.01, n=3). 
 
6.3.3. CCL-2 deficient MSC have reduced therapeutic efficacy in 
excisional mouse model 
Excisional wounding of mice was carried out (as described in section 6.2.8.) and 
image analysis was performed to calculate the wound size at d-0. No significant 
differences in wound area were observed at d-0 (Figure 6.4 B left).  
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Application of WT MSC accelerated wound closure at all time points compared to 
Control (Figure 6.4 B right). On d-3, MSC-WT treated wounds had a wound size 
of 72.35% ± 4.1 (MSC-WT vs Control, p=0.053, n≥8) compared to control; 87.48% 
± 4.2 while MSC-KO had a mean wound size of 88.74% ± 4.1 (MSC-WT vs MSC-
KO p=0.034, n≥8) By d-5, MSC-WT treated group had a wound size of 54.23% ± 
2.7 vs Control 71.24% ± 3.9 vs CCL-2 KO; 72.39% ± 2.5. (Control vs MSC-WT 
p<0.001, Control vs MSC-KO p=0.945, MSC-WT vs MSC-KO p<0.001, n≥8). On d-
7, MSC-WT treated group was 37.05% ± 3.12 vs Control; 56.67% ± 4.46 vs CCL-2 
KO; 59.59% ± 3.04 (Control vs MSC p<0.001, Control vs MSC-KO p=0.828, MSC-
WT vs MSC-KO p<0.001, n≥8). Finally, on d-10, MSC-WT wounds were 8.26% ± 
1.05 vs Control wounds; 13.58% ± 3.89 vs CCL-2 KO group; 19.01% ± 3.5 (Control 
vs MSC-WT p=0.390, Control vs MSC-KO p=0.425, MSC-WT vs MSC-KO p=0.032, 
n≥8). MSC-KO did not accelerate wound closure and there was no statistical 
difference between this group and the control group at any time point.  
 
6.3.4. MSC-KO do not enhance re-epithelialisation of excisional 
wounds 
Injection of MSC into the wounds accelerated re-epithelialisation as measured on 
d-10 (Control; 2290 μm ± 668 vs MSC; 272.1 μm ± 136 and CCL-2 KO 1198 μm ± 
199, Control vs MSC-WT p=0.002, Control vs MSC-KO p=0.11, MSC-WT vs MSC-
KO p=0.165, n≥8). Several MSC-WT treated wounds were fully re-epithelialised 
at the time of analysis. Epithelial gap was reduced in MSC-KO group but, this was 
not statistically different to Control. 
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Using ImageJ, granulation area was also measured and found to be largest in the 
control group (Control; 22583 μm2 ± 2268 vs MSC-WT; 13273 μm2 ± 2021 vs 
MSC-KO; 19615 μm2 ± 2162, Control vs MSC-WT p=0.011, Control vs MSC-KO 
p=0.606, MSC-WT vs MSC-KO p=0.097, n≥8). MSC-WT treated wounds had 
statistically significantly smaller granulation area indicating resolution of 
inflammatory response and wound maturation. 
 
6.3.5. MSC derived CCL-2 is required for angiogenic effect  
To determine if MSC derived CCL-2 was important for induction of an angiogenic 
response to cell therapy, wound sections were stained for CD31 (green) and 
blood vessel density within the wound bed was calculated (Figure 6.6 A). 
Vessel density was significantly improved with application of MSC-WT to the 
wounds compared to Control (Control; 7.5 ± 1.6 vs MSC-WT; 25.4 ± 3.2 vs MSC-
KO; 10.7 ± 2.8, Control vs MSC-WT p<0.001, Control vs MSC-KO p=0.632, MSC-
WT vs MSC-KO p=0.003, n≥8). In contrast, CCL-2 deficient MSC did not 
significantly increase vessel density compared to control. 
CD31 mRNA expression was also quantified by qRT-PCR in wounds samples 
taken from 5 animals per group (Figure 6.6 B). No significant difference was 
found between the groups. VEGFa expression was also quantified and found to 
be marginally higher in both MSC-WT and MSC-KO groups however, no 
significant differences were observed between the groups (Control; 1 ± 0.02 vs 
MSC-WT; 1.15 ± 0.1 vs MSC-KO; 1.07 ± 0.06, Control vs MSC-WT p=0.364, Control 
vs MSC-KO p=0.717, MSC-WT vs MSC-KO, p=0.721, n=5). 
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6.3.6. MSC derived CCL-2 is required for reduced inflammatory 
response and accumulation of CD206+ macrophages   
To characterise neutrophil response, d-10 wound sections were stained for the 
neutrophil marker Ly6G (Figure 6.7 A). Wounds treated with MSC-WT showed 
a significant reduction in Ly6G+ neutrophil infiltration compared to PBS treated 
controls (Control; 29.87 ± 4.83, vs MSC-WT; 11.27 ± 1.82, vs MSC-KO; 25.13 ± 
4.83, Control vs MSC-WT, p<0.001, Control vs MSC-KO, p=0.435, MSC-WT vs MSC-
KO, p=0.009, n≥8). while MSC-KO have a significant amount Ly6G+ positive cells 
remaining within the wound similar to control wounds. Sustained neutrophil 
presence or late re-entry of neutrophils can indicate ongoing inflammatory 
response, possibly due to lack of epithelium. 
Whilst the adaptive system does not play a major role in normal cutaneous 
wound healing, the pan T-Cell markers was used to evaluate T-cell presence 
within the wound (Figure 6.7 B). As expected T-cell numbers are low at d-10, 
however there is a trend towards more CD3+ T-cells in both MSC-WT and MSC-
KO groups compared to the control group (Control; 3.6 ± 1.33, vs MSC-WT; 9.62 
± 1.86, vs CCL2 KO MSC; 8.2 ± 2.33, Control vs MSC-WT, p=0.1, Control vs MSC-
KO, p=0.246, MSC-WT vs MSC-KO, p=0.857, n≥8). While this was not statistically 
significant, it may indicate that T-cell infiltration is driven by MSC but is not CCL-
2 dependent.  
CCL-2 is classically associated with monocyte and macrophage recruitment, to 
investigate the response towards MSC derived CCL-2, immunohistochemistry 
was performed on tissues sections for pan macrophage marker F4/80 (red) 
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(Figure 6.8 A). To determine the polarisation of macrophages towards 
reparative M2 phenotype, sections were co-stained with CD206 (green). 
Quantification was performed of positive cells within the wound bed. No 
significant difference in macrophages numbers was observed within the wound 
between treatment groups (Control; 67.9 ± 6.0, vs MSC-WT; 63.7 ± 5.6, vs CCL2 
KO MSC; 65.2 ± 2.6, Control vs MSC-WT p=0.826, Control vs MSC-KO p=0.92, MSC-
WT vs MSC-KO p=0.98, n≥8) (Figure 6.8 B Left). However, the frequency of 
CD206+ macrophages was greatly increased in MSC-WT treated group (Control; 
10.5% ± 1.7, vs MSC-WT; 29.0% ± 2.5, vs MSC-KO; 14.8% ± 1.5, Control vs MSC 
p<0.001, Control vs MSC-KO p=0.277, MSC-WT vs MSC-KO p<0.001, n≥8). MSC-
KO treated wounds had significantly less CD206+ macrophages compared to 
MSC-WT group. There was no significant difference between MSC-KO and control 
groups.  
 
Polarisation of macrophages from inflammatory to reparative phenotype is 
believed to exist on a continuum and is associated with increased expression of 
CD206, increased IL-10 and reduced TNFα cytokine levels within the wound. To 
further characterise the inflammatory cytokine profile of the wound, qRT-PCR 
was performed on wound samples from d-10 (Figure 6.9). Significantly, there 
was a dramatic increase with IL-10 expression with MSC-WT treated wounds 
compared to both control and MSC-KO treated wounds (Control; 1.04 ± 0.13 vs 
MSC; 2.13 ± 0.39 vs MSC-KO; 1.07 ± 0.21, Control vs MSC-WT p=0.037, Control vs 
MSC-KO p=0.998, MSC-WT vs MSC-KO p=0.02, n=5). There was no significant 
difference between MSC-KO and control, groups.  
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The expression of IL-6 was also evaluated and while it was not statistically 
significant, there was a trend towards increased expression that was observable 
in both MSC treated groups compared to controls (Control; 1.12 ± 0.26 vs MSC-
WT; 2.11 ± 0.68 vs MSC-KO; 1.85 ± 0.6, Control vs MSC-WT p=0.517, Control vs 
MSC-KO p=0.634, MSC-WT vs MSC-KO p=0.944, n=5). Conversely, CCL-2 
expression was increased in MSC-WT treated wounds compared to MSC-KO and 
control groups (Control; 1.03 ± 0.11 vs MSC-WT; 2.03 ± 0.38 vs MSC-KO; 1.33 ± 
0.27, Control vs MSC-WT p=0.09, Control vs MSC-KO p=0.746, MSC-WT vs MSC-
KO p=0.208, n=5). This could be as a result of MSC transplantation, but as it is not 
statistically different could be due to biological variation. Similarly, no significant 
difference was observed between groups for TNFα, which may have resolved by 
d-10 (Control; 1.02 ± 0.07 vs MSC-WT; 1.46 ± 0.28 vs MSC-KO; 1.01 ± 0.13, 
Control vs MSC-WT p=0.234, Control vs MSC-KO p>0.999, MSC vs MSC-KO 
p=0.161, n=5). 
 
6.3.7. CCL-2 deficient MSC have reduced immunomodulatory 
capacity 
 
To verify in vivo results that CCL-2 is required for efficient M2 polarisation, 
MSC-WT and MSC-KO were co-cultured with LPS stimulated macrophages and 
supernatant concentrations of TNFα and IL-10 were assessed (as described in 
section 6.2.6).  
In response to LPS stimulation of macrophages significantly increased TNFα 
secretion associated with activated M1 macrophage phenotype (Mφ + LPS; 1601 
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pg/ml ± 61.8 vs Mφ; 106.7 pg/ml ± 13.3, p<0.001 n=3). Co-culture of MSC-WT 
significantly reduced TNFα to baseline secretion consistent with increased M2 
polarisation and this was only observed when cultured with stimulated 
macrophages (MSC-WT + Mφ + LPS; 285.8 pg/ml ± 22.31, vs Mφ + LPS; 1601 
pg/ml ± 61.8, p< 0.001, n=3).  
MSC-KO were not as efficient as MSC-WT in reducing TNFα and associated M2 
polarisation as significantly greater concentrations of TNFα were detected in this 
group (MSC-KO + Mφ + LPS; 682.3pg/ml ± 23.28, vs MSC-WT + Mφ + LPS; 285.8 
pg/ml ± 22.31, p<0.001, n=3). MSC-KO were, however, able to induce a 
statistically significant reduction in TNFα, albeit smaller (Mφ + LPS vs MSC-KO 
+ Mφ + LPS, p<0.001, n=3).   
Detection of IL-10 in supernatants demonstrated both MSC-WT and MSC-KO 
were capable of increasing IL-10 in response to stimulated macrophages (Mφ + 
LPS; 94.96 pg/ml ± 9.9 vs MSC-WT + Mφ + LPS; 470.6 pg/ml ± 13.4 vs MSC-KO 
+ Mφ + LPS; 522.1 pg/ml ± 19.3, Mφ + LPS vs MSC-WT + Mφ + LPS p<0.001, 





Figure 6.1 Both MSC and MSC-KO have tri differentiation potential 
WT MSC and MSC-KO were exposed to various differentiating media and subsequently differentiated 
into A) adipocytes (verified with Oil red o) B) osteocytes (alizarin red stain) and C) chondrocytes 
(toluidine blue stain). Both cell populations were readily able to differentiate into these lineages, 
while cells cultured in control media did not differentiate. Representative images of differentiation 





Figure 6.2 Cell surface antigen expression of MSC 
Isolated MSC were characterised for expression of cell surface markers using FACS. Both MSC-WT 
and MSC-KO were found to express common MSC cell surface antigens CD90, SCA-1 and CD29 (as 
indicated by orange histograms). MSC were negative for CD45. Control isotype represented in grey 





Figure 6.3 MSC secreted CCL-2 and stimulated migration of macrophages in vitro 
A) Cells culture supernatants collected at 24h from both MSC-WT and MSC-KO were assayed for 
CCL-2 secretion using ELISA. Under unstimulated conditions MSC secrete CCL-2 (0.25ng/ml), no 
CCL-2 was detected in MSC-KO supernatants (n=3). B) Transwell migration assay, Images of 
migrated macrophages (stained with Hoechst live stain, blue) demonstrate significantly reduced 




Figure 6.4 CCL-2 deficiency reduces therapeutic efficacy of MSC 
A) Images of mouse excisional wounds at d-0 and at d-10. Two 5 mm punch wounds were created 
on the dorsum of each mouse. B) Left - Wound area was quantified at d-0 and no significant 
differences were observed between any of the groups (n≥ 11, ns, not significant).  Time course of 
wound closure from image analysis demonstrated accelerated wound closure in MSC-WT treated 
wounds (n≥8, * = MSC-WT vs Control, *** p<0.001). MSC-KO completely abrogated this therapeutic 
effect and were not statistically different to control treated wounds, but were statistically different 




Figure 6.5 CCL-2 deficiency delayed wound re-epithelialisation compared to WT MSC 
A) Histological samples taken at d-10 post wounding were stained with H&E. Images of stained 
tissue sections were taken at 4x. Black arrows indicate migrating front of Keratinocytes; insets show 
magnified image of migrating front. Scale bar, 100 μm. B) Left- Quantification of unepithelialised 
gap demonstrated significantly reduced unepithelialised wound in MSC-WT treated wounds 
compared to both control and MSC-KO (n≥8 ns, not significant * p<0.05, ** p<0.01). B) Right - 
Granulation area was measured using ImageJ software indicated significantly reduced area in 
MSC-WT treated wounds compared to control suggestive of reduced inflammatory response and 




Figure 6.6 Application of WT MSC increased vascularity of wounds  
A) Representative images of wound sections at d-10 post wounding, probed with CD31 antibody 
(green) and nuclei counter stained with DAPI (blue) scale bar, 50 μm. Vessels per high power field 
were quantified within the wound bed, white arrows indicate intact vessel lumens. MSC treated 
wounds had increased vessel density compared to both control and MSC-KO treated wounds (n≥8 
ns, not significant * p<0.05, ** p<0.01, *** p<0.001). B) qRT-PCR expression of CD31 and VEGFa was 
assessed from wound samples containing both wound and healed wound margin, no significant 





Figure 6.7 MSC altered immune response in CCL-2 dependent mechanism 
A) Representative images of wound sections d-10 post wounding, stained for neutrophil marker 
Ly6G (green), cell nuclei were counter stained with DAPI (blue) scale bar, 50 μm. MSC-WT treated 
wounds had significantly reduced neutrophil infiltration at d-10 compared to control and MSC–KO 
treated wounds (n≥8, ns, not significant ** p<0.01, *** p<0.001). B) Representative images of wound 
sections d-10 post wounding, stained for T-cell marker CD3 (green), cell nuclei stained with DAPI 
(blue) scale bar, 50 μm. Both MSC-WT and MSC-KO treated wounds had a trend towards increased 
CD3+ T-cells within the wound bed at d-10 however this was not statistically different to controls 




Figure 6.8 MSC derived CCL-2 is required for alteration of macrophage phenotype  
A) Representative images of wound sections d-10, stained for pan macrophage marker F4/80 (red) 
and M2 marker CD206 (green), cell nuclei were counter stained with DAPI (blue), for clarity 
arrowheads indicate CD206+ cells, scale bar, 50 μm. B) Left- total macrophage within the wound 
bed, no difference between any of the groups was detected at d-10 (n≥8 ns, not significant). B) Right- 
percentage macrophages co-expressing CD206 was significantly increased in MSC-WT treated 






Figure 6.9 MSC alter expression of wound  cytokines  
 Analysis of cytokine expression (qRT-PCR) from samples containing both wound and healed wound 
margin at d-10. Application of MSC significantly increased IL-10 associated with macrophage M2 
transition, which was abrogated with MSC-KO (n=5, ns, not significant * p<0.05). No difference in 
















Figure 6.10 CCL-2 deficiency reduced MSC immunomodulatory capacity 
A) Co-culture of MSC-WT in direct cell contact with stimulated macrophages (LPS 30ng/ml) 
significantly reduced TNFα as detected by ELISA in culture supernatants at 48h. MSC-KO were also 
able to reduce TNFα however, not to the same extent as MSC-WT (n=3 *** p<0.001). B) Detection of 
IL-10 in supernatants demonstrate both MSC-WT and MSC-KO were capable of significantly 






In the introduction of this thesis a strong rationale was presented for a role of 
CCL-2 in MSC therapy in cutaneous wound healing. Briefly, CCL-2 is a potent 
chemotactic cytokine which is well known recruiter of monocytes and 
macrophage [127, 250, 264]. Wound healing is a complex process involving 
several different cell types and includes phases of pathogen clearance, 
proliferation, re-epithelisation and remodelling. Cells of the myeloid lineage are 
one of the main effector cells in wound repair and secrete the largest amounts of 
cytokines which control the progression of wound healing phases [138, 240, 
241]. Therefore, it is quite plausible to assume CCL-2 may play a role in MSC 
therapy. 
However, several reasons were cited for why the role of MSC derived CCL-2 may 
not be so clear (in section 6.1.) due in part to chemokine redundancy, decoy 
receptors and post translational modifications to the chemokine. Clearly, what is 
evident form this study is that CCL-2 has a profound effect on many aspects of 
MSC therapy in a mouse model of excisional wound healing. 
Several studies have corroborated the therapeutic effect of MSC therapy in 
cutaneous wound healing [20, 50, 58, 61, 102, 265], the effects of which, have 
been  observed in mouse [41], rabbit [266], rat [110], pig [115] and human [47]. 
The molecular mechanisms behind this accelerated wound healing are still being 
delineated, however, certain aspects are now well established. As outlined in 
section 1.2.4, MSC therapy accelerates wound closure, involving earlier 
granulation tissue formation [110] and increased re-epithelialisation [56]. This 
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is driven by a potent angiogenic effect which has been observed both in vivo and 
in vitro, and is mediated primarily through VEGF secretion [56, 267]. Finally, MSC 
are potent immune-modulators of both adaptive and innate immune systems, 
and several chemokines have been identified (TSG-6 [102], IDO or inducible NOS 
[98] and PGE2 [88] as responsible for altering the inflammatory environment.  
In the context of cutaneous wounds, macrophages and neutrophils are key 
drivers and inhibitors of wound progression. MSC are involved in a phenotypic 
switch of inflammatory macrophages towards a reparative type phenotype (M2) 
associated with reduced TNFα and increased IL-10 production [244]. To 
understand how CCL-2 may play a role in MSC accelerated wound healing it is 
useful to look at each of these parameters and see how they are connected. 
Re-epithelisation is a major milestone in wound healing and is influenced by 
several factors, including proliferation, migration and differentiation of 
keratinocytes at the wound edges.  One of the key therapeutic benefits of MSC 
therapy, as observed in this study, is accelerated re-epithelialisation [56]. CCR-2 
has recently been found to be expressed by normal keratinocytes, although these 
cells are not responsive to CCL-2 treatment [268].  MSC secrete many cytokines 
such as FGF-7, IGF and EGF [58] and MSC CM has been shown to accelerate 
keratinocyte migration in vitro [269]. To what extent this drives re-
epithelialisation in vivo is unknown. CCL-2 is not involved in the secretion of 
these cytokines, so it is unlikely that MSC-KO would have an abnormal cytokine 
profile. A more plausible explanation is through the early formation of 
granulation tissue. In excisional wound healing, the dermal layer is removed and 
therefore keratinocytes have no substrate to migrate on.  In mice, wound closure 
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is driven by wound contraction, however in this study, a sutured ring prevented 
this from occurring.  Lack of contraction required granulation tissue to be formed 
to allow re-epithelisation and wound closure to progress. MSC therapy 
accelerates the formation of granulation tissue [110, 270] and CCL-2 may be 
involved in this respect. Granulation tissue is a vascular dense connective tissue 
consisting of a provisional extra cellular matrix of fibronectin, fibrin and other 
components and is required substrate for keratinocytes to migrate on. Increased 
angiogenesis in MSC treated wounds accelerate the process of granulation tissue 
formation, thereby, providing a substrate for keratinocytes to migrate across, 
leading to augmented re-epithelialisation that was observed in this study. 
 
6.4.1. CCL-2 and angiogenesis 
In this study a significantly increased angiogenic response in MSC treated 
wounds was manifested in increased vascular density in the wound bed. This 
phenomenon has been reported by several other studies and is believed to be a 
major contributor to accelerated wound closure [56, 74, 76, 110, 265]. CCL-2 
plays a pivotal role in angiogenesis and importantly, no significant increase in 
vascularisation was observed in MSC-KO treated wounds. While a significant 
increase in CD31 immunostaining was observed, no difference in mRNA 
expression of VEGF or CD31 was found. One possible explanation for this 
aberrant finding is that CD31 immunostaining staining was quantified in the 
wound bed, whereas, the sample used for qRT-PCR analysis contained both the 
wound and the healed wound margins which may have skewed the results. By 
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d-10, VEGF may also have normalised between the groups. Early sprouting of 
endothelial cells is dependent on presence of VEGF however as the vessels 
mature, VEGF is no longer required.  
The role of angiogenesis during wound repair is well established and involves the 
migration and proliferation of vascular cells. CCL-2 induces downstream effects 
on SMCs and endothelial cells [271]. Vascular SMC (VSMC) express CCR-2 and 
when treated with CCL-2 induces significant proliferative response, primarily 
through NF-κB and activator protein 1 [271].  
In addition, endothelial cells express CCR-2 and migrate in response to CCL-2 
[272]. In a Chick CAM assay, administration of CCL-2 was as potent an inducer of 
angiogenesis as VEGF, and could also be inhibited through VEGF inhibition [273]. 
Similarly, Matrigel plugs and aortic rings seeded with CCL-2 induced significant 
angiogenesis in a leukocyte independent and CCR-2 dependent manner [272]. 
Treatment of human endothelial cells with CCL-2 induces hypoxia inducible 
factor 1 (HIF-1) gene expression this in turn induces VEGF A165 in the aortic wall 
[273]. The activation of CCR-2 by binding of CCL-2 also induces a transcription 
factor called monocyte chemotactic protein induced protein (MCPIP) [274]. 
Over-expression of MCPIP in human umbilical vein endothelial cells (HUVECs) 
induced an angiogenic response [275]. Treatment with CCL-2 induced MCPIP and 
capillary like tube formation [275]. Cadherins 12 and 19, trans-membrane 
proteins involved in cell adhesion, induced upon CCL-2 stimulation, were 
required for tube formation and were MCPIP dependent [275].  
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MSC CM can induce an angiogenic response in endothelial cells and may have a 
protective effect under hypoxic conditions which is CCL-2 dependent [74]. 
Endothelial cells cultured under hypoxia for 24h displayed a 16% reduction in 
caspase 3 activation when cultured in MSC CM and only recombinant CCL-2 alone 
was able to replicate this [74]. 
In this study MSC-KO had a reduced angiogenic response and it is reasonable to 
suggest, as outlined above, that this may be mediated through a CCL-2 dependent 
reduction in both endogenous VEGF, reduced SMC and endothelial cell 
proliferative/survival responses. However, further in vitro studies are needed to 
fully characterise this reduced angiogenic response.  
 
6.4.2. CCL-2 and it role in MSC immune-modulation 
Another aspect of MSC therapy is the ability to regulate immune responses. MSC 
can modulate both adaptive an innate immune responses based on the micro 
environmental cues. MSC inhibit the proliferation and activity of B-cells [276], T-
cells [277] and NK cells though a range of cytokines such as TSG-6 and COX-2 
activity leading to downstream PGE2 release. One of the major attributes of MSC 
therapy in cutaneous wound healing is the ability to polarise macrophage 
phenotype towards reparative M2 type [20, 96, 97]. This is characterised with 
increased CD206+ macrophages within the wound, reduced inflammatory 
cytokine TNFα and increased IL-10, as was established in vitro in this study. This 
results in an accelerated progression of wound healing. As the inflammatory 
phase resolves, M2 macrophages increase fibroblast proliferation, allowing 
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formation of granulation tissue and vascularisation to occur. This study 
replicates earlier findings that MSC application in a mouse excisional wound 
healing model accelerates wound closure. Similarly, this study corroborates the 
finding that MSC application increases CD206+ macrophages within the wound 
and increases IL-10 expression associated with a reduced inflammatory 
response. Significantly, this work demonstrates a non-redundant role of MSC 
derived CCL-2 in this M1-M2 polarising mechanism. CCL-2 deficient MSC were 
unable to expand the M2 macrophage population within the wound as observed 
with MSC-WT and there was no significant increase in IL-10 compared to 
controls. Significantly, in vitro studies confirmed the CCL-2 deficient MSC had a 
reduced capacity to modulate TNFα secretion by stimulated macrophages.  To 
the best of the author’s knowledge this finding has not been established before. 
MSC derived CCL-2 could perhaps be inducing increased recruitment of 
monocytes into the wound as it is a potent chemotactic factor for monocytes and 
as transwell experiments indicate. However, at d-10 no difference was observed 
in total macrophage (F4/80+) numbers between the groups. There are several 
possible reasons that may account for this discrepancy. One possible explanation 
is that at d-10 macrophage numbers have levelled out between the groups and 
there may have indeed been differences at a much earlier time point. While this 
study clearly demonstrates that CCL-2 does play a significant role, these events 
underlying this mechanism occur during early stages of wound healing and are 
not fully captured in this study. It would be interesting to look at the evolution of 
macrophage populations at early time points, such as d-5. However, several other 
163 
 
studies have examined this area (as outlined below) and this may give some 
insight. 
In a study of diabetic murine wound healing, early macrophage infiltration was 
significantly inhibited compared to WT controls. Application of recombinant 
CCL-2 significantly increased macrophages numbers in the wounds and 
accelerated wound healing [278].  
Previous work by Jackman et al demonstrate that CCL-2 is quickly expressed in 
normal excisional wounds within the mouse [246]. Reaching a peak within 6 h 
after wounding and gradually declining therein, consistent with macrophage 
recruitment into the wound [279]. In this context, addition of MSC expressing 
CCL-2 may not function in recruiting monocytes to the wound per se, as the 
amount of CCL-2 globally, within the wound will already be quite high. It may, 
however, facilitate short range homing and cell contact between recruited 
monocytes/macrophages and MSC within the wound. 
Nemeth et al elegantly elucidated the mechanisms of M2 polarisation, in a series 
of co-culture experiments they demonstrate that a significant increase in IL-10 
only occurs when stimulated macrophages are co-cultured with MSC [96]. If 
cultured in a transwell system, no significant increase in IL-10 is observed, 
demonstrating the requirement of cell contact to initiate polarisation [96]. 
Conversely, TNFα was only significantly reduced with direct co-culture of MSC 
and stimulated macrophages [96]. Other studies have reported similar results 
[100, 280].  In this study, these findings were exactly replicated with WT MSC. 
However, MSC-KO were not as efficient in repolarising stimulated macrophages 
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and reducing TNFα, establishing a possible causative mechanism for the reduced 
efficacy of MSC-KO observed in-vivo.  
Using a series of inhibitors, Nemeth et al explored the signalling pathways 
involved and demonstrated that cell contact induces iNOS signalling (IDO in 
human MSC [98]) which elevates COX-2, simultaneously TNFα from macrophage 
binds TNNFR-1 and also up-regulates NF-κB further inducing downstream COX. 
Increased COX leads to the synthesis of PGE2 which then binds to EP-4 and EP-2 
on the macrophage increases IL-10 release. In this study in vitro co-culture of WT 
MSC was able to significantly increase IL-10 in stimulated macrophages. 
Conversely to previous findings with TNFα, MSC-KO were also capable of 
inducing IL-10, this could potentially be happing in an IL-6 dependent manner 
[281]. The time point of 48 h used in these experiments may also not capture 
possible early induction of IL-10 by MSC-WT.  While no difference in IL-10 was 
observed in-vitro, it should be noted that IL-10 was significantly increased in WT 
MSC treated wounds and not MSC-KO treated wounds. In-vitro co-cultures may 
also not entirely reflect the complex multi cellular environment present in-vivo.  
The in vivo data presented here in conjunction with reduced in vitro macrophage 
recruitment and reduced capacity to inhibit TNFα, suggests that CCL-2 is 
required for local contact of MSC and macrophages which facilitates increased 
M2 polarisation. 
MSC derived CCL-2 may also directly influence macrophage polarisation [282]. 
M1 polarised macrophages isolated from CCR-2 -/- deficient mice show reduced 
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IL-10 expression compared to wild type, while normal M1 when stimulated with 
CCL-2 increased  IL-10 secretion [282].  
MSC may also have secondary inhibitory effects based on IL-10, increased IL-10 
from other immune cells, such as macrophages, can inhibit rolling, adhesion and 
trans-epithelial migration of neutrophils [95] and may prevent their re-entry into 
the wound cutting off the negative feedback loop in response to macrophage 
stimulation. This is consistent with observations in this study, where MSC treated 
wounds had increased expression of IL-10 and significantly less Ly6G+ 
neutrophils present compared to MSC-KO and control treated wounds at d-10. 
In Conclusion, in this chapter a role for MSC derived CCL-2 was established in M2 
polarisation. MSC alter their secretome in response to environmental cues which 
skews M2 polarisation accelerating wound closure. As outlined in this discussion 
one of the major environmental cues driving this is TNFα. In chapter 5 a 
therapeutic benefit was demonstrated from pre-stimulation of MSC with TNFα in 
a porcine burn model. The next chapter will examine if this can be applied to 
excisional wound healing in a mouse model, and using the MSC-KO, determine if 






7. Assessment of TNFα pre-treatment of MSC in a 






The application of MSC for excisional wound healing is beneficial as several 
studies, including results presented in Chapter 6, have confirmed [20, 50, 56, 
102]. This therapeutic response is driven in part through attenuation of the 
body’s inflammatory response and promotion of innate reparative responses [20, 
102]. This immune modulatory function is mediated by several key factors 
including PGE2, TSG-6, IL-6 and IL-8 [85, 96, 255].  
MSC respond to micro-environmental cues in their proximity them which under 
particular circumstances can be either anti-inflammatory or pro-inflammatory 
mediators [283]. This has led to the concept of MSC licensing, whereby MSC are 
stimulated with pro inflammatory cytokines to prime them before therapeutic 
application [228, 229]. Several studies have reported beneficial effects when MSC 
were primed or pre-treated with various inflammatory cytokines such as TNFα, 
IL-1β and IFNγ [229, 231, 234]. In Chapter 5, TNFα was used to pre-treat porcine 
MSC prior to application in a partial thickness burn wound. Pre-treatment 
significantly increased the therapeutic response, augmented re-epithelisation of 
the wounds and improved the immunomodulatory response. In a mouse model 
of excisional wound healing human MSC CM taken from TNFα pre-treated MSC 
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was also found to be beneficial [80]. MSC CM was generated by culturing AD-MSC 
in 10ng/ml of TNFα for 48h. Wounds (8mm punch) were treated daily with 20 μl 
topical application of CM [80]. Application of CM accelerated wound closure 
compared to MSC CM without pre-treatment, and this was mediated in part 
through IL-6 and IL-8  both of which were significantly increased in MSC CM after 
TNFα stimulation [80]. However, these experiments were performed in an 
unsplinted wound model, which may not accurately reflect human wound 
healing, as it is driven primarily through wound contraction [284, 285].  
Several studies have established that TNFα stimulation of MSC induces the 
secretion of a wide variety of factors including VEGF, HGF, TSG-6, PGE2 and CCL-
2 [72, 79, 105, 286]. In Chapter 6, it was established that CCL-2 is required for 
MSC induced therapeutic effect in an excisional mouse model. Previous studies 
have implicated TNFα in a similar process in tumour development [132]. In a 
study by Ren et al, MSC were found in the developing tumour stroma and 
secreted large amounts of CCL-2 [132]. This in turn recruited macrophages to the 
tumour stroma allowing them to interact with MSC where they are polarised 
towards an M2 type phenotype (known as tumour associated macrophages) in a 
CCR2 dependent process [132]. This reduced the inflammatory response and 
promoted tissue repair, similar to application of MSC and formation of 
granulation tissue in a cutaneous wound. At the heart of this process is a 
MSC/macrophage interaction driven through TNFα/CCL-2. Taken together, 
these studies suggest that TNFα pre-treatment may enhance the therapeutic 
efficacy of MSC in an excisional wound model and this process could be driven 
through a TNFα/CCL2 axis involving MSC and macrophages.  
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Therefore, the experiments described in this chapter were designed to answer 
two questions, 1) does TNFα pre-treatment enhance MSC therapeutic response 
in a mouse excisional wound healing model (as established in the pig in chapter 
5) and 2) If TNFα pre-treatment does enhance MSC efficacy, is this process driven 
through MSC derived CCL-2? 
 
7.1.1. Chapter aims  
 To determine if TNFα pre-treatment of MSC is beneficial in a mouse model 
of excisional wound healing 
 To evaluate if CCL-2 is required for enhanced therapeutic response using 
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7.2. Materials and methods 
The response of MSC to TNFα pre-treatment was evaluated in mouse excisional 
wound healing model as described in section 6.2. This study was performed in 
batches in tandem with previous study outlined in chapter 6  using the same 
control group. For clarity the results of the combined study have been broken 
into separate chapters; Chapter 6 (which deals with the role of MSC derived CCL-
2 in accelerated wound healing) and Chapter 7 (which investigates the effect of 
TNFα pre-treatment on MSC efficacy and the role of CCL-2). Several animals had 
to be excluded from all groups as the sutured ring came off at an early time point. 
In the control group two animals were excluded (n=9), in MSC-WT group one 
animal was excluded as sutured ring came off (n=8), while in MSC-KO group two 
animals were excluded for the same reason (n=8). 
 
7.2.1. Evaluation of CCL-2 cytokine secretion in response to 
TNFα in murine MSC 
CCL-2 cytokine secretion in murine MSC was evaluated in response to TNFα. The 
cells were first plated in 6 well plate and grown until confluent. The cells were 
then stimulated with either 5, 10, or 50ng/ml of TNFα (R&D systems) in complete 
media. Normal complete media without TNFα was used as a control and CCL-2 




7.2.2. TNFα pre-treatment of Murine MSC 
After cells had been isolated and characterised (as described in sections 6.2.1- 
6.2.3) MSC-WT and MSC-KO were grown to confluency and stimulated with 50 
ng/ml murine recombinant TNFα (R&D systems) in complete culture media for 
24 h prior to administration to the wounds (as described in section 6.2.8). TNFα 







7.3.1. TNFα increased MSC derived CCL-2 secretion in a dose 
dependent manner  
 
Detection of CCL-2 in MSC-WT supernatants demonstrated a significant increase 
in CCL-2 in a dose dependent manner in response to TNFα stimulation (Control; 
0.5 ng/ml ± 0.12, vs TNFα 5 ng/ml; 1.9 ng/ml ±  0.51, vs TNFα 10ng/ml; 2.61 
ng/ml ±  0.63  vs TNFα 50ng/ml;  6.5 ng/ml ±  1.6) (Control vs TNFα 5 ng/ml 
p=0.056, Control vs TNFα 10 ng/ml p= 0.03, Control vs TNFα 50ng/ml p=0.02,  
n=3)(Figure 7.1. A)   As 50 ng/ml TNFα stimulation induced the greatest CCL-2 
response, it was decided to use this concentration for further experiments. 
Migratory response of macrophages towards MSC-WTT and MSC-KOT was 
investigated as shown in Figure 7.1 B. Macrophage migration was significantly 
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increased in response to MSC-WTT compared to pre-treated MSC-KOT or control 
(Control; 9.28 ± 1.6, vs MSC TNF; 122.6 ± 2, vs CCL-2 KO TNF; 58.8 ± 18.5. 
Control vs MSC-WTT TNF p<0.001, Control vs MSC-KOT; p=0.03, MSC-WTT vs 
MSC-KOT p=0.004, n=3). 
 
7.3.2. TNFα pre-treatment of CCL-2 deficient MSC increased 
therapeutic efficacy in excisional mouse model 
TNFα pre-treatment of MSC-WT marginally increased wound closure compared 
to MSC-WT as presented in section 6.3.3 (combined wound healing rates shown 
in Appendix V). MSC-WTT significantly increased wound closure at all time points 
compared to control group (Figure 7.2). TNFα pre-treatment of CCL-2 deficient 
MSC improved wound closure, which became statistically significant on d-7  
compared to control (Figure 7.2)  (Control; 59.7% ± 3.5 vs MSC-WTT; 27.6% ± 
3.9 vs MSC-KOT; 40.9% ±4.6, (Control; vs MSC-WTT p<0.001, Control vs MSC-KOT 
p=0.011, MSC-WTT vs MSC-KOT p=0.079, n≥8). By d-10 no significant difference 
was observed between MSC-KOT and control group (Control; 15.3 ±4.0 vs MSC-
WTT; 3.7% ± 0.7 vs MSC-KOT; 12.1% ± 1.5, (Control; vs MSC-WTT p<0.005, Control 




7.3.3. TNFα pre-treatment of WT MSC enhanced re-
epithelialisation of excisional wounds 
To determine re-epithelialisation of wounds, histological sections were stained 
with H&E (as described in section 2.7.1) and unepithelialised length quantified 
(described in section 6.2.8). MSC-WTT treated wounds demonstrated 
statistically significant increase in re-epithelisation compared to control group 
(Control; 2292 μm ± 668, vs MSC-WTT; 0 μm vs MSC-KOT; 1861 μm ±370,  Control 
vs  MSC-WTT p=0.001, MSC-WTT vs MSC-KOT p=0.009, n≥8 ) Figure 7.2. In all 
cases MSC-WTT treated wounds exhibited complete re-epithelisation.  MSC-KOT 
treated wounds had a marginally smaller wound gap than controls; however, this 
was not statistically significant (Control vs MSC-KOT, p=0.75 n≥8). Measurement 
of granulation area demonstrates a statistically significant reduction in MSC-WTT 
wounds compared to control treated wounds (Control; 22583 μm2 ± 2268, vs 
MSC-WTT; 13499 μm2± 1973 vs MSC-KOT; 19884 μm2 ±1796) (Control vs MSC-
WTT p=0.021, Control vs MSC-KOT p=0.58, MSC-WTT vs MSC-KOT p= 0.12 n≥8) 
Figure 7.3 B. 
 
7.3.4. MSC derived CCL-2 was required for enhanced 
angiogenesis  
To measure angiogenic stimulus of MSC-WTT or MSC-KOT wound sections were 
stained with CD31 and vessel density quantified (as described in section 6.2). 
Application of MSC-WTT significantly increased vessel density compared to 
control measured at d-10 within the wound bed, a statistically significant 
173 
 
difference was also observed between MSC-WTT and MSC-KOT (Control; 7.5 ± 1.6, 
vs MSC-WTT; 26.4 ± 2.9, vs MSC-KOT; 11.03 ± 0.9, (Control vs MSC-WTT p<0.001, 
Control vs MSC-KOT p=0.33, MSC-WTT vs MSC-KOT p<0.001, n≥8). Pre-treatment 
of cells with TNFα had no significant effect compared to untreated cells as 
presented in section 6.3.5. No significant differences were detected by qRT-PCR 
analysis for CD31 in either group (Control; 1.09 ± 0.05, vs MSC-WTT; 0.04 ± 2.9, 
vs CCL2 KO MSCT; 0.81 ± 0.1, Control vs MSC-WTT p=0.33, Control vs MSC-KOT 
p=0.17, MSC-WTT vs MSC-KOT p=0.87, n=5). Similarly, qRT-PCR analysis of VEGF 
expression across the wound and wound margin demonstrated no statistically 
significant differences (Control; 1.0 ± 0.2, vs MSC-WTT; 0.79 ± 0.03, vs MSC KOT; 
0.87 ± 0.07, Control vs MSC-WTT p=0.2, Control vs MSC-KOT p=0.69, MSC-WTT vs 
MSC-KOT p=0.91, n=5).   
 
7.3.5. MSC derived CCL-2 was required for reduced 
inflammatory response and accumulation of CD206+ 
macrophages   
To examine the neutrophil response at d-10, wound sections were probed with 
Ly6G primary antibody and subsequently detected using a secondary 488 
fluorochrome antibody. As shown in Figure 7.5, MSC-WTT treatment of wounds 
significantly reduced neutrophil invasion into the wound (Control; 29.9 ± 4.8, vs 
MSC-WTT; 10.6 ± 1.7, vs MSC-KOT; 16.0 ± 2.2, Control vs  MSC-WTT p<0.001, 
Control vs MSC-KOT p=0.009, MSC-WTT  vs MSC-KOT p=0.435, n≥8). MSC-KOT 
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treated wounds also contained fewer neutrophils compared to control treated 
wounds at d-10. 
To evaluate if MSC treatment altered T-cell response, total T-cell numbers were 
measured using pan T-cell marker CD3. While both MSC-WTT and MSC-KOT 
groups had a trend towards increased CD3+ T-cells, no statistical differences 
were observed between the groups (Control; 3.6 ± 1.3, vs MSC-WTT; 11.6 ± 2.9, 
vs MSC-KOT; 7.2 ± 3.4, n≥8, Control vs MSC-WTT p=0.11 Control v MSC-KOT 
p=0.55, MSC-WTT vs MSC-KOT p=0.57). 
 
7.3.6. Inflammatory cytokine analysis at d-10  
Wound samples which included both wound and healed wound margins were 
used for isolation of mRNA to detect expression of several inflammatory 
cytokines such as IL-10, IL-6, CCL-2 and TNFα (Figure 7.7.) No significant 
differences were observed in any of the groups for either IL-10 (Control; 1.04 ± 
1.3, vs MSC-WTT; 1.47 ± 0.25, vs MSC-KOT; 1.12 ± 0.24, n=5, Control vs MSC-WTT 
p=0.35, Control vs MSC-KOT p=0.96, MSC-WTT vs MSC-KOT p=0.54) IL-6 (Control; 
1.12 ± 0.26, vs MSC-WTT; 1.21 ± 0.27, vs MSC-KOT; 13.23 ± 37.52, n=5, Control vs 
MSC-WTT p=0.99 Control v MSC-KOT p=0.19, MSC-WTT vs MSC-KOT p=0.15). 
Similarly, no differences were observed in CCL-2 (Control; 1.17 ± 0.07, vs MSC-
WTT; 0.92 ± 0.16, vs MSC-KOT; 0.62 ± 0.08, n=5, Control vs MSC-WTT p=0.79 
Control v MSC-KOT p=0.79, MSC-WTT vs MSC-KOT p=0.37) or TNFα (Control; 1.04 
± 0.11, vs MSC-WTT; 0.82 ± 0.14, vs MSC-KOT; 1.26 ± 0.36, n=5, Control vs MSC-





Figure 7.1  TNFα increased MSC derived CCL-2 secretion in a dose dependent manner 
A) Cells culture supernatants collected from MSC-WT stimulated with increasing concentration of 
TNFα for 24h. Supernatants were assayed for CCL-2 using ELISA.TNFα stimulation of MSC-WT 
increased CCL-2 secretion in a dose dependent manner. (n=3, ns, not significant * p<0.05). B) 
Transwell migration assay demonstrated reduced macrophage migration (stained blue with 




Figure 7.2 CCL-2 deficient MSC responded to TNFα pre-treatment 
A) Images of mouse excisional wounds at d-0 and at d-10. Two 5 mm punch wounds were created 
on the dorsum of each mouse. B) Left - Wound area was quantified at d-0, no significant differences 
were observed between the groups. B) Right - Time course of wound closure from image analysis 
demonstrated accelerated wound closure in MSC-WTT treated wounds. This was statistically 
different from controls at all time points.  MSC-KOT had reduced efficacy and were only statistically 
different from control treated wounds on day 7. (n≥8, * = MSC vs Control, + = MSC-KO vs Control, # = 




Figure 7.3 MSC-WTT enhanced re-epithelialisation  
A) Histological samples taken at d-10 were stained with H&E. Black arrows indicate migrating front 
of keratinocytes, insets show magnified image of migrating front. Images taken at 4x, Scale bar, 
100 μm. B) Left - By d-10 MSC-WTT Treated wounds were all completely re-epithelialised, no 
statistical differences were observed between MSC-KOT and control groups (n≥8, ns, not significant, 
** p<0.01). Granulation area was only significantly decreased in MSC-WTT treated wounds, 
suggestive of a reduced inflammatory response and increased wound maturity (n≥8, ns, not 




Figure 7.4 MSC derived CCL-2 was required for angiogenic effect  
A) Representative images of wound sections d-10 post wounding, stained for CD31 (green) and 
nuclei counter stained with DAPI (blue) scale bar, 50 μm. Vessels per high power field were 
quantified within the wound bed (intact vessel lumens highlighted with arrowheads) and show 
statistically significantly increased vessel density in MSC-WTT treated wounds compared to control 
and MSC-KOT treated wounds (n≥8, ns, not significant, *** p<0.001). B) No statistically significant 
differences of CD31 or VEGFa expression were detected by analysis qRT-PCR of tissue samples from 




Figure 7.5 Neutrophil invasion was attenuated by both MSC-WTT and MSC-KOT treatment  
A) Representative images of wound sections d-10 post wounding, stained for neutrophil marker 
Ly6G (green), cell nuclei were counter stained with DAPI (blue) scale bar, 50 μm. Reductions in 
neutrophil numbers were observed in MSC-WTT and MSC-KOT compared to control groups (n>8, 
** p<0.01, *** p<0.001). B) Representative images of wound sections d-10 post wounding, stained 
for T-cell marker CD3 (green, indicated with arrowheads for clarity), cell nuclei were counter 
stained with DAPI (blue), no significant difference was observed between any of the groups. Scale 




Figure 7.6 Both MSCT and MSC-KOT increased CD206+ macrophages within the wound  
A) Wound sections at d-10 post wounding stained for pan macrophage marker F4/80 (red) and M2 
marker CD206 (green, indicated with arrow heads for clarity), cell nuclei were counter stained with 
DAPI (blue) scale bar, 50 μm. B) Left - Total macrophage quantification within the wound, no 
difference was observed between any of the groups B) Right - Percentage macrophages co-
expressing CD206, significantly increased in MSC-WTT treated wounds compared to control and 




Figure 7.7 Neither MSCT and MSC-KOT altered wound expression of selected cytokines 
qRT-PCR analysis of d-10 wound samples containing both wound and healed wound margin. No 
statistically significant differences were observed in any of the groups for either IL-10 IL-6, CCL-2 or 





In this study, TNFα was used to pre-treat MSC prior to application in a mouse 
excisional wound model. This study was conducted to ascertain if TNFα pre-
treatment was effective in improving MSC efficacy (as seen in pig burn model) 
and also to determine if CCL-2 was involved in this response. 
A range of concentrations (10-50 ng/ml) of TNFα have been used to pre-treat 
MSC as reported in the literature [72, 79, 230].  In the pig model a concentration 
of 10 ng/ml was selected as it was the only practical concentration when 
stimulating large amounts of cells. The hypothesis was that TNFα was inducing 
CCL-2 secretion and that this may further enhance macrophage recruitment. 
Therefore, experiments were conducted to evaluate CCL-2 secretion in response 
to TNFα pre-treatment. A range of concentrations from 5-50 ng/ml were 
assessed. CCL-2 was found to be maximally secreted when stimulated with 50 
ng/ml TNFα and induced significantly more macrophage migration compared to 
unstimulated MSC as presented in chapter 6. A significantly reduced migratory 
response was observed with MSC-KOT.  
Results from this study demonstrated that TNF pre-treatment of MSC 
significantly enhanced re-epithelialisation of wounds. By d-10, all wounds had 
completely re-epithelialised, as compared to findings from chapter 6. Wound 
closure, as measured by macroscopic image analysis, was also accelerated. Taken 
together these data are in broad agreement with several other studies, including 
results presented in chapter 5, that reported increased MSC efficacy when pre-
treated with TNFα [75, 80, 229]. 
183 
 
TNFα pre-treatment of CCL-2 deficient MSC was also found to induce an 
increased therapeutic response. While still largely inferior to WT MSC, a 
statistically significant increase compared to control was observed in wound 
closure on d-7. This suggests the benefits observed from TNFα pre-treatment my 
not be entirely dependent on CCL-2; however, CCL-2 deficiency still greatly 
attenuates the therapeutic response. These results are in agreement with 
previous published studies that suggest TNFα stimulates MSC to secrete a wide 
variety of factors not limited to CCL-2 [79, 236, 286].  
Interestingly, no significant increase in angiogenic response was observed in 
wounds treated with MSC-WTT. TNFα is known to stimulate MSC to secrete VEGF 
and CCL-2, both potent inducers of angiogenesis [132, 236]. Nevertheless, no 
increase in CD31 vessel density was observed in either MSC-WTT or MSC-KOT. 
Studies using MSC CM generated from TNFα pre-treatment demonstrate 
increased angiogenesis and limb salvage in an ischemic limb model (MSC CM was 
generated by stimulating AD-MSC with TNFα (10ng/ml) for 48h) [75]. CM was 
injected (IM) three times a week for four weeks which resulted in increased 
blood flow with TNF MSC CM treatment and increased αSMA+ vessel density 
[75]. Blockade of either IL-6 or IL-8 significantly reduced vessel density and 
Doppler measured blood flow [75]. In a similar study the same investigators 
TNFα MSC CM significantly increased vessel density in cutaneous wounds 
compared to normal MSC CM [80]. Blockade of either IL-6 or IL-8 or both 
significantly reduced vessel densities [80]. Besides IL-6 and IL-8, TNFα 
stimulation of MSC increased several other angiogenic factors including CCL-2 
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[132]. In vitro TNFα pre-treatment (50 ng/ml) also increased VEGF secretion 
two-fold, suggesting that these pre-treated cells should be more angiogenic.  
Expression of IL-6 was assessed in the wound samples at d-10 however no 
significant difference was observed. The results demonstrate expression of IL-6 
across the entire wound including wound margin and does not reflect IL-6 
expression of applied MSC which may be greater. The role of MSC-WTT induced 
IL-6/IL-8 was not addressed in this study but it may act to support the functions 
of CCL-2, primarily through recruiting macrophages and inhibiting TNFα through 
induction of TNFα antagonists [287].    
CD3, a pan T-cell marker, was used to identify alterations in these populations as 
a result of MSC-WTT treatment. A small increase was observed in MSC-WTT but 
this was not statistically significant compared to control treated wounds. The 
time point of d-10 may be relevant here and it is not possible to rule out 
differences in these populations at earlier time points. In a previous study by 
English et al, TNFα pre-treated MSC were more effective in reducing alloantigen 
driven proliferation of splenocytes cells, this was driven primarily through 
increased PGE2 secretion from stimulated MSC [79]. To what extent MSC alter T-
lymphocyte response within the wound is not known and deserves further 
analysis. However, within cutaneous wounds it is the innate immune system, 
particularly macrophages that orchestrate the progression of wound healing, so 
T-cell modulation may not be so impactful [138].  
Analysis of macrophage populations within the wound indicate no significant 
difference between TNFα pre-treatment groups. Interestingly, there was a trend 
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towards increased F4/80+ macrophages within the wound at d-10 in MSC-KOT 
group. Most significantly however, was the percentage of CD206 macrophages in 
the MSC-KOT group. Compared to results presented in chapter 6, TNF pre-
treatment significantly increased CD206+ macrophages compared to untreated 
MSC-KO. This increased M2 polarisation is occurred in a CCL-2 independent 
fashion, possibly through IL-6.  Application of TNFα MSC CM in a cutaneous 
wound model also showed increased recruitment of CD68+ macrophages, which 
peaked at d-6, compared to control and MSC CM and was found to be IL-6 
dependent [80]. IL-6 acts similarly to CCL-2, is a potent recruiter of macrophages, 
and can reduce TNFα through induced secretion of TNFα antagonists [287]. 
Therefore, it is plausible that increased MSC-KOT efficacy may be occurring 
through IL-6 mechanisms, similarly to previous results reported by Heo et al [80]. 
Treatment of wounds with MSC-WTT significantly reduced neutrophil infiltration 
on d-10 compared to control. Contrasting results from chapter 6, this effect 
indicates no significant difference between MSC and MSCT treated wounds and 
may have plateaued in the current experimental setting. Interestingly, 
application of MSC-KOT reduced Ly6G + cells present in the wounds, with 
statistical analysis indicating a significant difference between MSC-KOT and 
control. This taken together with increased wound closure on d-7 and 
significantly increased M2 macrophage population suggest CCL-2 independent 
factors reduced the inflammatory environment induced by TNFα pre-treatment. 
The most likely candidate responsible for CCL-2 independent effect is IL-6 which 
may be functioning in a similar manner to CCL-2. It is merely speculative, but IL-
6 may be a redundant pathway for CCL-2 which is activated when cells are 
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exposed to highly inflammatory environment (such as TNFα at 50 ng/ml). It is 
also plausible that a lower inflammatory stimulus such as at (10 ng/ml as used in 
porcine study) may only initiate CCL-2 pathways. These are both interesting 
hypotheses that could be explored in future studies.  
Increased re-epithelialisation was demonstrated in MSC-WTT treated wounds, 
however this was not accounted for by any detected increase in angiogenic 
response or reduced inflammatory response. Similarly, no difference in 
granulation tissue area was observed between MSC-WT and MSC-WTT treated 
wounds. Here again, IL-6 may be a possible candidate cytokine, while no direct 
evidence of this was obtained, previous in vitro studies have established that IL-
6 induces keratinocyte migration through a fibroblast derived factor [288]. 
Similarly, wounds treated with TNFα stimulated MSC CM had increased wound 
closure and re-epithelialisation compared to normal MSC CM. Moreover, 
depletion of MSC CM with IL-6 antibodies attenuated this effect [80]. If IL-6 is a 
potent stimulator of keratinocyte migration through fibroblast activation, why 
then was there no increase in re-epithelisation observed in MSC-KOT treated 
wounds? One possible explanation is that as seen in chapter 6, MSC derived CCL-
2 is required for increased angiogenesis and increased resolution of 
inflammatory response. This increased M2 response is associated with fibroblast 
proliferation and the formation of granulation tissue and thereby, increased 
substrate for keratinocytes to migrate on.     
A limitation of this study is that the inflammatory changes described herein are 
not well captured at d-10, and may be somewhat normalised at that stage. M1 to 
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M2 transitions occur around d-5 post wounding and future studies including 
these time points may be required to better capture this response.  
Previous studies have demonstrated that TNFα stimulation of MSC increases 
expression of ICAM-1 and VCAM-1, which are adhesion molecules that allow MSC 
to interact with endothelial cells that line the vasculature and to home to sites of 
tissue damage. TNFα pre-treatment of MSC may also increase engraftment of 
MSC, possibly through this mechanism allowing the cells to remain within the 
wound for a greater period of time and therefore extend the therapeutic window.  
This work affirms TNFα pre-treatment is beneficial for excisional wound healing 
in the mouse and is a simple and effective way to enhance efficacy of MSC therapy. 
It also has advantages over genetic modification of MSC, in that less processing 
and manipulation is required and it removes the requirement for viral vectors. 
This work also demonstrates that while beneficial effect of TNFα pre-treatment 
is not CCL-2 dependent, CCL-2 is required for proper function of MSC therapy, 
and lack of CCL-2 severely attenuates the therapeutic response. Fundamental 
understanding of how these interactions work will allow us to engineer better 





8. General Discussion 
 
 
8.1. Summary of work 
 
The work outlined in the preceding chapters contributes significantly to the 
understanding of MSC derived CCL-2 in accelerated wound healing. In chapter 6, 
it was established that CCL-2 was required for MSC therapeutic benefit in 
excisional wound healing. Results showed that CCL-2 deficiency inhibited 
macrophage recruitment and may affect downstream local interactions, reducing 
MSC efficiency in repolarising macrophages towards an M2 phenotype.   
This feature of M2 polarisation is a hallmark of MSC therapy in cutaneous wound 
healing and CCL-2 was first suggested to be implicated in this process by Chen et 
al who noted MSC secrete significant amounts of CCL-2 [58]. However, the 
functional significance of these observations has not been addressed until now. 
Several elegant studies have elucidated the mechanism by which MSC exert an 
immunomodulatory effect and induce M2 polarisation [85, 96, 255]. This consists 
of several factors including PGE2, TSG-6 and IDO among others [85, 96, 102]. 
Activated inflammatory macrophages express TNFα which induces the 
expression of TSG-6, this binds to CD44 and activates NF-κB downstream 
signalling in macrophages to reduce TNFα secretion [105]. Concurrently, TNFα 
also induces COX-2 in MSC which is metabolised to PGE2 [85]. This binds to EP2 
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receptors on macrophages activating NF-κB and also downstream cAMP 
pathways, reducing TNFα and promoting expression of IL-10 [289]. 
Macrophages also secrete other factors that are involved in this crosstalk such as 
IL-1 and IFNγ [98]. Additionally, IDO induced in human MSC by IFNγ stimulates 
the catabolism of tryptophan to Kynurenic acid which has also been shown to 
inhibit LPS stimulated TNFα secretion [98, 290]. 
Proximity is vital in these interactions in that studies have shown that 
immunomodulatory factors like PGE2 and Gal-1 function locally [88, 96, 
291](unlike TSG-6 which can act more systemically [235]) and in vitro 
modulation of both T-cell and macrophage inflammatory responses require cell-
cell contact as opposed to transwell co-culture [88, 96, 255]. Further evidence of 
this local interaction is provided by immunostaining of wounds treated with MSC, 
which confirms co-localisation of MSC with CD11b+ macrophages and this co-
localisation is concomitant with increased expression of CD206 and Arginase-1 
(an enzyme associated with M2 phenotype) within the wound [20]. Moreover, 
other studies have observed these MSC/immune cell aggregates in a mouse 
model of colitis [292].  
At the centre of this interaction is CCL-2. In this study, we show that CCL-2 
deficient MSC are unable to increase wound closure and this is associated with 
reduced CD206+ macrophages and increased neutrophils present in the wound, 
indicative of ongoing inflammatory response. Crucially, in chapter 6 we 
established that CCL-2 deficient MSC are not as efficient in inhibiting TNFα from 
LPS stimulated macrophages as WT MSC, under in vitro co-cultures. These data 
support the hypothesis that CCL-2 acts locally, facilitating close cell contact 
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allowing for crosstalk between MSC and macrophages and subsequent 
repolarisation. 
CCL-2 may also play a role in other aspects of this MSC/macrophage interaction. 
For example, recent studies have emerged describing some novel mechanisms 
for MSC mediated macrophage polarisation. MSC do not reside in great numbers 
in the wound for long (less than a week [61, 293]), yet still have a therapeutic 
effect [61, 149]. One mechanism may be a consequence of phagocytosis; 
macrophages that phagocytosed MSC expressed higher levels of IL-10 and TGF-β 
and had reduced levels of IL-6 compared to macrophages that did not 
phagocytose any MSC [294].  Liu et al, have also demonstrated that MSC secrete 
greater amounts of TSG-6 when undergoing apoptosis [295], so it is possible that 
phagocytosing macrophages may subsequently come in contact with TSG-6 
which could account for the increased M2 polarisation. Phinney et al describe a 
novel process of mitophagy whereby the mitochondria of stressed MSC are 
shuttled across cell membrane and taken up by macrophages; simultaneously 
MSC secrete exosomes containing PGE2 which inhibit activation of macrophages 
[296]. It is conceivable that CCL-2 could also be facilitating these interactions. 
However, it is not known how pervasive these newly described mechanisms are 
and whether they extend to CCL-2.  
CCL-2 may also benefit macrophage polarisation through other downstream 
mediators. The MCP-1 induced protein (MCPIP), was first found to be highly 
expressed after exposure to CCL-2 (then under the MCP-1 nomenclature), and 
recent studies have demonstrated that MCPIP is required for IL-4 induced M2 
polarisation in vitro and genetically modified macrophages overexpressing 
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MCPIP display several M2 markers and have reduced TNFα levels when delivered 
in a peritoneal inflammatory model [297]. MCPIP mediated its action through 
inhibition of NF-κB and sequential induction of ROS production, ER stress and 
increased autophagy [297]. MSC derived CCL-2 may therefore act as a negative 
feedback loop, during its interactions. For instance, MSC are stimulated by 
inflammatory macrophages secreting TNFα, this induces CCL-2 (as demonstrated 
in chapter 5), among others, which is in turn secreted by MSC and subsequently 
binds to CCR-2 on inflammatory macrophages thus inducing the expression of 
MCPIP [274]. MCPIP may supress TNFα through NF-κB inhibition [297], 
dampening the inflammatory response. Induced MCPIP may also account for 
increased angiogenesis in this interaction [275]. 
MSC derived CCL-2 not only influences the innate immune system, but may be a 
key mediator in MSC therapy, involved in all aspects of MSC interactions with 
immune cells [276, 298]. BM MSC lacking the ligand FasL, have a reduced ability 
to lower number of CD3+ T-cells or induce apoptosis and also fail to elevate 
Foxp3 reg T-cells as normal MSC do [86]. Subsequent investigation established 
that these cells did not secrete CCL-2, although it was abundant in the cytoplasm. 
Interestingly, overexpression of Fas restored cytokine secretion, suggesting that 
Fas has an essential role in CCL-2 secretion. Correspondingly, MSC isolated from 
CCL-2 knockout mice were defective in reducing the number of CD3+ T-cells. 
Other studies have confirmed that in a two way mixed lymphocyte reaction, CCL-
2 depletion of CM reduced MSC ability to modulate IFN-γ while both CCL-2 and 




MSC derived CCL-2 is also influential in modulating B-cell responses. MSC 
isolated from BM of Lupus (a systemic disease involving dysfunction of T-cell and 
polyclonal B cell activation) like mice have reduced CCL-2 expression and 
secretion [298]. When lupus MSC were applied to normal B cells, they were 
defective in reducing proliferation compared to normal MSC and treatment of 
normal MSC with anti-CCL-2 abrogated this effect. Treatment of B-cells with 
recombinant CCL-2 had little effect on proliferation; only proteolytic processing 
of CCL-2 by MMP-1 was able to recapitulate the MSC effect [298]. 
MSC CM also inhibits CD4+ T-cell activation through proteolytic processing of 
CCL-2 [299]. MSC driven matrix metalloproteinase processing of CCL-2 cleaves 
four N terminal amino acids to form an antagonist derivative. Administration of 
CCL-2 -/- knockout MSC were unable to reduce CD4+ T-cell infiltration into 
central nervous system and subsequent demyelination compared to wild type 
MSC [299]. 
Taken together, the work presented here and from previous studies 
demonstrates that CCL-2 is a central mediator in the interaction of MSC with 
various cells of both the innate and adaptive immune system. Dysfunction of MSC 
derived CCL-2 has profound effects on the efficacy of MSC therapy and may be 





8.2. Aspects of MSC therapy in wound healing mimics 
biological processes in tumour growth 
 
The parallels between wound healing and tumorigenesis have long been 
recognised [300]. In a seminal paper, Dvorak describes the striking similarities 
between the formulation of granulation tissue within the cutaneous wound and 
the development of tumour stroma, both consisting of a highly vascularised 
matrix of proliferative fibroblast cells intermixed with various immune cells 
[301]. Parallels in mechanism can also be drawn between the application of MSC 
therapy in cutaneous wounds and the development of tumour stroma [300, 301]. 
Several studies have described a mechanism whereby MSC recruit macrophages 
to the tumour site through CCL-2 [132, 133]. This interaction between MSC and 
macrophages induces an M2 type phenotype associated with 
immunosuppression [133] and angiogenesis [239], both of which support 
tumour growth in a CCL-2 dependent fashion [132]. Correspondingly, application 
of MSC into a cutaneous wound promotes the formation of granulation tissue 
through these same mechanisms of angiogenesis and immune suppression. This 
mechanism in tumorigenesis appears to mirror the mechanism of action of MSC 
therapy in cutaneous wounds and supports the findings of the work presented 
here. It should be noted that while the mechanisms appear similar and is 
something further insights can be garnered from, the author is not suggesting 
that application of MSC may induce tumour formation and to the best of the 




8.3. TNFα pre-treatment of MSC  
Another hallmark of cancer is a chronic inflammatory environment. Tumours 
secrete significant amounts of TNFα, and this further promotes the cycle as 
described above. Tumour associated MSC are more immunosuppressive and 
secrete greater amounts of CCL-2 [133]. Stimulation of normal BM-MSC with 
TNFα mimicked this effect [132]. As observed in the results presented here, TNFα 
pre-treated MSC significantly increased efficacy. However, this was shown to 
mostly occur in a CCL-2 independent fashion. Other candidates include IL-6, 
shown to enhance wound healing in TNF pre-treated MSC CM [80], which may 
act synergistically with CCL-2. In fact, a close association was established for 
these two cytokines. Stimulation monocytes with either IL-6 or CCL-2 was found 
to induce the other cytokine [262]. CCL-2 induced a four-fold expression of IL-6 
in CD11b human monocytes. This was associated with increased phagocytic 
activity and increased expression of CD206, markers of M2 phenotype [262, 282]. 
In this work, TNFα pre-treatment enhanced the efficacy of MSC therapy in both 
animal models. In vitro studies demonstrate increased immunosuppressive 
properties when pre-treated with TNFα [79]. Recent findings suggest that 
stimulation of MSC with inflammatory cytokines may also reduce heterogeneity 
[302]. In a study by Szabo et al, they generated mouse BM-MSC clones and found 
that some clones displayed marked heterogeneity in terms of in vitro 
differentiation capability and immunosuppressive capacity in a mouse model 
delayed type hypersensitivity, this observed heterogeneity is a major 
impediment in the field of MSC research [303]. MSC were pre-treated with IFNγ 
(100 ng/ml) and TNFα (50 ng/ml) for 24 h which remarkably abolished 
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previously observed heterogeneity [302]. These recent findings need to be 
independently verified, but may be a promising avenue of research and hugely 
significant for the field as a whole, going forward. These findings could also 
account for some of the beneficial effects observed in inflammatory cytokine pre-
treatment studies such as presented in chapters 5 and 7. 
Pre-treatment of MSC with inflammatory cytokines such as TNFα may be an easy 
step to reduce heterogeneity and improve efficacy. Repeated TNFα stimulation 
can prolong and also increase secretion of CCL-2 and other immunomodulatory 
cytokines [132]. Allogenic AD-MSC are a readily available source of MSC that is 
amenable to further characterisation/enrichment (via section using a specific or 
expanded set of cell surface antigens) and pre-treatment with TNFα. Repeated 
TNFα stimulation is a process that could be easily incorporated into a 
manufacturing process, for an off the shelf allogenic cell therapy product. 
 
8.4. Future directions  
MSC therapy holds much promise and research in this area has expanded 
immensely. Many lines of evidence now affirm that delivery of this therapy is safe. 
Several clinical trials and pre-clinical studies have shown promising results in 
certain pathologies. This work herein builds on the vast wealth of knowledge that 
has been gained and validates that AD-MSC are therapeutically equivalent to BM-
MSC in a clinically relevant burn wound model. This will allow future studies to 
focus on optimising AD-MSC therapy. This work also demonstrates that TNFα 
pre-treatment is an effective way to enhance efficacy of MSC therapy. The broad 
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mechanisms of MSC therapy have been established; however, greater 
understanding of these mechanisms will lead to further insights to improve the 
efficacy of this treatment.  In this regard, this work establishes for the first time, 
a pivotal role of MSC derived CCL-2 in accelerated wound healing.  
In this study AD-MSC were validated as being therapeutically equivalent to BM-
MSC at both baseline and in response to stimulation with inflammatory cytokine 
TNFα. One of the primary advantages of AD-MSC is the amount of cells that can 
be isolated. Many grams of tissue can be harvested from which vast quantities of 
MSC can be isolated using simple digestion protocols. Now that this cell source 
has been validated as therapeutically equivalent, dose escalation studies should 
be performed using this established burn model. The dosage used in this study 
was based on a previous pilot study [149] and the work of Falanga et al [50], who 
used concentrations of 1x106 cells/cm2 and reported beneficial results. However, 
it has not been established if an increased concentration of cells would lead to 
better wound healing outcomes. In MI studies high doses of MSC had a negative 
effect, becoming entrapped in the vasculature and forming thrombus [150]. 
Further in-depth studies are required in the pig model to determine the optimal 
dosage. The pig model is ideal for dosing studies as it is more readily translatable 
to humans due to its similar anatomical size and skin structure. Scaling up from 
concentrations used in rodents based on dosage/weight can be problematic and 
may not a reliable indicator of dosage [304].  What may be most beneficial is 
multiple dosing strategies. Again, there is little research in this area; however, 
findings from several studies, including studies from this lab [61, 149], suggest 
that MSC do not survive long within the wound, with few surviving beyond a 
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week. Multiple dosing every 2-3 d could significantly bolster viable MSC to 
improve wound healing and these are additional hypotheses that could be 
explored.  
Stimulation of MSC with TNFα induces upregulation of adhesion molecules ICAM-
1 and VCAM-1 and may facilitate retention of MSC within the wound [91, 229] 
and increase homing of MSC to ischemic tissues [230].  TNFα pre-treatment of 
MSC increased persistence of MSC in infarcted myocardium of mice and was 
associated with improved cardiac function [229]. TNFα pre-treatment may 
improve the persistence of MSC in burn wounds and may account for increased 
efficacy observed in chapter 5. Further studies are required to characterise the 
effect of TNFα pre-treatment on MSC persistence in wounds. Pre-labelling of MSC 
with stable florescent dyes that are made cell impermeable upon cellular uptake 
would allow for accurate tracking of MSC persistence within the wound, which 
may be correlated with improved wound healing.  
In this work, a role for CCL-2 was established in a mouse model of excisional 
wound healing, it was also hypothesised that a similar mechanism may be at hand 
in the pig model. However, this has not been experimentally established and 
interpreting between the mouse and pig is challenging. Moreover, important 
differences exist between burn and excisional wounds [6]. Burn wounds induce 
increased vascular permeability and have a stronger and ongoing inflammatory 
reactions due to the presence of denatured proteins which must be removed 
through MMP degradation [6].  However, for practical reasons it was not possible 
to explore a possible CCL-2 mechanism in the pig. No genetically modified pigs 
are available and amount of reagents required to produce therapeutic doses of 
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porcine CCL-2 knockdown MSC is currently impractical. To validate our mouse 
model findings, future work could focus on the development of a pig burn model 
with smaller wounds, which would require reduced cell quantities. Further 
optimisation of transfection efficiency may also make this experiment more 
feasible. As AD-MSC have been shown to be therapeutically equivalent to BM-
MSC, future work should primarily focus on this cell source.  
The mechanism described in the mouse model involving CCL-2/MSC and 
macrophage interactions are not fully captured here and by d-10 these 
population dynamics may have peaked or may have been in decline. This study 
was designed to evaluate if CCL-2 deficiency affected MSC efficacy as measured 
by primary endpoints of wound closure and re-epithelisation.  Our findings 
suggest a more in-depth exploration of macrophage populations within the 
wound at an earlier time point (perhaps d-5) would give greater insight into how 
MSC derived CCL-2 is functioning. Multi-colour flow cytometry is a powerful tool 
and could be used to identify several cell populations within the wound at 
multiple time points. Well established digestion, labelling and gating protocols 
are available to characterise these cells [242]. 
MCPIP is induced by CCL-2 and could be a downstream mediator of the beneficial 
effects of MSC derived CCL-2 in terms of both angiogenesis and 
immunomodulation [275, 297]. It would be interesting to see if MCPIP is being 
expressed in MSC/macrophage interactions, and if so, it may be in part 




The model established in this thesis demonstrates that MSC derived CCL-2 is 
involved in the local recruitment of CCR2+ macrophages, facilitating cell contact 
(or close proximity) and thus allowing for the repolarisation of macrophages 
towards an M2 phenotype, through factors that have been well described in the 
literature [96]. This results in reduced inflammatory response and increased 
wound healing. Conversely, this model implies that MSC deficient for CCL-2 
would have reduced ability to facilitate MSC/macrophage contact. If this is true, 
then one would expect to find a greater number of WT MSC in close proximity 
with macrophages during the early stages of administration (d2-4) compared to 
CCL-2 deficient MSC. This could be confirmed by labelling MSC with a stable non-
transferable cell fluorescent dyes and immunostaining wound sections for pan 
macrophage marker, like F4/80. Quantification of co-localisation may provide 
further corroborative proof of this proposed model. 
In this study, MSC were isolated from CCL-2 KO mice. These mice are normal in 
size and do not display any gross physical or behavioural abnormalities [139]. 
Thioglycollate induced peritonitis results in impaired recruitment of monocytes 
and macrophages to peritoneal cavity in these mice consistent with CCL-2 
deficiency [139]. As demonstrated in Chapter 6, isolated cells were classified as 
MSC under ISCT guidelines. However, one cannot rule out entirely, the possibility 
that CCL-2 KO may result in the isolation of a specific or different subpopulation 
of BM-MSC. To fully control for this, recovery of CCL-2, may be considered. This 
would require lenti-viral over-expression of CCL-2 in MSC-KO and the in-vivo 
experiments to be repeated. However, one could argue that MSC are 
heterogeneous by their nature and variation will exist from isolation to isolation, 
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based on what cells randomly adhere to flasks, in addition to donor variation and 
clonal heterogeneity present, that was recently demonstrated [302]. 
 This thesis contributes to the field by deepening our understanding of the 
mechanism of action of MSC therapy and establishes AD-MSC as an optimal 
source that can be enhanced through TNFα pre-treatment. One of the major 
issues facing the MSC field is the characterisation of MSC and the heterogeneity 
present in these populations. This has resulted in mixed and conflicting reports 
of therapeutic efficacy. Research is ongoing in an attempt to define specific cell 
surface antigens or expand immunophenotypic profiles associated with these 
cells. Similarly, others are attempting to characterise these cells based on 
predicators of efficacy. In a recent study by Lee et al they describe TSG-6 
expression in human MSC as a predictor of efficacy in corneal repair [104]. Lee et 
al also found that TSG-6 expression was strongly correlated with increased 
immunomodulatory capacity and corneal repair but was negatively correlated 
with osteogenic potential. The expression of TSG-6 was found to vary widely 
between donors [104]. Comparatively, this thesis finds that CCL-2 is required for 
MSC therapeutic functioning and may also be a useful addition in building a 
profile of paracrine factors that are required for MSC therapeutic effect allowing 
for further characterisation of these cells. 
TNFα pre-treatment has recently been shown to reduce heterogeneity of clonal 
MSC and this thesis also demonstrated increased efficacy in response to TNFα 
pre-treatment. MSC response to TNFα could also be used as a possible way to 
further characterise these cells for therapeutic use. Other attempts to develop 
standardised immunomodulatory or potency assays such as suppression  T-cell 
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proliferation [305] or corneal inflammatory model [104] may also be beneficial 
to determine potency [104, 306]. The validation that AD-MSC is therapeutically 
equivalent in this work supports the generation of large banks of AD-MSC which 
could be further characterised and enriched (using methods outlined above). 
These batches could be sorted based on potency or blended to achieve 
homogenous populations and reduce batch to batch variations.  
In conclusion, MSC therapy provides an easy way to deliver a cocktail of factors 
to the appropriate cells at the most auspicious time. The use of CM or exosomes 
is also beneficial and may be more amenable to an off the shelf product. However, 
MSC have the ability to home to specific sites of injury and respond to the 
changing microenvironment through interactions with various cells. These 
interactions are extremely complex, yet through ongoing research these 
complexities can be unravelled. Ultimately we would like to achieve a level of 
sophistication to be able to deliver the right sequence of factors to specific target 
cells during a defined period to modulate wound healing without the necessity of 
delivering allogenic cells. However, this is some way off and for the moment, MSC 
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Comparison of Fibrin only groups from animals used in chapter 4 and 










Comparison of wound closure and re-epithelialisation rates from results 
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